arthritis, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, arthritis

A SE, Moses PD, George R. Ocular manifestations of Behcet's disease. Indian Pediatr. 42: 942-945 (2005). *
Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J. Immunol. 162: 1246-1251 (1999). *
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr. Top. Med. Chem. 6: 151-163 (2006).
Abbott JD, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin. Investig. Drugs 13: 1007-1018 (2004).
Abdel Fattah NS, Hassan HE, Galal ZA, El Okda ES. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res. Notes 2: 44 (2009). *
Abdel-Naser MB, Wollina U, El Hefnawi MA, Habib MA, El Okby M. Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency. J. Drugs Dermatol. 5: 370-372 (2006).
Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4: 1162-1169 (2006).
Abdelmoula LC, Ben M'Barek R, Yahia CB, Tekaya R, Testouri N, Chaabouni L, Zouari R. Update in treatment of psoriatic arthritis. Tunis. Med. 86: 1036-1041 (2008).
Abdelouahab N, Heard CM. Dermal and transcutaneous delivery of the major glycoside constituents of Harpagophytum procumbens (devil's claw) in vitro. Planta Med. 74: 527-531 (2008).
Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, Koenders MI, van den Berg WB. Shift from Toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum. 58: 3753-3764 (2008). *
Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118: 205-216 (2008). *
Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, van der Meer JW, Netea MG, van den Berg WB. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56: 2957-2967 (2007). *
Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 58: 2196-2205 (2008). *
Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG.. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 56: 2080-2091 (2007). *
Abe K, Klaften M, Narita A, Kimura T, Imai K, Kimura M, Rubio-Aliaga I, Wagner S, Jakob T, Hrabe de Angelis M. Genome-wide search for genes that modulate inflammatory arthritis caused by Ali18 mutation in mice. Mamm. Genome 20: 152-161 (2009).
Abe M. Complement activation and inflammation. Rinsho Byori 54: 744-756 (2006).
Abe T, Takeuchi T. Rheumatoid arthritis and tumor necrosis factor alpha. Autoimmunity 34: 291-303 (2001).
Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 33: 37-44 (2006).
Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda SI, Tsutsumi Y. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J. Immunol. Methods 335: 71-78 (2008). *
Abebe F, Mustafa T, Nerland AH, Bjune GA. Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin. Exp. Immunol. 143: 180-192 (2006). *
Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol. Rev. 14: 50-52 (2006).
Abel B, Kurrer M, Shamshiev A, Marty RR, Eriksson U, Gunthert U, Kopf M. The osteopontin - CD44 pathway is superfluous for the development of autoimmune myocarditis. Eur. J. Immunol. 36: 494-499 (2006). *
Abeles AM, Marjanovic N, Park J, Attur M, Chan ES, Al-Mussawir H, Dave M, Fisher MC, Stuchin SA, Abramson SB, Pillinger MH. Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitors. Arthritis Rheum. 56: 2840-2853 (2007). *
Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis - cartilage destruction and the regulation of matrix metalloproteinases. Bull. Hosp. Jt. Dis. 64: 20-24 (2006).
Ablassmaier B, Hartmann J. A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake. Zentralbl. Chir. 129: 510-512 (2004).
Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D, George J. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79: 2364-2369 (2006). *
Ablin JN, Goldstein Z, Aloush V, Matz H, Elkayam O, Caspi D, Swartzenberg S, George J, Wohl Y. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol. Int. 29: 257-262 (2009). *
Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun. Rev. 5: 331-337 (2006).
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H. Chronic inflammatory autoimmune disorders and atherosclerosis. Ann. N. Y. Acad. Sci. 1107: 56-67 (2007). *
Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chales G. Cutaneous lupus induced by etanercept in rheumatoid arthritis. Rev. Med. Interne. 29: 744-747 (2008).
Abraham C, Hart J, Locke SM, Baker AL. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 172-176 (2008). *
Abrams B. Long-term sleep apnea as a pathogenic factor for cell-mediated autoimmune disease. Med. Hypotheses 65: 1024-1027 (2005).
Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41: 972-980 (2002). *
Abramson SB, Attur M, Yazici Y. Prospects for disease modification in osteoarthritis. Nat. Clin. Pract. Rheumatol. 2: 304-312 (2006). *
Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv. Drug Deliv. Rev. 58: 212-225 (2006). *
Abreu JR, Grabiec AM, Krausz S, Spijker R, Burakowski T, Maslinski W, Eldering E, Tak PP, Reedquist KA. The presumed hyporesponsive behavior of rheumatoid arthritis T lymphocytes can be attributed to spontaneous ex vivo apoptosis rather than defects in T cell receptor signaling. J. Immunol. Jun 12 [Epub ahead of print] (2009).
Abunasser J, Forouhar FA, Metersky ML. Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. Chest 134: 850-853 (2008). *
Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br. J. Biomed. Sci. 59: 173-179 (2002).
Acheson DW. Foodborne infections. Curr. Opin. Gastroenterol. 15: 538 (1999).
Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets 11: 1369-1384 (2007).
Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 26: 121-129 (2008).
Adachi T, Toishi T, Takashima E, Hara H. Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro. Biol. Pharm. Bull. 29: 2095-2098 (2006). *
Adachi Y, Hinoda Y, Takahashi H, Nakagawa N, Sakamoto H, Itoh F, Endo T, Suzuki S, Imai K. Rheumatoid arthritis associated with ulcerative colitis. J. Gastroenterol. 31: 590-595 (1996).
Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr. Pharm. Des. 14: 1217-1224 (2008).
Adak M, Gupta JK. Evaluation of anti-inflammatory activity of Calotropis gigantea (AKANDA) in various biological system. Nepal. Med. Coll. J. 8: 156-161 (2006).
Adam O. Dietary fatty acids and immune reactions in synovial tissue. Eur. J. Med. Res. 8: 381-387 (2003).
Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R, Forth W. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol. Int. 23: 27-36 (2003). *
Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *
Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells. Arthritis Res. Ther. 10: 225 (2008).
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J. Am. Acad. Dermatol. 51: 660-662 (2004).
Adams KM, Yan Z, Stevens AM, Nelson JL. The changing maternal "self" hypothesis: a mechanism for maternal tolerance of the fetus. Placenta 28: 378-382 (2007).
Adamson AS, Collins K, Laurence A, O'Shea JJ. The current STATus of lymphocyte signaling: new roles for old players. Curr. Opin. Immunol. 21: 161-166 (2009).
Adarichev VA, Bardos T, Christodoulou S, T Phillips M, Mikecz K, Glant TT. Major histocompatibility complex controls susceptibility and dominant inheritance, but not the severity of the disease in mouse models of rheumatoid arthritis. Immunogenetics 54: 184-192 (2002). *
Adarichev VA, Vegvari A, Szabo Z, Kis-Toth K, Mikecz K, Glant TT. Congenic strains displaying similar clinical phenotype of arthritis represent different immunologic models of inflammation. Genes Immun. 9: 591-601 (2008). *
Adarichev VA, Vermes C, Hanyecz A, Ludanyi K, Tunyogi-Csapo M, Finnegan A, Mikecz K, Glant TT. Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis. Autoimmunity 39: 663-673 (2006).
Adarichev VA, Vermes C, Hanyecz A, Mikecz K, Bremer EG, Glant TT. Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation. Arthritis Res. Ther. 7: R196-R207 (2005). *
Adcock I, Evans PC. Resolution of inflammatory responses: a brief introduction. Biochem. Soc. Trans. 35: 261-262 (2007). *
Addo A, Le J, Li W, Aksentijevich I, Balow J Jr, Lee A, Gregersen PK, Kastner DL, Remmers EF. Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility. Scand. J. Rheumatol. 34: 198-203 (2005). *
Adebajo AO, Mitchell C. Patient's ethnicity and use of therapies in rheumatoid arthritis. J. Rheumatol. 34: 233 (2007).
Adisen E, Karaca F, Gurer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin. Exp. Dermatol. 33: 164-166 (2008). *
Adlesic M, Verdrengh M, Bokarewa M, Dahlberg L, Foster SJ, Tarkowski A. Histamine in rheumatoid arthritis. Scand. J. Immunol. 65: 530-537 (2007). *
Adorini L. Antigen-based immunointervention in human autoimmune diseases. Trends Biotechnol. 22: 547-549 (2004). *
Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4: 404-412 (2008).
Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ, Tak PP. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J. Gen. Virol. 88: 1717-1721 (2007). *
Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman D, Gould DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Vervoordeldonk MJ, Tak P. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann. Rheum. Dis. 66: 1143-1150 (2007). *
Adriaansen J, Kuhlman RR, Holten JV, Kaynor C, Vervoordeldonk MJ, Tak PP. Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum. Gene Ther. 17: 985-996 (2006).
Adriaansen J, Tas SW, Klarenbeek PL, Bakker AC, Apparailly F, Firestein GS, Jorgensen C, Vervoordeldonk MJ, Tak PP. Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann. Rheum. Dis. 64: 1677-1684 (2005). *
Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45: 656-668 (2006). *
Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 45: 937-943 (2006). *
Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med. Wkly. 132: 414-422 (2002). *
Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is down-regulated by interleukin-1beta in articular chondrocytes. Arthritis Res. Ther. 9: R31 (2007). *
Afonso V, Champy R, Mitrovic D, Collin P, Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 74: 324-329 (2007). *
Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 148: 32-46 (2007). *
Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum. 48: 2632-2644 (2003). *
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 5: 289-293 (2004). *
Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 46: 2445-2452 (2002). *
Aganna E, Zeharia A, Hitman GA, Basel-Vanagaite L, Allotey RA, Booth DR, Hawkins PN, Thacker C, Syndercombe-Court D, McDermott MF. An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 46: 245-249 (2002). *
Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 35: 515-519 (2008). *
Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr. Opin. Rheumatol. 18: 268-276 (2006).
Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J. Rheumatol. 35: 1737-1744 (2008).
Aggarwal A, Agarwal S, Misra R. Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5(+) and CXCR3(+) CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA). Clin. Exp. Immunol. 148: 515-519 (2007). *
Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756 (2003). *
Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441 (2004). *
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186 (2006).
Aggarwal P, Aggarwal A, Gupta S, Misra R. Osteopenia is common in adult male patients with active juvenile idiopathic arthritis. J. Rheumatol. 33: 1642-1645 (2006).
Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 60: 1112-1118 (2009). *
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914 (2003). *
Agirbasli M, Inanc N, Baykan OA, Direskeneli H. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin. Exp. Rheumatol. 24: 580-583 (2006).
Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85 (2003). *
Agrawal C, Raghav SK, Gupta B, Das RH, Chaturvedi VP, Goswami K, Das HR. Tumor necrosis factor-alpha microsatellite polymorphism association with rheumatoid arthritis in Indian patients. Arch. Med. Res. 36: 555-559 (2005).
Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin. Rheumatol. 26: 201-204 (2007). *
Agrawal S, Srivastava R, Sharma B, Pandya S, Misra R, Aggarwal A. IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to anklyosing spondylitis in Indian patients. Clin. Rheumatol. 27: 573-576 (2008). *
Agrup C. Immune-mediated audiovestibular disorders in the paediatric population: a review. Int. J. Audiol. 47: 560-565 (2008).
Aguillon G JC, Cruzat C A, Contreras-Levicoy J, Dotte G A, Pesce R B, Aravena MO, Salazar A L, Catalan M D, Abello C P, Aguirre D A, Llanos M C, Cuchacovich TM. Emergent therapies for rheumatoid arthritis. Rev. Med. Chil. 133: 969-976 (2005).
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453 (2003).
Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211: 75-84 (2006).
Aguillon JC, Cruzat A, Cuenca J, Cuchacovich M. Tumor necrosis factor alpha genetic polymorphism as a risk factor in disease. Rev. Med. Chil. 130: 1043-1050 (2002).
Aguirre S, Silber AM, Brito ME, Ribone ME, Lagier CM, Marcipar IS. Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection. J. Clin. Microbiol. 44: 3768-3774 (2006). *
Ahlqvist E, Bockermann R, Holmdahl R. Fragmentation of two quantitative trait loci controlling collagen-induced arthritis reveals a new set of interacting subloci. J. Immunol. 178: 3084-3090 (2007). *
Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br. J. Dermatol. 156: 1010-1014 (2007). *
Ahmad R, Qureshi HY, El Mabrouk M, Sylvester J, Ahmad M Dr, Zafarullah M. Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma. Ann. Rheum. Dis. 66: 782-789 (2007). *
Ahmad R, Sylvester J, Zafarullah M. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell. Signal. 19: 2549-2557 (2007). *
Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 48: 807-813 (2003). *
Ahmad YA, Bruce IN. Genetic epidemiology: systemic lupus erythematosus. Arthritis Res. 3: 331-336 (2001). *
Ahmadi K, McCruden AB. Macrophage may responses to androgen via its receptor. Med. Sci. Monit. 12: BR15-BR20 (2005). *
Ahmadi S, Powell FC. Pyoderma gangrenosum: uncommon presentations. Clin. Dermatol. 23: 612-620 (2005).
Ahmadi-Simab K, Schnitzler P. Whipple's disease with normal duodenal histology and ankylosing spondylitis. Dtsch. Med. Wochenschr. 134: 127-130 (2009).
Ahmed MM, Berney SM, Wolf RE, Hearth-Holmes M, Hayat S, Mubashir E, Vanderheyde H, Chang WL, King JW. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am. J. Med. Sci. 331: 252-256 (2006).
Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. South. Med. J. 99: 1209-1215 (2006).
Ahn BC, Lee SW, Lee J. Intense accumulation of F-18 FDG in colonic wall in adult onset Still disease with pseudomembranous colitis. Clin. Nucl. Med. 33: 806-808 (2008).
Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 1056: 218-233 (2005). *
Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98: 1162-1169 (1990).
Ahrens ET, Morel PA. In vivo imaging of autoimmune disease in model systems. Curr. Top. Dev. Biol. 70C: 215-238 (2005).
Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361 (2007). *
Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto M, Makimura M, Matsumura H. The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life Sci. 79: 764-771 (2006). *
Aiello M, Chetta A, Marangio E, Zompatori M, Olivieri D. Pleural involvement in systemic disorders. Curr. Drug Targets Inflamm. Allergy 3: 441-447 (2004).
Aigner E, Schmid I, Osterreicher CH, Zwerina J, Schett G, Strasser M, Niksic F, Hohla F, Ramsauer T, Dorn U, Patsch W, Datz C. Contribution of anti-cyclic citrullinated peptide and rheumatoid factors for the diagnosis of arthropathy in patients with hereditary hemochromatosis. Ann. Rheum. Dis. 66: 1249-1251 (2007). *
Aimbire F, Albertini R, Pacheco MT, Castro-Faria-Neto HC, Leonardo PS, Iversen VV, Lopes-Martins RA, Bjordal JM. Low-level laser therapy induces dose-dependent reduction of TNFalpha levels in acute inflammation. Photomed. Laser Surg. 24: 33-37 (2006).
Ainola M, Mandelin J, Liljestrom M, Konttinen YT, Salo J. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 240-246 (2008).
Ainola M, Valleala H, Nykanen P, Risteli J, Hanemaaijer R, Konttinen YT. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature. Arthritis Rheum. 58: 3394-3401 (2008). *
Aithal GP. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998 (2007). *
Aittoniemi J, Baer M, Soppi E, Vesikari T, Miettinen A. Mannan binding lectin deficiency and concomitant immunodefects. Arch. Dis. Child. 78: 245-248 (1998). *
Ajiro J, Narita I, Sato F, Saga D, Hasegawa H, Kuroda T, Nakano M, Gejyo F. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod. Rheumatol. 16: 294-299 (2006). *
Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what's going on? J. Immunol. 177: 2039-2045 (2006). *
Akabane H, Miyagawa N, Nii H, Inami Y, Togawa M, Tanaka H, Inagaki N, Nagai H. The effect of a newly synthesized indazole compound, TAS-3-124, on experimental autoimmune disease. Biol. Pharm. Bull. 27: 1218-1223 (2004). *
Akama H. Antibody to IL-1 or IL-15. Nippon Rinsho 65: 1227-1230 (2007).
Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr. Metab. Immune Disord. Drug Targets 6: 383-394 (2006).
Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J. Leukoc. Biol. 76: 227-236 (2004). *
Akar N, Hasipek M, Ozturk A, Akar E, Tekin M. Serum amyloid A1 -13 T/C alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. J. Nephrol. 19: 318-321 (2006).
Akasaka Y, Abe K, Sato T, Inoue H. Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis. Neuropeptides 39: 467-474 (2005). *
Akhavani MA, Larsen H, Paleolog E. Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand. J. Rheumatol. 36: 83-90 (2007).
Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G, Distler JH. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 60: 1129-1136 (2009). *
Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. 57: 837-844 (2007). *
Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113: 1328-1333 (2004). *
Akisu C, Delibas SB, Ozkoc S. Evaluation of three different ELISA kits for the diagnosis of trichinellosis. Mikrobiyol. Bul. 39: 325-331 (2005).
Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL, Epplen JT. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int. J. Immunogenet. 33: 59-61 (2006). *
Akkari R, Burbiel JC, Hockemeyer J, Muller CE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr. Top. Med. Chem. 6: 1375-1399 (2006).
Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract. Res. Clin. Rheumatol. 20: 539-557 (2006).
Akkurt MO, Bektaser B, Ocguder A, Oguz T, Solak S. An unusual complication of familial Mediterranean fever: protracted arthritis with bilateral coxarthrosis and intraosseous amyloidosis of femoral head. Mod. Rheumatol. 15: 358-360 (2005).
Akritidis N, Papadopoulos A, Pappas G. Long-term follow-up of patients with adult-onset Still's disease. Scand. J. Rheumatol. 35: 395-397 (2006). *
Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56: 1273-1285 (2007). *
Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O'Shea JJ, Kastner DL. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 69: 301-314 (2001). *
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360: 2426-2437 (2009). *
Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46: 3340-3348 (2002). *
Al-Arfaj A. HLA-DR pattern of rheumatoid arthritis in Saudi Arabia. Ann. Saudi Med. 21: 92-93 (2001).
Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol. Int. 27: 1119-1123 (2007). *
Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A. Frequency of abnormal thyroid function tests in Kuwaiti arabs with autoimmune diseases. Med. Princ. Pract. 17: 61-65 (2008).
Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A. Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome and Graves' disease. Singapore Med. J. 48: 847-849 (2007). *
Al-Awadi A, Olusi SO, Al-Zaid N, Prabha K. Serum B2-microglobulin concentration correlates with urinary concentrations of type 1 collagen cross-linked N-telopeptides and deoxypyridinoline in rheumatoid arthritis. Ann. Saudi Med. 18: 113-116 (1998).
Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, McHugh N. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford) 41: 525-530 (2002). *
al-Jarallah KF, Singal DP, Buchanan WW. Immunogenetics of psoriatic arthritis. Immunol. Invest. 22: 81-86 (1993).
Al-Mayouf SM. Familial arthropathy in Saudi Arabian children: demographic, clinical, and biochemical features. Semin. Arthritis Rheum. 36: 256-261 (2007). *
Al-Mayouf SM, Al-Sonbul A, Al Jumaah S, Al-Hemidan A. Sarcoidosis: a delayed or missed diagnosis in children. Ann. Saudi Med. 26: 220-223 (2006).
Al-Shukaili AK, Al-Jabri AA. Rheumatoid arthritis, cytokines and hypoxia. What is the link? Saudi Med. J. 27: 1642-1649 (2006).
Al-Swailem R, Al-Rayes H, Sobki S, Arfin M, Tariq M. HLA-DRB1 association in Saudi rheumatoid arthritis patients. Rheumatol. Int. 26: 1019-1024 (2006). *
Al-Wahadneh AM, Dahabreh MM. Familial mediterranean fever in children: a single centre experience in Jordan. East. Mediterr. Health J. 12: 818-823 (2006).
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin. Arthritis Rheum. 36: 182-188 (2006). *
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J. Rheumatol. 35: 1354-1358 (2008). *
Alamoudi OS. Sleep-disordered breathing in patients with acquired retrognathia secondary to rheumatoid arthritis. Med. Sci. Monit. 12: CR530-CR534 (2006). *
Alansari A, Gul A, Inanc M, Ordi J, Teh LS, Ollier WE, Gonzalez-Gay MA, Hajeer AH. Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus. Saudi Med. J. 25: 1445-1448 (2004).
Alarcon GS. Psoriatic arthritis, methotrexate, and liver toxicity. J. Clin. Rheumatol. 7: 213-214 (2001).
Alarcon-Riquelme ME. Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus. Arthritis Res. Ther. 6: 169-173 (2004). *
Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52: 1138-1147 (2005). *
Alavi A, Axford JS. The pivotal nature of sugars in normal physiology and disease. Wien. Med. Wochenschr. 156: 19-33 (2006).
Alayli G, Kara N, Tander B, Canturk F, Gunes S, Bagci H. Association of transforming growth factor beta1 gene polymorphism with rheumatoid arthritis in a Turkish population. Joint Bone Spine 76: 20-23 (2009). *
Albani S, Roudier J. Molecular basis for the association between HLA DR4 and rheumatoid arthritis. From the shared epitope hypothesis to a peptidic model of rheumatoid arthritis. Clin. Biochem. 25: 209-212 (1992).
Albers HM, Kurreeman FA, Stoeken-Rijsbergen G, Brinkman DM, Kamphuis SS, van Rossum MA, Girschick HJ, Wouters C, Saurenmann RK, Hoppenreijs E, Slagboom P, Houwing-Duistermaat JJ, Verduijn W, Huizinga TW, Ten Cate R, Toes RE, Schilham MW. Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis. Arthritis Rheum. 60: 901-904 (2009). *
Albert D, Clarkin C, Komoroski J, Brensinger CM, Berlin JA. Wegener's granulomatosis: possible role of environmental agents in its pathogenesis. Arthritis Rheum. 51: 656-664 (2004). *
Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 105: 15005-15009 (2008). *
Albrecht J, Atzeni F, Baldini C, Bombardieri S, Dalakas MC, Demirkesen C, Yazici H, Mat C, Werth VP, Sarzi-Puttini P. Skin involvement and outcome measures in systemic autoimmune diseases. Clin. Exp. Rheumatol. 24: S52-S59 (2006).
Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, Lionaki S, Reddy CB, Chin H, Dempsey AA, Jennette JC, Falk RJ. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int. 72: 853-864 (2007).
Alemany-Rodriguez MJ, Aladro Y, Amela-Peris R, Perez-Vieitez MC, Reyes-Yanez MP, Deniz-Naranjo MC, Sanchez-Garcia F. Autoimmune diseases and multiple sclerosis. Rev. Neurol. 40: 594-597 (2005).
Alenius GM. Psoriatic arthritis - new insights give new options for treatment. Curr. Med. Chem. 14: 359-366 (2007).
Alenius GM, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin. Exp. Rheumatol. 27: 120-123 (2009).
Alenius GM, Friberg C, Nilsson S, Wahlstrom J, Dahlqvist SR, Samuelsson L. Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis. J. Rheumatol. 31: 2230-2235 (2004). *
Alese OB, Irabor DO. Pyoderma gangrenosum and ulcerative colitis in the tropics. Rev. Soc. Bras. Med. Trop. 41: 664-667 (2008). *
Alessandri C, Priori R, Modesti M, Mancini R, Valesini G. The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clin. Rev. Allergy Immunol. 34: 45-49 (2008). *
Alessandri C, Sorice M, Bombardieri M, Conigliaro P, Longo A, Garofalo T, Manganelli V, Conti F, Esposti ED, Valesini G. Anti-phospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res. Ther. 8: R180 (2006). *
Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis Res. Ther. 11: 112 (2009).
Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 56: 3226-3235 (2007). *
Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23: S100-S108 (2005).
Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum. Dis. Clin. North Am. 32: 9-44 (2006).
Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin. Exp. Rheumatol. 24: S045-S051 (2006). *
Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br. J. Dermatol. Jun 4 [Epub ahead of print] (2009).
Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet. Disord. 8: 37 (2007). *
Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9: 296-302 (2005).
Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 36: 2768-2780 (2006). *
Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2005). *
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2003). *
Alfredo CS, Nunes NA, Len CA, Barbosa CM, Terreri MT, Hilario MO. Henoch-Shonlein purpura: recurrence and chronicity. J. Pediatr. (Rio J.) 83: 177-180 (2007).
Ali AA, Moatter T, Baig JA, Iqbal A, Hussain A, Iqbal MP. Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate - a hospital-based study. J. Pak. Med. Assoc. 56: 452-456 (2006).
Ali M, Manolios N. Proteomics in rheumatology: a new direction for old diseases. Semin. Arthritis Rheum. 35: 67-76 (2005). *
Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 56: 2708-2714 (2007). *
Alizadeh BZ, Valdigem G, Coenen MJ, Zhernakova A, Franke B, Monsuur A, van Riel PL, Barrera P, Radstake TR, Roep BO, Wijmenga C, Koeleman BP. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum. Mol. Genet. 16: 2552-2559 (2007). *
Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin. Exp. Rheumatol. 25: 60-66 (2007).
Allanore Y, Seror R, Chevrot A, Kahan A, Drape JL. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum. 56: 2747-2754 (2007). *
Allcock RJ, Windsor L, Gut IG, Kucharzak R, Sobre L, Lechner D, Garnier JG, Baltic S, Christiansen FT, Price P. High-density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging. Hum. Mutat. 24: 517-525 (2004).
Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F. Targeting C5a: recent advances in drug discovery. Curr. Med. Chem. 12: 217-236 (2005).
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358: 221-230 (2008). *
Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis. Immunogenetics 50: 220-227 (1999).
Allen RL, Trowsdale J. Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors. Curr. Mol. Med. 4: 59-65 (2004).
Allen-Brady K, Horne BD, Malhotra A, Teerlink C, Camp NJ, Thomas A. Analysis of high-density single-nucleotide polymorphism data: three novel methods that control for linkage disequilibrium between markers in a linkage analysis. BMC Proc. 1 Suppl. 1: S160 (2007). *
Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 23-32 (2009).
Alonso D, Elgart GW, Schachner LA. Blau syndrome: a new kindred. J. Am. Acad. Dermatol. 49: 299-302 (2003).
Alonso-Ruiz A, Pijoan JI, Ansuategui E, Calabozo M, Urkaregi A, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet. Disord. 9: 52 (2008). *
Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis. Rheumatol. Int. 27: 865-868 (2007). *
Aloysius MM, Kaye PV, Lobo DN. Non-steroidal anti-inflammatory drug (NSAID)-induced colonic strictures and perforation: a case report. Dig. Liver Dis. 38: 276-278 (2006).
Alpers DH. The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr. Opin. Gastroenterol. 18: 203-208 (2002).
Alpigiani MG, Haupt R, Parodi S, Calcagno A, Poggi E, Lorini R. Coeliac disease in 108 patients with juvenile idiopathic arthritis: a 13-year follow-up study. Clin. Exp. Rheumatol. 26: 162 (2008).
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).
Alsaeid K, Alawadhi A, Al-Saeed O, Haider MZ. Human leukocyte antigen DRB1*04 is associated with rheumatoid arthritis in Kuwaiti patients. Joint Bone Spine 73: 62-65 (2006). *
Alsaeid K, Haider MZ, Ayoub EM. Angiotensin converting enzyme gene insertion-deletion polymorphism is associated with juvenile rheumatoid arthritis. J. Rheumatol. 30: 2705-2709 (2003).
Alsaeid K, Haider MZ, Sharma PN, Ayoub EM. The prevalence of human leukocyte antigen (HLA) DR/DQ/DP alleles in Kuwaiti children with oligoarticular juvenile idiopathic arthritis. Rheumatol. Int. 26: 224-228 (2006). *
Alsaeid KM, Haider MZ, al-Awadhi AM, Srivastva BS, Ayoub EM. Role of human leukocyte antigen DRB1*0307 and DRB1*0308 in susceptibility to juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 21: 399-402 (2003).
Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg JE, Sibilia J, Wachsmann D. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum. 56: 3202-3214 (2007). *
Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand. J. Rheumatol. 37: 155-157 (2008).
Alter M, Wittmann M, Volker B, Kapp A, Werfel T, Gutzmer R. Successful treatment of pemphigus foliaceus with rituximab: report of 3 cases. Hautarzt. Jan 18 [Epub ahead of print] (2009).
Althoff CE, Hermann KG, Braun J, Sieper J. Ankylosing spondylitis - current state of imaging including scoring methods. Z. Rheumatol. 65: 688-699 (2006).
Altindag O, Karakoc M, Kocyigit A, Celik H, Soran N. Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin. Biochem. 40: 167-171 (2007). *
Altobelli E, Maccarone M, Petrocelli R, Marziliano C, Giannetti A, Peris K, Chimenti S. Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health 7: 59 (2007). *
Altomare G, Ayala F, Berardesca E, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Peserico A, Guerra AP, Vena GA. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol. Ther. 21 Suppl. 2: S1-S14 (2008).
Altschuler EL, Kast RE. Bupropion for Blau syndrome. Med. Hypotheses 62: 297-298 (2004).
Altuwaijri S, Chuang KH, Lai KP, Lai JJ, Lin HY, Young FM, Bottaro A, Tsai MY, Zeng WP, Chang HC, Yeh S, Chang C. Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells. Mol. Endocrinol. 23: 444-453 (2009). *
Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R. Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 27: 110-118 (2006).
Alvarez I, Collado J, Daura X, Colome N, Rodriguez-Garcia M, Gallart T, Canals F, Jaraquemada D. The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401). Arthritis Rheum. 58: 1630-1639 (2008). *
Alvarez Madrid C, Gonzalez Fernandez A, Lisbona Munoz M, Molina Rodriguez MA, Merino Munoz R, Garcia-Consuegra Molina J. Thyroid disorders and childhood rheumatic diseases. An. Pediatr. (Barc.) 70: 53-56 (2009).
Alvarez-Rodriguez L, Carrasco E, Lopez-Hoyos M, Mata C, Fernandez-Prieto L, Ruiz-Soto M, Calvo J, Rodriguez-Valverde V, Ruiz T, Blanco R, Corrales A, Martinez-Taboada VM. Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: association of IL-1RN*2/2 genotype with polymyalgia rheumatica. Hum. Immunol. 70: 49-54 (2009).
Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther. Clin. Risk Manag. 4: 345-351 (2008).
Amano K. Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy. Intern. Med. 45: 991-992 (2006). *
Amano K. Biological agents. Nippon Rinsho 67: 593-598 (2009).
Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL, Godessart N. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br. J. Pharmacol. 149: 666-575 (2006). *
Ambrose NL, O Connell PG. Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis. Clin. Exp. Rheumatol. 25: 660 (2007).
Ambrosio C, Alexandre M, Malcata A. Sternoclavicular joint in psoriatic arthritis. Acta Reumatol. Port. 34: 138 (2009).
Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K. Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J. Gastroenterol. 41: 444-449 (2006). *
Amengual O, Atsumi T, Komano Y, Kataoka H, Horita T, Yasuda S, Koike T. A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus. Arthritis Rheum. 56: 2803-2805 (2007). *
Amer R, Bamonte G, Forrester JV. Resolution of juvenile idiopathic arthritis-associated uveitis after development of common variable immunodeficiency. Eur. J. Ophthalmol. 17: 666-668 (2007).
American Academy of Family Physicians. Information from your family doctor. Rheumatoid arthritis: what you should know. Am. Fam. Physician 72: 1049-1050 (2005).
Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut 55: 1059-1060 (2006). *
Amezcua-Guerra LM, Prieto P, Bojalil R, Pineda C, Amigo MC. Microscopic polyangiitis associated with primary biliary cirrhosis: a causal or casual association? J. Rheumatol. 33: 2351-2353 (2006).
Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gomez-Garcia L, Vargas A, Bojalil R. Presence of antibodies against cyclic citrullinated peptides (anti-CCP) in patients with rhupus: a cross-sectional study. Arthritis Res. Ther. 8: R144 (2006). *
Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C. Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. Bone 44: 1143-1150 (2009).
Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl. Acad. Sci. U.S.A. 93: 14014-14019 (1996). *
Amin EA, Welsh WJ. A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors. J. Chem. Inf. Model. 46: 2104-2109 (2006). *
Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 56: 1787-1797 (2007). *
Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 43: 658-661 (2004). *
Amital H, Barak V, Winkler RE, Rubinow A. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann. N. Y. Acad. Sci. 1110: 649-660 (2007). *
Amital H, Gershwin EM, Shoenfeld Y. Reshaping the mosaic of autoimmunity. Semin. Arthritis Rheum. 35: 341-343 (2006). *
Amital H, Govoni M, Maya R, Meroni PL, Ori B, Shoenfeld Y, Tincani A, Trotta F, Sarzi-Puttini P, Atzeni F. Role of infectious agents in systemic rheumatic diseases. Clin. Exp. Rheumatol. 26: S27-S32 (2008).
Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF. Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice. Clin. Vaccine Immunol. 13: 289-296 (2006). *
Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 72: 1100-1116 (2006).
Amoroso P, Vergani D, Wojcicka BM, McFarlane IG, Eddleston AL, Tee DE, Williams R. Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis. Clin. Exp. Immunol. 42: 95-98 (1980). *
Amos CI, Chen WV, Lee A, Li W, Kern M, Lundsten R, Batliwalla F, Wener M, Remmers E, Kastner DA, Criswell LA, Seldin MF, Gregersen PK. High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun. 7: 277-286 (2006). *
Amos CI, Chen WV, Remmers E, Siminovitch KA, Seldin MF, Criswell LA, Lee AT, John S, Shephard ND, Worthington J, Cornelis F, Plenge RM, Begovich AB, Dyer TD, Kastner DL, Gregersen PK. Data for Genetic Analysis Workshop (GAW) 15 Problem 2, genetic causes of rheumatoid arthritis and associated traits. BMC Proc. 1 Suppl. 1: S3 (2007). *
Amoura Z, Dode C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, Grateau G, Wechsler B, Piette JC. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis Rheum. 52: 608-611 (2005). *
Amria S, Hajiaghamohseni LM, Harbeson C, Zhao D, Goldstein O, Blum JS, Haque A. HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition. Eur. J. Immunol. 38: 1961-1970 (2008). *
Amu S, Stromberg K, Bokarewa M, Tarkowski A, Brisslert M. CD25-expressing B-lymphocytes in rheumatic diseases. Scand. J. Immunol. 65: 182-191 (2007). *
Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M. The human immunomodulatory CD25(+) B cell population belongs to the memory B cell pool. Scand. J. Immunol. 66: 77-86 (2007). *
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4: 807-818 (2007). *
Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of adalimumab on joint disease features of patients with psoriatic arthritis detected by magnetic resonance imaging. Ann. Rheum. Dis. Feb 9 [Epub ahead of print] (2009).
Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J. Cell. Biochem. 97: 226-232 (2006). *
Ananthakrishna R, Goel R, Padhan P, Mathew J, Danda D. Relapsing polychondritis: case series from South India. Clin. Rheumatol. 28 Suppl. 1: S7-S10 (2009).
Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M. Rheumatoid arthritis association in Colombian population is restricted to HLA-DRB1*04 QRRAA alleles. Genes Immun. 3: 56-58 (2002). *
Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M. TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjogren's syndrome. Semin. Arthritis Rheum. 31: 396-405 (2002). *
Anaya JM, Correa PA, Mantilla RD, Jimenez F, Kuffner T, McNicholl JM. Rheumatoid arthritis in African Colombians from Quibdo. Semin. Arthritis Rheum. 31: 191-198 (2001). *
Anaya JM, Mantilla RD, Correa PA. Immunogenetics of primary Sjogren's syndrome in Colombians. Semin. Arthritis Rheum. 34: 735-743 (2005). *
Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sjogren's syndrome. J. Rheumatol. 33: 2227-2234 (2006).
Ancuta C, Ancuta E, Iordache C, Ceausu M, Chirieac R. Immunohistochemical study of skeletal muscle in rheumatoid myositis. Rom. J. Morphol. Embryol. 50: 223-227 (2009).
Anders HJ, Zecher D, Pawar RD, Patole PS. Molecular mechanisms of autoimmunity triggered by microbial infection. Arthritis Res. Ther. 7: 215-224 (2005). *
Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J. Leukoc. Biol. 85: 243-250 (2009). *
Anderson DW. Cytokines as drug targets. IDrugs 4: 375-377 (2001).
Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4: 314-320 (2004).
Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, Berndt SI, Ricker W, Parsons R, Engels EA. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int. J. Cancer 125: 398-405 (2009). *
Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br. J. Cancer 100: 822-828 (2009).
Anderson P, Phillips K, Stoecklin G, Kedersha N. Post-transcriptional regulation of proinflammatory proteins. J. Leukoc. Biol. 76: 42-47 (2004). *
Andersson A. Genetic control of disease in an experimental model for Sjogren's syndrome. Arthritis Res. Ther. 11: 102 (2009).
Andersson A, Kokkola R, Wefer J, Erlandsson-Harris H, Harris RA. Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility. J. Leukoc. Biol. 76: 1118-1124 (2004). *
Andersson AK, Feldmann M, Brennan FM. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand. J. Immunol. 68: 103-111 (2008). *
Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res. Ther. 10: 204 (2008). *
Andersson EC, Svendsen P, Svejgaard A, Holmdahl R, Fugger L. A molecule basis for the HLA association in rheumatoid arthritis. Rev. Immunogenet. 2: 81-87 (2000).
Andersson IE, Dzhambazov B, Holmdahl R, Linusson A, Kihlberg J. Probing molecular interactions within class II MHC A(q)/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J. Med. Chem. 50: 5627-5643 (2007). *
Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach EM. CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J. Exp. Med. 205: 1975-1981 (2008). *
Andersson M, Svenungsson E, Khademi M, Lampa J, Brundin L, Wallstrom E. No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab. Ann. Rheum. Dis. 65: 1237-1240 (2006). *
Andersson ML, Petersson IF, Karlsson K, Jonsson NE, Mansson B, Heinegard D, Saxne T. Diurnal variation in serum levels of cartilage oligomeric matrix protein (COMP) in individuals with knee osteoarthritis or rheumatoid arthritis. Ann. Rheum. Dis. 65: 1490-1494 (2006). *
Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. J. Intern. Med. 255: 344-350 (2004). *
Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72: 1084-1091 (2002). *
Andersson U, Tracey KJ. HMGB1 in sepsis. Scand. J. Infect. Dis. 35: 577-584 (2003).
Andersson U, Tracey KJ. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum. Dis. Clin. North Am. 30: 627-637, xi (2004).
Andersson UG, Tracey KJ. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J. Intern. Med. 255: 318-319 (2004). *
Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA, Moutsopoulos HM. Sjogren's syndrome in systemic lupus erythematosus. J. Rheumatol. 17: 201-204 (1990).
Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 56: 622-630 (2007). *
Andreakos E. Common and uncommon features of rheumatoid arthritis and chronic obstructive pulmonary disease: clues to a future therapy. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 85-92 (2004).
Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol. Rev. 202: 250-265 (2004). *
Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum. 60: 994-1005 (2009). *
Andreakos E, Sacre S, Foxwell BM, Feldmann M. The Toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front. Biosci. 10: 2478-2488 (2005).
Andreas K, Haupl T, Lubke C, Ringe J, Morawietz L, Wachtel A, Sittinger M, Kaps C. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res. Ther. 11: R15 (2009). *
Andreas K, Luebke C, Haeupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res. Ther. 10: R9 (2008). *
Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, Engelman DM, Reshetnyak YK. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc. Natl. Acad. Sci. U.S.A. 104: 7893-7898 (2007). *
Andren M, Johanneson B, Alarcon-Riquelme ME, Kleinau S. IgG Fc receptor polymorphisms and association with autoimmune disease. Eur. J. Immunol. 35: 3020-3029 (2005). *
Andreoli L, Malacarne F, Ceribelli A, Kutschera I, Tincani A. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. Ann. N. Y. Acad. Sci. 1109: 531-537 (2007). *
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436 (2003).
Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J. Rheumatol. 30: 2315-2318 (2003).
Angotti C. Arthritis and skin disease. Skinmed. 4: 293-297 (2005).
Angulo JM, Sigal LH, Espinoza LR. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin. Arthritis Rheum. 28: 187-192 (1998). *
Angyal A, Prechl J, Sarmay G. Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases. Expert Opin. Biol. Ther. 7: 691-704 (2007).
Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper cells - origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. May 12 [Epub ahead of print] (2009).
Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol. Res. Apr 7 [Epub ahead of print] (2009). *
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180: 688-692 (2008). *
Anshu A, Chee SP. Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica 221: 275-278 (2007).
Antol�n J, Azahara M, Hernandez C, Blanco M, Mao L, Ciguenza R. Tuberculous peritonitis after treatment with adalimumab. Scand. J. Infect. Dis. 40: 677-678 (2008).
Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 41: 537-542 (2008).
Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Exp. Rheumatol. 26: S39-S47 (2008).
Antonelli A, Sedie AD, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J. Rheumatol. 33: 2026-2028 (2006).
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52: 1227-1236 (2005). *
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). J. Rheumatol. 35: 869-876 (2008).
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, Boumpas DT. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin. Exp. Rheumatol. 25: 23-28 (2007).
Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin. Investig. Drugs 15: 181-184 (2006).
Antoniu SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab? Curr. Opin. Investig. Drugs 8: 927-932 (2007).
Antoniv TT, Ivashkiv LB. Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 54: 2711-2721 (2006). *
Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J. Rheumatol. 33: 647-651 (2006).
Anzilotti C, Riente L, Pratesi F, Chimenti D, Sedie AD, Bombardieri S, Migliorini P. IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders. Rheumatology (Oxford) 46: 1579-1582 (2007). *
Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180-1184 (2009). *
Apan TZ, Gursel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Behcet's disease. Clin. Rheumatol. 26: 885-889 (2007). *
Appel H, Kuon W, Kuhne M, Wu P, Kuhlmann S, Kollnberger S, Thiel A, Bowness P, Sieper J. Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Arthritis Res. Ther. 6: R521-R534 (2004). *
Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O. Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Intern. Med. 46: 605-609 (2007). *
Araico A, Terencio MC, Alcaraz MJ, Dominguez JN, Leon C, Ferrandiz ML. Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor. Life Sci. 80: 2108-2117 (2007). *
Arakaki O, Yamamoto Y, Awazawa R, Nonaka K, Taira K, Asato Y, Hagiwara K, Oyama B, Ishii N, Hashimoto T, Uezato H. Case of linear immunoglobulin A bullous dermatosis associated with acquired hemophilia. J. Dermatol. 35: 437-446 (2008).
Araujo EP, De Souza CT, Ueno M, Cintra DE, Bertolo MB, Carvalheira JB, Saad MJ, Velloso LA. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 148: 5991-5997 (2007). *
Arbour L, Rupps R, Field L, Ross P, Erikson A, Henderson H, Hill W, Yoshida E. Characteristics of primary biliary cirrhosis in British Columbia's First Nations population. Can. J. Gastroenterol. 19: 305-310 (2005).
Archer JR. Search for cross-reactivity between HLA B27 and Klebsiella pneumoniae. Ann. Rheum. Dis. 40: 400-403 (1981). *
Ardigo M, Giuliani A, de Felice C, Mastroianni A, Berardesca E. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. J. Drugs Dermatol. 7: 935-939 (2008).
Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res. Ther. 10: 218 (2008). *
Ardoin SP, Pisetsky DS. The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation. Mod. Rheumatol. 18: 319-326 (2008). *
Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. 61: 111-119 (2003). *
Arend WP. The mode of action of cytokine inhibitors. J. Rheumatol. Suppl. 65: 16-21 (2002).
Aries PM, Witte T, Lamprecht P. Report on the 34th Meeting of the German Clinical Immunology Workgroup, Frankfurt, 03.-04.11.2006. Z. Rheumatol. 66: 63-64 (2007).
Arii K, Kumon Y, Sugahara K, Nakatani K, Ikeda Y, Suehiro T, Hashimoto K. Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B. Mol. Immunol. 45: 463-469 (2008). *
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169 (2004). *
Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res. Ther. 10: 202 (2008). *
Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin. Drug Saf. 7: 411-419 (2008).
Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56: 274-279 (2007). *
Aristodemou P, Stanford M. Therapy insight: the recognition and treatment of retinal manifestations of systemic vasculitis. Nat. Clin. Pract. Rheumatol. 2: 443-451 (2006). *
Arita K, Shimizu T, Hashimoto H, Hidaka Y, Yamada M, Sato M. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl. Acad. Sci. U.S.A. 103: 5291-5396 (2006). *
Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Omega-3 fatty acids in rheumatoid arthritis: an overview. Semin. Arthritis Rheum. 27: 366-370 (1998).
Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 46: 529-532 (2007). *
Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol. Int. 28: 205-215 (2008). *
Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 99: 2694-2702 (2002). *
Arlestig L, Wallberg Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S. Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25: 866-871 (2007).
Armagan O, Ekim A, Dinc A, Oner C. Ankylosing spondylitis in a patient with Turner syndrome: a case report. Rheumatol. Int. 27: 1177-1180 (2007). *
Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205: 331-337 (2008). *
Arman A, Yilmaz B, Coker A, Inanc N, Direskeneli H. Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 643-648 (2006).
Arnett FC, Hamilton RG, Reveille JD, Bias WB, Harley JB, Reichlin M. Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum. 32: 413-419 (1989).
Arnett HA, Viney JL. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. Adv. Drug Deliv. Rev. 59: 1084-1092 (2007).
Arnold JN, Dwek RA, Rudd PM, Sim RB. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol. Lett. 106: 103-110 (2006).
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25: 21-50 (2007). *
Arostegui JI, Aldea A, Modesto C, Rua MJ, Arguelles F, Gonzalez-Ensenat MA, Ramos E, Rius J, Plaza S, Vives J, Yague J. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum. 50: 4045-4050 (2004). *
Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, Garcia-Consuegra J, Naranjo A, Ramos E, de Paz P, Rius J, Plaza S, Yague J. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 56: 3805-3813 (2007). *
Arostegui JI, Yague J. Hereditary systemic autoinflammatory diseases. Part II: cryopyrin-associated periodic syndromes, pediatric systemic granulomatosis and PAPA syndrome. Med. Clin. (Barc.) 130: 429-438 (2008).
Arrington JL, McMurray DN, Switzer KC, Fan YY, Chapkin RS. Docosahexaenoic acid suppresses function of the CD28 costimulatory membrane receptor in primary murine and Jurkat T cells. J. Nutr. 131: 1147-1153 (2001). *
Artac H, Bozkurt B, Talim B, Reisli I. Sarcoid-like granulomas in common variable immunodeficiency. Rheumatol. Int. Mar 27 [Epub ahead of print] (2009). *
Artlett CM, O'Hanlon TP, Lopez AM, Song YW, Miller FW, Rider LG. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum. 48: 2567-2572 (2003). *
Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).
Arvidson NG, Larsen A, Aaseth J, Larsson A. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. Scand. J. Clin. Lab. Invest. 67: 337-342 (2007). *
Asada Y, Isomoto H, Shikuwa S, Wen CY, Fukuda E, Miyazato M, Okamoto K, Nakamura T, Nishiyama H, Mizuta Y, Migita K, Ito M, Kohno S. Development of ulcerative colitis during the course of rheumatoid arthritis: association with selective IgA deficiency. World J. Gastroenterol. 12: 5240-5243 (2006). *
Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H. Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis. Science 319: 624-627 (2008). *
Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses. J. Dermatolog. Treat. 19: 318-326 (2008).
Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, Tamaki K. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br. J. Dermatol. 155: 330-336 (2006). *
Aseni P, Di Sandro S, Mihaylov P, Lamperti L, De Carlis LG. Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone. World J. Gastroenterol. 14: 5471-5473 (2008). *
Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, Yoshida T. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur. J. Pharmacol. 558: 199-207 (2007). *
Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin. Rheumatol. 27: 261-264 (2008). *
Ashok D, Kiely P. Bowel associated dermatosis - arthritis syndrome: a case report. J. Med. Case Reports 1: 81 (2007). *
Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Coster L, Jacobsson L, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann. Rheum. Dis. 68: 648-653 (2009).
Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20: 334-339 (2008).
Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20: 138-144 (2008).
Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin. Rheumatol. 27: 377-380 (2008). *
Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251 (2007). *
Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, Lord JM, Scheel-Toellner D. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum. 56: 1776-1786 (2007). *
Assous N, Gossec L, Dieude P, Meyer O, Dougados M, Kahan A, Allanore Y. Rituximab therapy in rheumatoid arthritis in daily practice. J. Rheumatol. 35: 31-34 (2008).
Astorga G, Cubillos A, Masson L, Silva JJ. Active rheumatoid arthritis: effect of dietary supplementation with omega-3 oils. A controlled double-blind trial. Rev. Med. Chil. 119: 267-272 (1991).
Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, Sieper J. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum. 52: 892-901 (2005). *
Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J. Clin. Rheumatol. 12: 291-293 (2006).
Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin. Rheumatol. 26: 499-504 (2007). *
Ates A, Kinikli G, Turgay M, Akay G, Tokgoz G. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin. Rheumatol. 26: 538-545 (2007). *
Ates A, Kinikli G, Turgay M, Duman M. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin. Rheumatol. 23: 421-425 (2004). *
Ates A, Turkcapar N, Olmez U, Tiryaki O, Duzgun N, Uguz E, Duman M. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol. Int. 27: 715-722 (2007). *
Ates O, Dalyan L, Musellim B, Hatemi G, Turker H, Ongen G, Hamuryudan V, Topal-Sarikaya A. NRAMP1 (SLC11A1) gene polymorphisms that correlate with autoimmune versus infectious disease susceptibility in tuberculosis and rheumatoid arthritis. Int. J. Immunogenet. 36: 15-19 (2009). *
Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. Clin. Rheumatol. 27: 1243-1248 (2008). *
Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol. Rev. 32: 956-973 (2008). *
Atouf O, Benbouazza K, Brick C, Bzami F, Bennani N, Amine B, Hajja-Hassouni N, Essakali M. HLA polymorphism and early rheumatoid arthritis in the Moroccan population. Joint Bone Spine 75: 554-558 (2008). *
Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies-are they worth assaying? Thromb. Res. 114: 533-538 (2004). *
Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML. Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody. J. Autoimmun. 28: 55-58 (2007).
Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, Sarzi-Puttini P. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun. Rev. 8: 431-437 (2009).
Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J. Gastroenterol. 15: 2469-2471 (2009). *
Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P. Infections and treatment of patients with rheumatic diseases. Clin. Exp. Rheumatol. 26: S67-S73 (2008).
Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev. 6: 529-536 (2007).
Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity 41: 87-91 (2008).
Atzeni F, Doria A, Maurizio T, Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun. Rev. 6: 553-558 (2007).
Atzeni F, Sarzi-Puttini P. Early rheumatoid arthritis. Reumatismo 59: 100-117 (2007).
Atzeni F, Sarzi-Puttini P, Deportu S, Cutolo M, Carrabba M, Straub RH. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin. Exp. Rheumatol. 26: 103-108 (2008).
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4: 144-152 (2005).
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 1051: 559-569 (2005). *
Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, Weiss A. The structure, regulation, and function of ZAP-70. Immunol. Rev. 228: 41-57 (2009). *
Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C, Offner H. A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells. Ann. N. Y. Acad. Sci. 1110: 630-640 (2007). *
Aud D, Peng SL. Mechanisms of disease: transcription factors in inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 2: 434-442 (2006). *
Audo R, Combe B, Coulet B, Morel J, Hahne M. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ. May 1 [Epub ahead of print] (2009).
Audrain MA, Gourbil A, Muller JY, Esnault LM. Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. J. Autoimmun. 9: 569-574 (1996).
Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56: 1175-1186 (2007). *
Auger I, Ragni E, Reviron D, Rossi D, Roudier J. Immune response to 70 kD heat shock proteins and rheumatoid arthritis: implication of HLA-DRB1*0401. Clin. Exp. Rheumatol. 25: 933-934 (2007).
Auger I, Roudier C, Guis S, Balandraud N, Roudier J. HLA-DRB1*0404 is strongly associated with anti-calpastatin antibodies in rheumatoid arthritis. Ann. Rheum. Dis. 66: 1588-1593 (2007).
Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum. 52: 3424-3432 (2005). *
Aune TM, Maas K, Moore JH, Olsen NJ. Gene expression profiles in human autoimmune disease. Curr. Pharm. Des. 9: 1905-1917 (2003).
Aune TM, Maas K, Parker J, Moore JH, Olsen NJ. Profiles of gene expression in human autoimmune disease. Cell. Biochem. Biophys. 40: 81-96 (2004).
Avalos P, Camacho FM. Practical management of adalimumab. Actas. Dermosifiliogr. 99 Suppl. 3: 25-27 (2008).
Aversano M, Caiazzo P, Iorio G, Ponticiello L, Lagana B, Leccese F. Improvement of chronic idiopathic urticaria with L-thyroxine: a new TSH role in immune response? Allergy 60: 489-493 (2005). *
Avila-Portillo LM, Vargas-Alarcon G, Andrade F, Alarcon-Segovia D, Granados J. Linkage disequilibrium of HLA-DR3 and HLA-DR4 with HLA-B alleles in Mexican patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 12: 497-502 (1994).
Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum. 58: 119-129 (2007). *
Avnon LS, Abu-Shakra M, Flusser D, Heimer D, Sion-Vardy N. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate? Rheumatol. Int. 27: 919-925 (2007). *
Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin. Pharmacother. 9: 1121-1128 (2008).
Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-CCP (cyclic citrullinated protein) antibodies in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 65: 845-851 (2006). *
Avriel A, Zeller L, Flusser D, Abu Shakra M, Halevy S, Sukenik S. Coexistence of psoriatic arthritis and systemic lupus erythematosus. Isr. Med. Assoc. J. 9: 48-49 (2007). *
Awale M, Mohan CG. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase. J. Mol. Model. 14: 937-947 (2008).
Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67: 1603-1609 (2008).
Aydin G, Keles I, Atalar E, Orkun S. Extensive erosive arthropathy in a patient with Behcet's disease: case report. Clin. Rheumatol. 24: 645-647 (2005).
Aydinli B, Ozturk G, Balik AA, Aslan S, Erdogan F. Spontaneous rupture of the spleen in secondary amyloidosis: a patient with rheumatoid arthritis. Amyloid 13: 160-163 (2006).
Aydog E, Yesilli O, Sever A, Usan H. Dermatitis herpetiformis and rheumatoid arthritis. Saudi Med. J. 27: 881-884 (2006).
Ayer LM, Rubin RL, Dixon GH, Fritzler MJ. Antibodies to HMG proteins in patients with drug-induced autoimmunity. Arthritis Rheum. 37: 98-103 (1994).
Azar D, Martin F. Paediatric uveitis: a Sydney clinic experience. Clin. Experiment. Ophthalmol. 32: 468-471 (2004).
Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum. Med. J. Malaysia 63: 51-54 (2008).
Azuma T, Ishimaru H, Hatta K, Kori Y. Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis. Mod. Rheumatol. 17: 253-255 (2007). *
B'chir Hamzaoui S, Harmel A, Bouslama K, Abdallah M, Ennafaa M, M'rad S, Ben Dridi M; le groupe tunisien d'etude sur la maladie de Behcet. Behcet's disease in Tunisia. Clinical study of 519 cases. Rev. Med. Interne. 27: 742-750 (2006).
Babic-Naglic D. Early rheumatoid arthritis. Reumatizam 55: 26-33 (2008).
Babyn P, Doria AS. Radiologic investigation of rheumatic diseases. Pediatr. Clin. North Am. 52: 373-411 (2005).
Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O. Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behcet's disease. Clin. Exp. Dermatol. 31: 699-701 (2006). *
Bache I, Nielsen NM, Rostgaard K, Tommerup N, Frisch M. Autoimmune diseases in a Danish cohort of 4,866 carriers of constitutional structural chromosomal rearrangements. Arthritis Rheum. 56: 2402-2409 (2007). *
Bacher S, Schmitz ML. The NF-kappa B pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10: 2827-2837 (2004).
Bachmeyer C, Rohaut B. Sarcoidosis mimicking rheumatoid arthritis. Presse. Med. 35: 623-624 (2006).
B�ckdahl L, Guo JP, Jagodic M, Becanovic K, Ding B, Olsson T, Lorentzen JC. Definition of arthritis candidate risk genes by combining rat linkage-mapping results with human case control association data. Ann. Rheum. Dis. Dec 9 [Epub ahead of print] (2008). *
Badelon I. Eye and spondylarthropathies. Rev. Prat. 49: 1995-1998 (1999).
Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ, Durez P, Houssiau FA, Lauwerys BR. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res. Ther. 11: R57 (2009). *
Badsha H, Kong KO, Tak PP. Rheumatoid arthritis in the United Arab Emirates. Clin. Rheumatol. 27: 739-472 (2008). *
Bae E, Kim WJ, Kang YM, Suk K, Koh EM, Cha HS, Ahn KS, Huh TL, Lee WH. Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis. Clin. Exp. Immunol. 148: 410-418 (2007). *
Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr. Opin. Rheumatol. 16: 254-261 (2004).
Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini RM, Feltelius N, Enblad G, Sundstrom C, Klareskog L, Askling J, Rosenquist R. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum. 54: 3774-3781 (2006). *
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54: 692-701 (2006). *
Baerwald CG, Panayi GS, Lanchbury JS. Corticotropin releasing hormone promoter region polymorphisms in rheumatoid arthritis. J. Rheumatol. 24: 215-216 (1997).
Baeten D, De Keyser F, Veys EM, Theate Y, Houssiau FA, Durez P. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann. Rheum. Dis. 63: 489-493 (2004). *
Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum. 58: 730-733 (2008). *
Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyser F. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum. 44: 2255-2262 (2001).
Baeten D, Steenbakkers PG, Rijnders AM, Boots AM, Veys EM, De Keyser F. Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum. 50: 444-451 (2004). *
Bagnato G, De Filippis LG, Caliri A, Bruno A, Gambardella N, Muscatello MR, Cambria R, Zoccali R. Comparation of levels of anxiety and depression in patients with autommune and chronic-degenerative rheumatic: preliminary data. Reumatismo 58: 206-211 (2006).
Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32: 469-476 (2005).
Baharav E, Mor F, Halpern M, Quintana F, Weinberger A. Tropomyosin-induced arthritis in rats. Clin. Exp. Rheumatol. 25: S86-S92 (2007).
Baharav E, Mor F, Halpern M, Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J. Nutr. 134: 1964-1969 (2004). *
Bai S, Kitaura H, Zhao H, Chen J, Muller JM, Schule R, Darnay B, Novack DV, Ross FP, Teitelbaum SL. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J. Clin. Invest. 115: 2742-2751 (2005). *
Baici A, Muntener K, Willimann A, Zwicky R. Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biol. Chem. 387: 1017-1021 (2006).
Baidoo L, Lichtenstein GR. What next after infliximab? Am. J. Gastroenterol. 100: 80-83 (2005). *
Baier G, Asadullah K, Zugel U. The immunological synapse: kinases in T cell signalling as potential drug targets. Immunol. Lett. 105: 3-5 (2006).
Baig S, Alamgir M. The extrahepatic manifestations of hepatitis B virus. J. Coll. Physicians Surg. Pak. 18: 451-457 (2008).
Baillat D, Leprivier G, Regnier D, Vintonenko N, Begue A, Stehelin D, Aumercier M. Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter. Oncogene 25: 5764-5776 (2006). *
Baines M, Ebringer A. HLA and disease. Mol. Aspects Med. 13: 263-378 (1992).
Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 12: 174-185 (2009).
Bajtner E, Nandakumar KS, Engstrom A, Holmdahl R. Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen. Arthritis Res. Ther. 7: R1148-R1157 (2005). *
Baker DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord. 4: 196-210 (2004). *
Baker KP. BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun. Rev. 3: 368-375 (2004).
Bakland G, Nordvag BY, Nossent HC. Efficacy of anti-tumour necrosis factor alpha therapy with etanercept in chronic polyarthritis. Tidsskr. Nor. Laegeforen. 123: 2561-2564 (2003).
Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Rheum. 53: 850-855 (2005). *
Balaban B, Yasar E, Ozgul A, Dincer K, Kalyon TA. Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis. Rheumatol. Int. 25: 641-644 (2005). *
Balandraud N, Gouret P, Danchin EG, Blanc M, Zinn D, Roudier J, Pontarotti P. A rigorous method for multigenic families' functional annotation: the peptidyl arginine deiminase (PADs) proteins family example. BMC Genomics 6: 153 (2005). *
Balandraud N, Guis S, Baptiste Meynard J, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 57: 762-767 (2007). *
Balandraud N, Roudier J, Roudier C. Epstein-Barr virus and rheumatoid arthritis. Autoimmun. Rev. 3: 362-367 (2004).
Balbir-Gurman A, Guralnik L, Best LA, Vlodavsky E, Yigla M, Menahem Nahir A, Braun-Moscovici Y. Accelerated pulmonary nodulosis and sterile pleural effusion in a patient with psoriatic arthropathy during methotrexate therapy: a case report. J. Clin. Rheumatol. 15: 29-30 (2009).
Balbir-Gurman A, Schapira D, Nahir M. Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis. Semin. Arthritis Rheum. 30: 242-248 (2001). *
Baldassano VF Jr. Ocular manifestations of rheumatic diseases. Curr. Opin. Ophthalmol. 9: 85-88 (1998).
Baldassarre ME, Altomare MA, Fanelli M, Carbone D, Di Bitonto G, Mautone A, Laforgia N. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr. Metab. Immune Disord. Drug Targets 7: 1-5 (2007).
Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am. J. Med. 83: 95-103 (1987).
Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 48: 1408-1413 (2003). *
Balducci-Silano PL, Layrisse ZE. HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population. Associations with other HLA-alleles. J. Autoimmun. 8: 425-437 (1995).
Baldys-Waligorska A, Kusnierz-Cabala B, Huszno B. A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease. Endokrynol. Pol. 57: 536-540 (2006).
Ball R, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW, Braun MM. HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum. 60: 1179-1186 (2009). *
Balog A, Gal J, Gyulai Z, Zsilak S, Mandi Y. Tumour necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis. Acta Microbiol. Immunol. Hung. 51: 263-269 (2004).
Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, Gyulai Z, Mandi Y. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71: 274-280 (2004).
Balsa A, Pascual-Salcedo D, Mart�n J. Antibodies to citrullinated peptides in rheumathoid arthritis. Med. Clin. (Barc.) 128: 668-673 (2007).
Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin. Immunol. 129: 249-255 (2008).
Ban Y, Taniyama M, Tozaki T, Tomita M, Ban Y. Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases. BMC Med. Genet. 1: 1 (2000). *
Ban Y, Tozaki T, Taniyama M, Nakano Y, Yoneyama KI, Ban Y, Hirano T. Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population. Autoimmunity 42: 126-130 (2009).
Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179: 4101-4109 (2007). *
Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 177: 1904-1912 (2006). *
Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm. Venereol. 86: 456-457 (2006).
Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56: 2503-2511 (2007). *
Bank I, Ben-Horin S, Goldstein I, Koltakov A, Langevitz P, Ehrenfeld M, Rosenthal E, Gur H. The effect of blockade of tumor necrosis factor alpha on VLA-1+T-cells in rheumatoid arthritis patients. J. Clin. Immunol. 27: 580-588 (2007). *
Bankhurst AD, Nunez SE, Draeger HT, Kettwich SC, Kettwich LG, Sibbitt WL Jr. A randomized controlled trial of the reciprocating procedure device for intraarticular injection of corticosteroid. J. Rheumatol. 34: 187-192 (2007).
Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNFalpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279: 32633-32642 (2004). *
Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf. 30: 27-46 (2007).
Bansback N, Brennan A, Symmons D, Nixon R, Madan J, Harrison M, Watson K. Comment on: modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply. Rheumatology (Oxford) 47: 1107 (2008).
Bansback N, Young A, Brennan A, Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis. J. Rheumatol. 33: 1503-1510 (2006).
Bansi DS, Lo S, Chapman RW, Fleming KA. Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 8: 111-116 (1996).
Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A(3) adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin. Investig. Drugs 16: 1601-1613 (2007).
Baraf HS. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr. Pharm. Des. 13: 2228-2236 (2007).
Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res. Ther. 10: R104 (2008). *
Barash J, Goldzweig O. Possible role of streptococcal infection in flares of juvenile idiopathic arthritis. Arthritis Rheum. 57: 877-880 (2007). *
Barcellos LF, Kamdar BB, Ramsay PP, Deloa C, Lincoln RR, Caillier S, Schmidt S, Haines JL, Pericak-Vance MA, Oksenberg JR, Hauser SL. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 5: 924-931 (2006).
Bardazzi G, Mannoni A, d'Albasio G, Bonanomi AG, Trallori G, Benucci M, Serni U, Pacini F. Spondyloarthritis in patients with ulcerative colitis. Ital. J. Gastroenterol. Hepatol. 29: 520-524 (1997).
Bardin T. Psoriatic rheumatism. Rev. Prat. 54: 60-68 (2004).
Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, Mathieu S, Grinnell C, Erickson J, Rosenberg SH, Schwartz AJ, Hugunin M, Tarcsa E, Elmore SW, McRae B, Murtaza A, Wang LC, Ghayur T. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J. Immunol. 182: 7482-7489 (2009).
Baricordi OR, Govoni M, Rizzo R, Trotta F. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment. Ann. Rheum. Dis. 66: 1125-1126 (2007). *
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60: 946-954 (2009). *
Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149: 217-225 (2007). *
Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum. 54: 3244-3253 (2006). *
Barland P. Antibodies to citrullinated peptides: current role in diagnosis, prognosis, and pathogenesis of rheumatoid arthritis. New Developments in Rheumatic Diseases 1: 6-9 (2004). *
Barnabe CC, Leclercq SA, Fitzgerald AA. The development of inflammatory arthritis and other rheumatic diseases following stem cell transplantation. Semin. Arthritis Rheum. May 31 [Epub ahead of print] (2008). *
Barnes PJ. Nuclear factor-kappa B. Int. J. Biochem. Cell Biol. 29: 867-870 (1997).
Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 373: 1905-1917 (2009). *
Barnes T, Moots RJ, Goodacre J. Cytokine medicines in clinical practice: current issues. Cytokine 32: 62-66 (2005).
Barnetche T, Constantin A, Cantagrel A, Cambon-Thomsen A, Gourraud PA. New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples. Arthritis Res. Ther. 10: R26 (2008). *
Barnetche T, Constantin A, Gourraud PA, Abbal M, Garnier JG, Cantagrel A, Cambon-Thomsen A. Microsatellite typing of the human leucocyte antigen region: analytical approach and contribution to rheumatoid arthritis immunogenetic studies. Tissue Antigens 68: 390-398 (2006). *
Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, Bunting KD, Ryan JJ. Stat5 expression is required for IgE-mediated mast cell function. J. Immunol. 177: 3421-3426 (2006). *
Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 52: 1773-1784 (2005). *
Barr C. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis. J. Infus. Nurs. 30: 96-104 (2007).
Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J. Rheumatol. Jun 1 [Epub ahead of print] (2009).
Barrera P, Balsa A, Alves H, Westhovens R, Maenaut K, Cornelis F, Fritz P, Bardin T, Ceu Maia M, Lopes-Vaz A, Pascual Salcedo D, de la Concha E, Radstake T, van de Putte LB, Migliorini P, Prudhomme JF, Charron D, Spyropoulou M, Mendes A, Spaepen M, et al. Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF). J. Rheumatol. 28: 968-974 (2001).
Barrera P, Faure S, Prud'homme JF, Balsa A, Migliorini P, Chimenti D, Radstake TR, van de Putte LB, Pascual-Salcedo D, Westhovens R, Maenaut K, Alves H, Lopes-Vaz A, Stravopoulos C, Spyropoulou M, Fritz P, Bardin T, Charron D, Lepage V, et al. European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA? Clin. Exp. Rheumatol. 19: 709-714 (2001).
Barreto AM, Bigolin MC, Ramos JC, Machado LP, Silva Ldos R, Silveira RB, Boguszewski MC. Growth hormone therapy for children with chronic diseases. Arq. Bras. Endocrinol. Metabol. 52: 774-782 (2008).
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962 (2008). *
Barrett MO, Bal BS. Septic arthritis of the hip in an immune competent adult: the significance of the differential diagnosis. J. Am. Board Fam. Med. 20: 307-309 (2007). *
Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1424-1429 (2007). *
Barrie III AM, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin. Appl. Immunol. Rev. 5: 225-240 (2005). *
Barsante MM, Cunha TM, Allegretti M, Cattani F, Policani F, Bizzarri C, Tafuri WL, Poole S, Cunha FQ, Bertini R, Teixeira MM. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br. J. Pharmacol. 153: 992-1002 (2008). *
Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of Graves' ophthalmopathy. Hormones (Athens) 1: 76-90 (2002).
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak P, Wolbink GJ. Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66: 921-926 (2007). *
Bartfai T, Waalen J, Buxbaum JN. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis? J. Rheumatol. 34: 488-492 (2007).
Bartke U, Venten I, Kreuter A, Gabbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br. J. Dermatol. 150: 784-786 (2004).
Bartolozzi G, Falcini F, Volpi M, Taccetti G, Tafi L. Arthropathies related to HLA-B27. Pediatr. Med. Chir. 12: 561-574 (1990).
Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, Worthington J. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum. 50: 1117-1121 (2004). *
Barton A, Bowes J, Eyre S, Symmons D, Worthington J, Silman A. Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis. Ann. Rheum. Dis. 64: 1311-1315 (2005). *
Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J. Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis Rheum. 52: 752-758 (2005). *
Barton A, Eyre S, Ke X, Hinks A, Bowes J, Flynn E, Martin P; YEAR Consortium; BIRAC Consortium, Wilson AG, Morgan AW, Emery P, Steer S, Hocking LJ, Reid DM, Harrison P, Wordsworth P, Thomson W, Worthington J. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum. Mol. Genet. Apr 9 [Epub ahead of print] (2009). *
Barton A, Eyre S, Myerscough A, Brintnell B, Ward D, Ollier WE, Lorentzen JC, Klareskog L, Silman A, John S, Worthington J; Arthritis Rheumatism Campaign National Repository. High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. Hum. Mol. Genet. 10: 1901-1906 (2001). *
Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, Worthington J. Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis Rheum. 50: 748-752 (2004). *
Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, Donn R. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 4: 487-491 (2003). *
Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J. A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology (Oxford) 39: 63-66 (2000). *
Barton A, Platt H, Salway F, Symmons D, Barrett E, Bukhari M, Lunt M, Zeggini E, Eyre S, Hinks A, Tellam D, Brintnell B, Ollier W, Worthington J, Silman A. Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann. Rheum. Dis. 63: 280-284 (2004). *
Barton A, Platt H, Salway F, Symmons D, Lunt M, Worthington J, Silman A. Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. J. Rheumatol. 31: 442-447 (2004). *
Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Gibbons L, Plant D; Wellcome Trust Case Control Consortium, Wilson AG, Marinou I, Morgan A, Emery P; YEAR consortium, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Worthington J. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum. Mol. Genet. 17: 2274-2279 (2008). *
Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Plant D, Gibbons LJ; Wellcome Trust Case Control Consortium; YEAR Consortium; BIRAC Consortium. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat. Genet. 40: 1156-1159 (2008). *
Barton AC, Bruce IN, Silman AJ. Genetic studies of psoriatic arthritis: dissecting joints and skin. J. Rheumatol. 28: 3-5 (2001).
Barton NJ, Stevens DA, Hughes JP, Rossi AG, Chessell IP, Reeve AJ, McQueen DS. Demonstration of a novel technique to quantitatively assess inflammatory mediators and cells in rat knee joints. J. Inflamm. (Lond.) 4: 13 (2007).
Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol. Assess. 8: 1-104 (2004). *
Barzilai O, Sherer Y, Ram M, Izahaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases. Are they truly notorious? A preliminary report. Ann. N. Y. Acad. Sci. 1108: 567-577 (2007). *
Basini G, Santini SE, Bussolati S, Grasselli F. Sanguinarine inhibits VEGF-induced Akt phosphorylation. Ann. N. Y. Acad. Sci. 1095: 371-376 (2007). *
Baslund B, Bendtzen K. Biopharmaceuticals in the treatment of rheumatoid arthritis. Ugeskr. Laeger. 170: 2108-2110 (2008).
Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, McInnes IB. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52: 2686-2692 (2005). *
Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am. J. Gastroenterol. 100: 2254-2261 (2005). *
Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin. Nucl. Med. 39: 124-145 (2009).
Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther. 4: 301-317 (2004).
Bates JS, Lessard CJ, Leon JM, Nguyen T, Battiest LJ, Rodgers J, Kaufman KM, James JA, Gilkeson GS, Kelly JA, Humphrey MB, Harley JB, Gray-McGuire C, Moser KL, Gaffney PM. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. Apr 23 [Epub ahead of print] (2009).
Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J. Rheumatol. 33: 234-243 (2006).
Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S195-S197 (2003).
Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, Damle A, Ortmann WA, Perrone A, Kantor AB, Gulko PS, Kern M, Furie R, Behrens TW, Gregersen PK. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 6: 388-397 (2005). *
Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, Shao T, Durham R, Kemshetti S, Schwarz E, Coe R, Kern M, Baechler EC, Behrens TW, Gregersen PK, Gulko PS. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol. Med. 11: 21-29 (2005). *
Bauer K, Yu X, Wernhoff P, Koczan D, Thiesen HJ, Ibrahim SM. Identification of new quantitative trait loci in mice with collagen-induced arthritis. Arthritis Rheum. 50: 3721-3728 (2004). *
Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E, Goedde S, Dinges H, Mueller-Ladner U, Renner C. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res. Ther. 8: R171 (2006). *
Bauerova K, Kucharska J, Mihalova D, Navarova J, Gvozdjakova A, Sumbalova Z. Effect of coenzyme Q(10) supplementation in the rat model of adjuvant arthritis. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 149: 501-503 (2005).
Bauerova K, Ponist S, Ondrejickova O, Komendova D, Mihalova D. Association between tissue gamma-glutamyl-transferase and clinical markers of adjuvant arthritis in Lewis rats. Neuro. Endocrinol. Lett. 27: S172-S175 (2006).
Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr. Opin. Drug Discov. Devel. 4: 635-650 (2001).
Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3: 170-176 (2002). *
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17: 425-431 (2003).
Baum H, Staines NA. MHC-derived peptides and the CD4+ T-cell repertoire: implications for autoimmune disease. Cytokines Cell Mol. Ther. 3: 115-125 (1997).
Baumal R, Broder I. Studies into the occurrence of soluble antigen-antibody complexes in disease. III. Rheumatoid arthritis and other human diseases. Clin. Exp. Immunol. 3: 555-569 (1968). *
Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, Alm GV, Ronnblom L. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 52: 1185-1195 (2005). *
Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J. Invest. Dermatol. 128: 871-881 (2008). *
Bayley JP, Baggen JM, van der Pouw-Kraan T, Crusius JB, Huizinga TW, Verweij CL. Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3CR1 and rheumatoid arthritis. Tissue Antigens 62: 170-174 (2003). *
Bayley JP, Bakker AM, Kaijzel EL, Huizinga TW, Verweij CL. Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. Rheumatology (Oxford) 42: 969-971 (2003). *
Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun. 5: 315-329 (2004). *
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3: 262-272 (2007). *
Bayry J, Siberil S, Triebel F, Tough DF, Kaveri SV. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov. Today 12: 548-552 (2007).
Bazzani C, Filippini M, Caporali R, Pallavicini FB, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Gorla R. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun. Rev. 8: 260-265 (2009).
Bazzichi L, Giuliano T, Rossi A, Mazzoni A, Grazzini T, De Feo F, Giacomelli C, Scatena F, Bombardieri S. Partial remission of refractory RA after adacolumn cytapheresis: a case report. Rheumatol. Int. 28: 295-297 (2008). *
Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, Darragh J, McIlrath J, Carr JM, Armit LJ, Clacher C, Malone L, Kollias G, Arthur JS. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol. Cell. Biol. 25: 10454-10464 (2005). *
Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev. Ind. Pharm. 33: 211-220 (2007). *
Becanovic K, Jagodic M, Sheng JR, Dahlman I, Aboul-Enein F, Wallstrom E, Olofsson P, Holmdahl R, Lassmann H, Olsson T. Advanced intercross line mapping of Eae5 reveals Ncf-1 and CLDN4 as candidate genes for experimental autoimmune encephalomyelitis. J. Immunol. 176: 6055-6064 (2006). *
Becker C, Dornhoff H, Neufert C, Fantini MC, Wirtz S, Huebner S, Nikolaev A, Lehr HA, Murphy AJ, Valenzuela DM, Yancopoulos GD, Galle PR, Karow M, Neurath MF. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177: 2760-2764 (2006). *
Becker H, Gaubitz M, Domschke W, Kucharzik T. Joint involvement in chronic inflammatory bowel disease - current diagnostics and treatment options. Z. Gastroenterol. 44: 497-502 (2006).
Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin. Immunol. Immunopathol. 56: 219-225 (1990).
Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 95: 9979-9984 (1998). *
Becker ML, Martin TM, Doyle TM, Rose CD. Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15. Arthritis Rheum. 56: 1292-1294 (2007). *
Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr. Rheumatol. Rep. 7: 427-433 (2005).
Becker-Merok A, Kalaaji M, Haugbro K, Nikolaisen C, Nilsen K, Rekvig OP, Nossent JC. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res. Ther. 8: R162 (2006). *
Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15: 570-576 (2006).
Becvar R, Stork J, Jansa P. New trends in diagnosis and treatment of systemic sclerosis. Vnitr. Lek. 52: 712-717 (2006).
Bedi MK. Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept. Skinmed. 6: 245-247 (2007).
Beech JT, Andreakos E, Ciesielski CJ, Green P, Foxwell BM, Brennan FM. T cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NF-kappaB: implications for rheumatoid arthritis. Arthritis Res. Ther. 8: R168 (2006). *
Beehler BC, Hei YJ, Chen S, Lupisella JA, Ostrowski J, Starrett JE, Tortolani D, Tramposch KM, Reczek PR. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J. Rheumatol. 30: 355-363 (2003).
Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS. The D-diastereomer of SHK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. J. Biol. Chem. 283: 988-997 (2008). *
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, Leehealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 103: 17414-17419 (2006). *
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75: 330-337 (2004). *
Begovich AB, Chang M, Schrodi SJ. Meta-analysis evidence of a differential risk of the FCRL3 -169T-->C polymorphism in white and East Asian rheumatoid arthritis patients. Arthritis Rheum. 56: 3168-3171 (2007). *
Behera AK, Hildebrand E, Szafranski J, Hung HH, Grodzinsky AJ, Lafyatis R, Koch AE, Kalish R, Perides G, Steere AC, Hu LT. Role of aggrecanase 1 in Lyme arthritis. Arthritis Rheum. 54: 3319-3329 (2006). *
Behrens EM, Beukelman T, Cron RQ. Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software. J. Rheumatol. 34: 234 (2007).
Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34: 1133-1138 (2007).
Behrens EM, Finkel TH, Bradfield JP, Kim CE, Linton L, Casalunovo T, Frackelton EC, Santa E, George Otieno F, Glessner JT, Chiavacci RM, Grant SF, Hakonarson H. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. Arthritis Rheum. 58: 2206-2207 (2008). *
Behrens F, Himsel A, Rehart S, Stanczyk J, Beutel B, Zimmermann SY, Koehl U, Moller B, Gay S, Kaltwasser JP, Pfeilschifter JM, Radeke HH. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann. Rheum. Dis. 66: 1151-1156 (2007). *
Beleznay Z, Regenass S. Diagnostics of autoimmune diseases. Ther. Umsch. 65: 529-537 (2008).
Belguith-Maalej S, Hadj-Kacem H, Kaddour N, Bahloul Z, Ayadi H. DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjogren syndrome and healthy subjects. Rheumatol. Int. Apr 10 [Epub ahead of print] (2009). *
Belinsky GS, Parke AL, Huang Q, Blanchard K, Jayadev S, Stoll R, Rothe M, Achenie LE, Gupta RR, Wu GY, Rosenberg DW. The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol. Sci. 97: 582-594 (2007). *
Bell DA. Can we rely on anti-citrulline antibody determination for the diagnosis of early rheumatoid arthritis? J. Rheumatol. 33: 2369-2371 (2006).
Bell DA, Hill JA, Cairns E. An intriguing relationship between the immune response to citrullinated vimentin and the HLA shared epitope: Comment on the article by Verpoort et al. Arthritis Rheum. 58: 3277 (2008). *
Bell JI. The molecular genetics of HLA-related disorders. Ciba Found. Symp. 130: 197-214 (1987).
Bell JT. A two-dimensional genome scan for rheumatoid arthritis susceptibility loci. BMC Proc. 1 Suppl. 1: S63 (2007). *
Bellinger DL, Lorton D, Brouxhon S, Felten S, Felten DL. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6: 5-27 (1996).
Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin. Rheumatol. 26: 1127-1129 (2007). *
Belniak E, Stelmasiak Z, Papuc E. Multiple sclerosis and other autoimmune diseases. Neurol. Neurochir. Pol. 41: 259-266 (2007).
Beltinger J, Froehlich F. Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey. Schweiz. Rundsch. Med. Prax. 94: 459-465 (2005).
Beltran E, Toll A, Pros A, Carbonell J, Pujol RM. Assessment of nailfold capillaroscopy by x 30 digital epiluminescence (dermoscopy) in patients with Raynaud phenomenon. Br. J. Dermatol. 156: 892-898 (2007). *
Ben-Shoshan M. CTLA-4Ig: uses and future directions. Recent Pat. Inflamm. Allergy Drug Discov. 3: 132-142 (2009).
Benazet JF, Reviron D, Mercier P, Roux H, Roudier J. HLA-DRB1 alleles associated with rheumatoid arthritis in southern France. Absence of extraarticular disease despite expression of the shared epitope. J. Rheumatol. 22: 607-610 (1995).
Bencsath M, Blaskovits A, Borvendeg J. Biomolecular cytokine therapy. Pathol. Oncol. Res. 9: 24-29 (2003). *
Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27: 269-274 (2007). *
Benderdour M, Tardif G, Pelletier JP, Di Battista JA, Reboul P, Ranger P, Martel-Pelletier J. Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. J. Rheumatol. 29: 1262-1272 (2002). *
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity - secondary publication. Ugeskr. Laeger. 169: 420-423 (2007).
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54: 3782-3789 (2006). *
Benedek TG. The history of bacteriologic concepts of rheumatic fever and rheumatoid arthritis. Semin. Arthritis Rheum. 36: 109-123 (2006). *
Benelli R, Lorusso G, Albini A, Noonan DM. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr. Pharm. Des. 12: 3101-3115 (2006).
Bengmark S. Advanced glycation and lipoxidation end products amplifiers of inflammation: the role of food. JPEN J. Parenter. Enteral Nutr. 31: 430-440 (2007). *
Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 56: 1569-1578 (2007). *
Benito-Garcia E, Feskanich D, Hu FB, Mandl LA, Karlson EW. Protein, iron and meat consumption and risk of rheumatoid arthritis: a prospective cohort study. Arthritis Res. Ther. 9: R16 (2007). *
Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, Emery P, Marzo-Ortega H. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 58: 3413-3418 (2008). *
Bennett JC. The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases. Arthritis Rheum. 58: S53-S57 (2008). *
Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2: 797-801 (2001). *
Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am. J. Ther. 12: 133-141 (2005).
Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin. Exp. Rheumatol. 27: 333-336 (2009).
Benucci M, Nenci G, Cappelletti C, Manfredi M. Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases. Recenti Prog. Med. 99: 363-366 (2008).
Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin. Rheumatol. 27: 91-95 (2008). *
Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M. Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers. Recenti Prog. Med. 97: 134-139 (2006).
Benveniste EN, Qin H. Type I interferons as anti-inflammatory mediators. Sci. STKE 416: pe70 (2007). *
Berbert AA, Kondo CR, Almendra CL, Matsuo T, Dichi I. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition 21: 131-136 (2005). *
Berdeli A, Ozyurek AR, Ulger Z, Gurses D, Levent E, Salar K, Gurpinar AR. Association of macrophage migration inhibitory factor gene -173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis. Rheumatol. Int. 26: 726-731 (2006). *
Berdeli A, Tabel Y, Celik HA, Ozyurek R, Dogrusoz B, Aydin HH. Lack of association between TNFalpha gene polymorphism at position -308 and risk of acute rheumatic fever in Turkish patients. Scand. J. Rheumatol. 35: 44-47 (2006). *
Berdowska I. Cysteine proteases as disease markers. Clin. Chim. Acta 342: 41-69 (2004). *
Berek C. Do B cells play an important role in the pathogenesis of rheumatoid arthritis? Z. Rheumatol. 64: 383-388 (2005).
Beretta L, Cappiello F, Moore JH, Barili M, Greene CS, Scorza R. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Rheum. 59: 974-983 (2008). *
Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G, Scorza R. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res. Ther. 10: R103 (2008). *
Beretta L, Scorza R. 5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population - authors' response. Arthritis Res. Ther. 11: 404 (2009).
Berg L, Ronnelid J, Sanjeevi CB, Lampa J, Klareskog L. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8. Arthritis Res. 2: 75-84 (2000). *
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *
Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res. Ther. 6: R303-R308 (2004). *
Berglund B, Nordstrom G. Symptoms and functional health status of individuals with Ehlers-Danlos syndrome (EDS). J. Clin. Rheumatol. 7: 308-314 (2001).
Bergman J, Schjott J. Hepatitis caused by Lotus-f3? Basic Clin. Pharmacol. Toxicol. 104: 414-416 (2009). *
Beri R, Peterlana D, Puccetti A, Simeoni S, Garzotti P, Biasi D, Caramaschi P, Tinazzi E, Lunardi C. HLA-DRB1 alleles and rheumatoid arthritis in northern Italy: lack of correlation with disease severity and extra-articular manifestations. Recenti Prog. Med. 96: 139-143 (2005).
Beris P; Anemia Working Group. Erythropoietin and intravenous iron to save blood in surgery. Schweiz. Rundsch. Med. Prax. 93: 1905-1910 (2004).
Berk DR, Bayliss SJ. Neutrophilic dermatoses in children. Pediatr. Dermatol. 25: 509-519 (2008).
Berkun Y, Atta IA, Rubinow A, Orbach H, Levartovsky D, Aamar S, Arbel O, Dresner-Pollak R, Friedman G, Ben-Yehuda A. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J. Rheumatol. 34: 1664-1669 (2007).
Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, Revel-Vilk S, Kenet G. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 55: 850-855 (2006). *
Berliner MN, Giesecke T, Bornhovd KD. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. Clin. J. Pain 23: 530-534 (2007).
Berlo SE, Guichelaar T, Ten Brink CB, van Kooten PJ, Hauet-Broeren F, Ludanyi K, van Eden W, Broeren CP, Glant TT. Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Arthritis Rheum. 54: 2423-2433 (2006). *
Berlo SE, van Kooten PJ, Ten Brink CB, Hauet-Broere F, Oosterwegel MA, Glant TT, Van Eden W, Broeren CP. Naive transgenic T cells expressing cartilage proteoglycan-specific TCR induce arthritis upon in vivo activation. J. Autoimmun. 25: 172-180 (2005).
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54: 2550-2557 (2006). *
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 53: 781-784 (2005). *
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46: 1157-1160 (2007). *
Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford) 46: 690-694 (2007). *
Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr. Opin. Rheumatol. 18: 129-134 (2006).
Bernatsky S, Ramsey-Goldman R, Lachance S, Pineau CA, Clarke AE. Lymphoma in a patient with systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 570-574 (2006). *
Berner IC, Dudler J. Viral arthritis. Rev. Med. Suisse. 2: 732-734, 737 (2006).
Bernotiene E, Palmer G, Gabay C. The role of leptin in innate and adaptive immune responses. Arthritis Res. Ther. 8: 217 (2006). *
Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 4: 513-516 (2002).
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: a population-based study. Gastroenterology 129: 827-836 (2005). *
Berntson L, Damgard M, Andersson-Gare B, Herlin T, Nielsen S, Nordal E, Rygg M, Zak M, Fasth A. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J. Rheumatol. 35: 2055-2061 (2008).
Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol. 8: 439-443 (2007).
Berthelot C, Cather J, Jones D, Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin. Lymphoma Myeloma 6: 329-332 (2006).
Berthelot C, Nash J, Duvic M. Coexistent psoriasis and lupus erythematosus treated with alefacept. Am. J. Clin. Dermatol. 8: 47-50 (2007).
Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Liote F, Goeb V, Azais I, Martin A, Pallot-Prades B, Maugars Y, Mariette X; on behalf of CRI (Club Rhumatismes et Inflammation). Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76: 28-34 (2009). *
Berthelot JM, Varin S, Cormier G, Tortellier L, Guillot P, Glemarec J, Maugars Y. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine 74: 144-147 (2007). *
Berthelot P, Carricajo A, Aubert G, Akhavan H, Gazielly D, Lucht F. Outbreak of postoperative shoulder arthritis due to Propionibacterium acnes infection in nondebilitated patients. Infect. Control Hosp. Epidemiol. 27: 987-990 (2006). *
Bertoli AM, Alarcon GS, Calvo-Alen J, Fernandez M, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: clinical features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 54: 1580-1587 (2006). *
Bertoli AM, Fernandez M, McGwin G Jr, Alarcon GS, Tan FK, Reveille JD, Vila LM. Systemic lupus erythematosus in a multiethnic US cohort: XXXVI. Influence of mannose-binding lectin exon 1 polymorphisms in disease manifestations, course, and outcome. Arthritis Rheum. 54: 1703-1704 (2006). *
Bertoli AM, Strusberg I, Fierro GA, Ramos M, Strusberg AM. Lack of correlation between satisfaction and knowledge in clinical trials participants: a pilot study. Contemp. Clin. Trials 28: 730-736 (2007).
Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr. Med. Chem. 9: 1033-1043 (2002).
Bertolini A, Tacchi R, Vergoni AV. Brain effects of melanocortins. Pharmacol. Res. 59: 13-47 (2009). *
Bertolotto M, Dallegri F, Dapino P, Quercioli A, Pende A, Ottonello L, Montecucco F. Sulphasalazine (SSZ) accelerates apoptosis in neutrophils exposed to immune-complexes (IC): role of caspase pathway. Clin. Exp. Pharmacol. Physiol. May 19 [Epub ahead of print] (2009). *
Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Kritikos H, Sidiropoulos P, Tzardi M, Kardassis D, Mamalaki C, Boumpas DT. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 60: 207-218 (2009). *
Beslek A, Onen F, Birlik M, Akarsu M, Akar S, Sari I, Gurler O, Akpinar H, Manisali M, Akkoc N. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease. Rheumatol. Int. 29: 955-957 (2009). *
Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, Rahman A. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum. 55: 892-899 (2006). *
Bessis N, Boissier MC. Gene therapy for patients with rheumatoid arthritis. Joint Bone Spine 73: 169-176 (2006). *
Bessis N, Boissier MC. Novel pro-inflammatory interleukins: potential therapeutic targets in rheumatoid arthritis. Joint Bone Spine 68: 477-481 (2001).
Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 46: 1005-1008 (2007). *
Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol. Dis. 24: 216-230 (1998). *
Beutler BA. The role of tumor necrosis factor in health and disease. J. Rheumatol. Suppl. 57: 16-21 (1999).
Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann. Rheum. Dis. 55: 66-68 (1996). *
Beyersdorf N, Hanke T, Kerkau T, Hunig T. CD28 superagonists put a break on autoimmunity by preferentially activating CD4(+)CD25(+) regulatory T cells. Autoimmun. Rev. 5: 40-45 (2006).
Bezerra EL, Vilar MJ, da Trindade Neto PB, Inoue Sato EL. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 52: 3073-3078 (2005). *
Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz. J. Med. Biol. Res. 38: 161-170 (2005). *
Bezerra MM, Brain SD, Girao VC, Greenacre S, Keeble J, Rocha FA. Neutrophils-derived peroxynitrite contributes to acute hyperalgesia and cell influx in zymosan arthritis. Naunyn. Schmiedebergs. Arch. Pharmacol. 374: 265-273 (2007).
Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal. 5: 107-115 (2009).
Bhambhani V, Abraham J, Sahni M, Harit AK, Khare S, Puliyel JM. Outbreak of Coxsackie B4 arthritis among newborns and staff of a neonatal unit. Trop. Doct. 37: 188-189 (2007).
Bhanji RA, Eystathioy T, Chan EK, Bloch DB, Fritzler MJ. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin. Immunol. 125: 247-256 (2007). *
Bhaskaran R, Palmier MO, Bagegni NA, Liang X, Van Doren SR. Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment. J. Mol. Biol. 374: 1333-1344 (2007). *
Bhat RM. Management of pyoderma gangrenosum - an update. Indian J. Dermatol. Venereol. Leprol. 70: 329-335 (2004).
Bhattacharya A, Rahman M, Banu J, Lawrence RA, McGuff HS, Garrett IR, Fischbach M, Fernandes G. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Faslpr mice by n-3 fatty acids. J. Am. Coll. Nutr. 24: 200-209 (2005). *
Bhattacharya A, Sun D, Rahman M, Fernandes G. Different ratios of eicosapentaenoic and docosahexaenoic omega-3 fatty acids in commercial fish oils differentially alter pro-inflammatory cytokines in peritoneal macrophages from C57BL/6 female mice. J. Nutr. Biochem. 18: 23-30 (2007). *
Bianchi A, Moulin D, Sebillaud S, Koufany M, Galteau MM, Netter P, Terlain B, Jouzeau JY. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes. Arthritis Res. Ther. 7: R1325-R1337 (2005). *
Bica BE, Gomes NM, Fernandes PD, Luiz RR, Koatz VL. Nitric oxide levels and the severity of juvenile idiopathic arthritis. Rheumatol. Int. 27: 819-825 (2007). *
Bidaguren A, Muller-Thyssen A, Blanco A, Mendicute J, Ubeda M. Retrobulbar optic neuritis associated with Infliximab. Arch. Soc. Esp. Oftalmol. 82: 109-112 (2007).
Bierbaum S, Sengler C, Gerhold K, Berner R, Heinzmann A. Polymorphisms within interleukin 15 are associated with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 24: 219 (2006).
Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91: 319-324 (2007). *
Bigazzi PE. Autoimmunity and heavy metals. Lupus 3: 449-453 (1994).
Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 56: 2557-2565 (2007). *
Bilavsky E, Yarden-Bilavsky H, Zevit N, Amir J. Primary meningococcal arthritis in a child: case report and literature review. Scand. J. Infect. Dis. 38: 396-399 (2006). *
Billich A. Drug evaluation: Apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 10: 53-59 (2007).
Billings PB, Hoch SO, White PJ, Carson DA, Vaughan JH. Antibodies to the Epstein-Barr virus nuclear antigen and to rheumatoid arthritis nuclear antigen identify the same polypeptide. Proc. Natl. Acad. Sci. U.S.A. 80: 7104-7108 (1983). *
Binard A, Alassane S, Devauchelle-Pensec V, Berthelot JM, Jousse-Joulin S, Chales G, Le Henaff C, Thorel JB, Hoang S, Youinou P, Saraux A. Outcome of early monoarthritis: a followup study. J. Rheumatol. 34: 2351-2357 (2007).
Bingham CO. Emerging therapeutics for rheumatoid arthritis. Bull. N.Y.U. Hosp. Jt. Dis. 66: 210-215 (2008). *
Bingham CO, Ince A, Haraoui B, Keystone EC, Chon Y, Baumgartner S. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr. Med. Res. Opin. 25: 1131-1142 (2009). *
Bingham SJ, Snowden J, McGonagle D, Richards S, Isaacs J, Morgan G, Emery P. Autologous stem cell transplantation for rheumatoid arthritis - interim report of 6 patients. J. Rheumatol. Suppl. 64: 21-24 (2001).
Bingham SJ, Snowden JA, Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases. Ann. Med. 32: 615-521 (2000).
Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoist C. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat. Immunol. 7: 284-292 (2006). *
Bircan Z, Usluer H. Protracted febrile myalgia mimicking polyarteritis nodosa. J. Clin. Rheumatol. 14: 222-225 (2008).
Birgisson H, Steingrimsson O, Guethnason T. Kingella kingae ostemyelitis and septic arthritis in paediatric patients. Six cases from the Department of Pediatrics, National University Hospital of Iceland. Laeknabladid. 86: 516-519 (2000).
Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S, Costin G, Das PK. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm. Venereol. 86: 209-214 (2006). *
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr. Drug Targets 9: 345-359 (2008).
Birlea SA, Fain PR, Spritz RA. A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch. Dermatol. 144: 310-316 (2008). *
Birmingham DJ, Nagaraja HN, Rovin BH, Spetie L, Zhao Y, Li X, Hackshaw KV, Yu CY, Malarkey WB, Hebert LA. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele. Arthritis Rheum. 54: 3291-3299 (2006). *
Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M. Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature. Expert Opin. Pharmacother. 10: 255-269 (2009).
Birnbaum J, Bartlett JG, Gelber AC. Clostridium difficile: an under-recognized cause of reactive arthritis? Clin. Rheumatol. 27: 253-255 (2008). *
Biro E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann. Rheum. Dis. 66: 1085-1092 (2007). *
Biro E, Szekanecz Z, Czirjak L, Danko K, Kiss E, Szabo NA, Szucs G, Zeher M, Bodolay E, Szegedi G, Bako G. Association of systemic and thyroid autoimmune diseases. Clin. Rheumatol. 25: 240-245 (2006). *
Bissett DL. Glucosamine: an ingredient with skin and other benefits. J. Cosmet. Dermatol. 5: 309-315 (2006).
Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett. 11: 1-4 (2006).
Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig. Dis. Sci. 49: 653-661 (2004). *
Biswas P, Mantelli B, Hasson H, Vecchi A, Saniabadi A, Lazzarin A, Beretta A. In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin. Immunol. 109: 355-358 (2003). *
Bittencourt PL, Farias AQ, Porta G, Cancado EL, Miura I, Pugliese R, Kalil J, Goldberg AC, Carrilho FJ. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J. Clin. Gastroenterol. 42: 300-305 (2008).
Bizzaro N. Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis. Clin. Chem. Lab. Med. 45: 150-157 (2007). *
Blackwell JM, Searle S. Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). Immunol. Lett. 65: 73-80 (1999).
Blackwell NM, Sembi P, Newson JS, Lawrence T, Gilroy DW, Kabouridis PS. Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor. Arthritis Rheum. 50: 2675-2684 (2004). *
Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5: 2087-2102 (2006). *
Blaho VA, Buczynski MW, Brown CR, Dennis EA. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of lyme arthritis. J. Biol. Chem. Jun 1 [Epub ahead of print] (2009). *
Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum. 37: 1380-1385 (1994).
Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today. 10: 197-204 (2005).
Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 52: 201-211 (2005). *
Blankenberg-Sprenkels SH, Fielder M, Feltkamp TE, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J. Rheumatol. 25: 743-747 (1998).
Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Muller GA. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand. J. Rheumatol. Feb 26 [Epub ahead of print] (2009).
Blass S, Engel JM, Burmester GR. The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences. Z. Rheumatol. 60: 1-16 (2001).
Blau EB. Familial granulomatous arthritis, iritis, and rash. J. Pediatr. 107: 689-693 (1985).
Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin. Cell. Dev. Biol. 17: 592-604 (2006). *
Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56: 965-971 (2007). *
Bleich A, Hopf S, Hedrich HJ, van Lith HA, Li F, Sartor RB, Mahler M. Genetic dissection of granulomatous enterocolitis and arthritis in the intramural peptidoglycan-polysaccharide-treated rat model of IBD. Inflamm. Bowel Dis. Jun 12 [Epub ahead of print] (2009).
Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsoe B, Torp-Pedersen S. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand. J. Rheumatol. 35: 341-345 (2006). *
Bloch AS. Low carbohydrate diets, pro: time to rethink our current strategies. Nutr. Clin. Pract. 20: 3-12 (2005).
Bloch I, Quintana FJ, Gerber D, Cohen T, Cohen IR, Shai Y. T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J. 21: 393-401 (2007). *
Blom AM, Nandakumar KS, Holmdahl R. C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice. Ann. Rheum. Dis. 68: 136-142 (2009).
Blomberg J. Newly discovered human retroviruses. Association with disease is still undetermined. Lakartidningen 97: 3597-3599, 3602-3603 (2000).
Bloom BJ, Toyoda M, Petrosian A, Jordan S. Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis. Rheumatol. Int. 27: 655-660 (2007). *
Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum. Gene Ther. 15: 189-201 (2004). *
Bluestone JA. A balanced attack. The Scientist May, 2007 (http://www.the-scientist.com/2007/05/01/s32/1/ ) (2007).
Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24: 233-238 (2006). *
Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 4: CD004525 (2003). *
Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, Tugwell P. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 3: CD003785 (2002). *
Blundell CD, Mahoney DJ, Cordell MR, Almond A, Kahmann JD, Perczel A, Taylor JD, Campbell ID, Day AJ. Determining the molecular basis for the pH-dependent interaction between the link module of human TSG-6 and hyaluronan. J. Biol. Chem. 282: 12976-12988 (2007). *
Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, Weichhart T, Saemann M, Smolen JS. Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of Toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum. 56: 1880-1893 (2007). *
Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis O, Klersy C, Montecucco C. High IgA rheumatoid factor levels are associated with poor clinical response to TNF-alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis. 66: 302-307 (2007). *
Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann. N. Y. Acad. Sci. 1109: 287-295 (2007). *
Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur. J. Clin. Microbiol. Infect. Dis. 27: 907-913 (2008). *
Bockelmann R, Gollnick H, Bonnekoh B. Anti-cyclic citrullinated peptide antibodies in psoriasis patients without arthritis. Arthritis Rheum. 54: 1701-1702 (2006). *
Bockermann R, Holmdahl R. Type II collagen without adjuvant induces eosinophilic arthritis. Eur. J. Immunol. 37: 540-548 (2007). *
Bockermann R, Schubert D, Kamradt T, Holmdahl R. Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase. Arthritis Res. Ther. 7: R1316-R1324 (2005). *
Bodenheimer HC Jr, Schaffner F. State of the art. Primary biliary cirrhosis and the immune system. Am. J. Gastroenterol. 72: 285-296 (1979).
Bodil Roth E, Theander E, Londos E, Sandberg-Wollheim M, Larsson A, Sj�berg K, Stenberg P. Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjogren's syndrome, multiple sclerosis and Alzheimer's disease. Scand. J. Immunol. 67: 626-631 (2008). *
Bodolay E, Derfalvi B, Gergely P, Poor G. When does an autoimmune disease begin? Importance of the early diagnosis. Orv. Hetil. 148: S25-S30 (2007).
Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T, Gunaydin R, Kuran B, Kotevoglu N, Bal A, Aydog E, Altay Z, Ugurlu H, Kocabas H, Olmez N, Yazgan P, Gursoy S, Madenci E, Ozel S, Delialioglu SU. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin. Rheumatol. 27: 1119-1125 (2008). *
Bodur H, Seckin U, Eser F, Ergul G, Seckin S. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol. Int. 29: 107-110 (2008). *
Boehncke WH, Adebajo A, Cauli A, Nash P, Salvarani C, Kavanaugh AF. Initiative for quality in psoriasis and psoriatic arthritis. J. Rheumatol. 35: 1431-1433 (2008).
Boehncke WH, Boehncke S. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. G. Ital. Dermatol. Venereol. 143: 307-313 (2008).
Boehncke WH, Buerger C, Boehncke S. Co-morbidities in psoriasis vulgaris. Hautarzt. 60: 116-121 (2009).
Boers M. Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree. Ann. Intern. Med. 144: 933-935 (2006). *
Boers M. Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. J. Rheumatol. 34: 661-663 (2007).
Boettger MK, Hensellek S, Richter F, Gajda M, Stockigt R, von Banchet GS, Brauer R, Schaible HG. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 58: 2368-2378 (2008). *
Bogas M, Afonso Mdo C, Araujo D. Erosive enteropathy in a patient with a polyarthritis. Acta Reumatol. Port. 31: 349-354 (2006).
Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64: 1057-1068 (2008). *
Bohanec Grabar P, Logar D, Tomsic M, Rozman B, Dolzan V. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis. Clin. Exp. Rheumatol. 27: 229-236 (2009).
Bohgaki T, Amasaki Y, Nishimura N, Bohgaki M, Yamashita Y, Nishio M, Sawada KI, Jodo S, Atsumi T, Koike T. Up regulated expression of tumour necrosis factor alpha converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann. Rheum. Dis. 64: 1165-1173 (2005). *
Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Macchioni P, Cimino L, Bajocchi G, Grazia Catanoso M, Pattacini L, Salvarani C. Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum. 54: 4011-4017 (2006). *
Boiers U, Lanig H, Sehnert B, Holmdahl R, Burkhardt H. Collagen type II is recognized by a pathogenic antibody through germline encoded structures. Eur. J. Immunol. 38: 2784-2795 (2008).
Boissier MC, Assier E, Falgarone G, Bessis N. Shifting the imbalance from Th1/Th2 to Th17/Treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 75: 373-375 (2008). *
Bokarewa M, Dahlberg L, Tarkowski A. Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis. Arthritis Res. Ther. 7: R1014-R1022 (2005). *
Bokarewa M, Hultgren O. Is interleukin-18 useful for monitoring rheumatoid arthritis? Scand. J. Rheumatol. 34: 433-436 (2005). *
Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand. J. Immunol. 66: 476-483 (2007). *
Bokarewa MI, Jin T, Tarkowski A. Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J. Rheumatol. 30: 1719-1724 (2003).
Boki KA, Drosos AA, Tzioufas AG, Lanchbury JS, Panayi GS, Moutsopoulos HM. Examination of HLA-DR4 as a severity marker for rheumatoid arthritis in Greek patients. Ann. Rheum. Dis. 52: 517-519 (1993). *
Boki KA, Panayi GS, Vaughan RW, Drosos AA, Moutsopoulos HM, Lanchbury JS. HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients. Arthritis Rheum. 35: 749-755 (1992).
Boland CR. Biology of cancer in ulcerative colitis and consequences for chemoprevention. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 82-83. May 7-8 (2004). *
Boldizsar F, Tarjanyi O, Nemeth P, Mikecz K, Glant TT. Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice. Int. Immunol. 21: 511-522 (2009).
Bollag WB. Potential role of sphingosine 1-phosphate in the pathogenesis of rheumatoid arthritis. J. Lipid Res. 49: 2281-2282 (2008). *
Bolstad AI, Jonsson R. Genetic aspects of Sjogren's syndrome. Arthritis Res. 4: 353-359 (2002). *
Bolz DD, Weis JJ. Molecular mimicry to Borrelia burgdorferi: pathway to autoimmunity? Autoimmunity 37: 387-392 (2004).
Bombardieri M, Barone F, Pittoni V, Alessandri C, Conigliaro P, Blades MC, Priori R, McInnes IB, Valesini G, Pitzalis C. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res. Ther. 6: R447-R456 (2004). *
Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester AG. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46: 1191-1199 (2007). *
Boms S, Sehr T, Jappe U, Enk A. First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept. Hautarzt. 59: 653-655 (2008).
Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res. Ther. 7: R1072-R1081 (2005). *
Bondanza A, Zimmermann VS, Dell'Antonio G, Cin ED, Balestrieri G, Tincani A, Amoura Z, Piette JC, Sabbadini MG, Rovere-Querini P, Manfredi AA. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum. 50: 1549-1560 (2004). *
Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int. J. Clin. Pract. 55: 211-216 (2001).
Bondeson J, Veress B, Lindroth Y, Lindgren S. Polymyositis associated with asymptomatic primary biliary cirrhosis. Clin. Exp. Rheumatol. 16: 172-174 (1998).
Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases and other destructive and inflammatory responses in osteoarthritis. Arthritis Res. Ther. 8: R187 (2006). *
Bonel HM, Boller C, Saar B, Tanner S, Srivastav S, Villiger PM. Short term changes in magnetic resonance Imaging and disease activity in response to infliximab. Ann. Rheum. Dis. Mar 26 [Epub ahead of print] (2009).
Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+CD25-Foxp3+ T cells in patients with systemic lupus erythematosus. J. Immunol. 182: 1689-1695 (2009).
Bonfiglioli R, Conde RA, Sampaio-Barros PD, Louzada-Junior P, Donadi EA, Bertolo MB. Frequency of HLA-B27 alleles in Brazilian patients with psoriatic arthritis. Clin. Rheumatol. 27: 709-712 (2008). *
Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, Ryu JH, Baeten D, Matteson EL. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 46: 70-75 (2007). *
Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 44: 126-129 (2005). *
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of randomized controlled trials. Ann. Rheum. Dis. Nov 19 [Epub ahead of print] (2008).
Bongi SM, Porfirio B, Rombola G, Palasciano A, Beneforti E, Bianucci G. Shared-epitope HLA-DRB1 alleles and sex ratio in Italian patients with rheumatoid arthritis. Joint Bone Spine 71: 24-28 (2004).
Bongiorno MR, Pistone G, Doukaki S, Arico M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol. Ther. 21 Suppl. 2: S15-S20 (2008).
Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol. Rev. 226: 132-146 (2008). *
Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo 59 Suppl. 1: 64-67 (2007). *
Bonkowsky JL, Bohnsack JF, Pennington MJ, Viskochil D, Thompson JA. Leukoencephalopathy, arthritis, colitis, and hypogammaglobulinemia (LACH) in two brothers: a novel syndrome? Am. J. Med. Genet. 128A: 52-56 (2004). *
Bonnevier JL, Zhang R, Mueller DL. E3 ubiquitin ligases and their control of T cell autoreactivity. Arthritis Res. Ther. 7: 233-242 (2005). *
Booker MJ, Flint J, Saravana S. Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report. Cases J. 1: 364 (2008). *
Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 171: 333-338 (2004). *
Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, Limburg PC, Tervaert JW. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43: 2025-2033 (2000). *
Boonen A, Vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, Lenaerts J, Van den Bosch F, Mielants H, Dewulf L, Vastesaeger N. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J. Rheumatol. May 15 [Epub ahead of print] (2009).
Boot EP, Koning GA, Storm G, Wagenaar-Hilbers JP, van Eden W, Everse LA, Wauben MH. CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res. Ther. 7: R604-R615 (2005). *
Booth AD, Wallace S, McEniery CM, Yasmin, Brown J, Jayne DR, Wilkinson IB. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum. 50: 581-588 (2004). *
Booth G, Newham P, Barlow R, Raines S, Zheng B, Han S. Gene expression profiles at different stages of collagen-induced arthritis. Autoimmunity 41: 512-521 (2008).
Booth S, Chohan S, Curran JC, Karrison T, Schmitz A, Utset TO. Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum. 57: 845-850 (2007). *
Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink B, van Doorn C, Stenger R, Bos ES, van Lierop MJ, Verheijden GF, Timmers M, van Staveren C. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39 (aa263-275) epitope: an MHC anchor variant peptide for immune modulation. Arthritis Res. Ther. 9: R71 (2007). *
Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, Barron KS, Holland SM, Kastner DL, Aksentijevich I. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 60: 1851-1861 (2009).
Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr. Med. Res. Opin. May 8 [Epub ahead of print] (2009).
Borba IA. Multiple factors determine the increased prevalence of atherosclerosis in rheumatoid arthritis. Acta Reumatol. Port. 33: 47-55 (2008). *
Borchardt JK. Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases. Drug News Perspect. 17: 607-614 (2004).
Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin. Arthritis Rheum. 34: 465-483 (2004). *
Borchers AT, Selmi C, Cheema G, Keen CL, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis. Autoimmun. Rev. 5: 279-298 (2006).
Borer JS. Cyclooxygenase inhibition: what should we do to resolve the confusion? An American perspective. J. Cardiovasc. Pharmacol. 47 Suppl. 1: S87-S91 (2006).
Borg AA, Davis MJ, Fowler PD, Shadforth MF, Dawes PT. Rifampicin in early rheumatoid arthritis. Scand. J. Rheumatol. 22: 39-42 (1993).
Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F, Nistico S, Chimenti S, Pallone F, Novelli G. Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population. Eur. J. Dermatol. 12: 540-542 (2002).
Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin. Rheumatol. 27: 443-447 (2008). *
Boross P, Verbeek JS. The complex role of Fcgamma receptors in the pathology of arthritis. Springer Semin. Immunopathol. 28: 339-350 (2006). *
Borowski LC, Lopes RP, Gonzalez TP, Dummer LA, Chies JA, Silveira IG, Keisermann M, Bauer ME. Is steroid resistance related to multidrug resistance-I (MDR-I) in rheumatoid arthritis? Int. Immunopharmacol. 7: 836-844 (2007).
Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Nunez-Cornejo C, Castera MD, Abad FJ. Urticaria due to etanercept in a patient with psoriatic arthritis. South. Med. J. 102: 304-305 (2009).
Borras-Blasco J, Nunez-Cornejo C, Gracia-Perez A, Rosique-Robles JD, Castera ME, Viosca E, Abad FJ. Parapharyngeal abscess in a patient receiving etanercept. Ann. Pharmacother. 41: 341-344 (2007).
Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin. Immunol. May 23 [Epub ahead of print] (2009). *
Bos JD. Psoriasis, innate immunity, and gene pools. J. Am. Acad. Dermatol. 56: 468-471 (2007).
Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP. The pathogenesis of inflammatory dermatoses, especially psoriasis. Ned. Tijdschr. Geneeskd. 150: 179-183 (2006).
Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J. Rheumatol. 35: 1972-1977 (2008).
Bosch T. Therapeutic apheresis - state of the art in the year 2005. Ther. Apher. Dial. 9: 459-468 (2005). *
Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 27: 833-839 (2008). *
Botes L, van der Westhuizen FH, Loots du T. Phytochemical contents and antioxidant capacities of two Aloe greatheadii var. davyana extracts. Molecules 13: 2169-2180 (2008).
Botha-Scheepers SA, Watt I, Slagboom E, de Craen AJ, Meulenbelt I, Rosendaal FR, Breedveld FC, Huizinga TW, Kloppenburg M. Innate production of tumor necrosis factor-alpha and interleukin-10 is associated with radiological progression of knee osteoarthritis. Ann. Rheum. Dis. 67: 1165-1169 (2008).
Botsios C, Ostuni P, Sfriso P, Furlan A, Fiocco U, Sgarabotto D, Todesco S. Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects. Reumatismo. 55: 224-235 (2003).
Botsios C, Sfriso P, Furlan A, Ostuni P, Biscaro M, Fiocco U, Todesco S, Punzi L. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis. Reumatismo 59: 32-37 (2007).
Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 46: 1042-1043 (2007). *
Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kalden JR, Voll RE. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Arthritis Rheum. 54: 927-938 (2006). *
Bottcher Y, Paufler T, Stehr T, Bertschat FL, Paschke R, Koch CA. Thyroid hormone resistance without mutations in thyroid hormone receptor beta. Med. Sci. Monit. 13: CS67-CS70 (2007). *
Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside - molecular basis of a pleiotrophic molecule. Am. J. Clin. Nutr. 76: 1151S-1157S (2002). *
Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18: 207-213 (2006). *
Bottomley WW, Cunliffe WJ. Acute Achilles tendonitis following oral isotretinoin therapy for acne vulgaris. Clin. Exp. Dermatol. 17: 250-251 (1992).
Bouali F, Berrah A, Si Ahmed-Bouali D, Harrieche F, Benhalima M, Hamladji RM, Arrada M. Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients). Rev. Med. Interne. 26: 777-783 (2005).
Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214 (2008). *
Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl. Acad. Sci. U.S.A. 104: 20878-20883 (2007). *
Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin. Rheumatol. 28 Suppl. 1: S53-S55 (2009).
Bouis D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol. Res. 53: 89-103 (2006). *
Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin. Arthritis Rheum. 34: 805-812 (2005). *
Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology (Oxford) 46: 178-179 (2007). *
Bourcier ME, Vinik AI. A 41-year-old man with polyarthritis and severe autonomic neuropathy. Ther. Clin. Risk Manag. 4: 837-842 (2008). *
Bourgault-Rouxel AS, Loughran TP, Zambello R, Epling-Burnette PK, Semenzato G, Donadieu J, Amiot L, Fest T, Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leuk. Res. 32: 45-48 (2008).
Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. Apr 30 [Epub ahead of print] (2009).
Bourikas LA, Sidiropoulos PI, Goulielmos GN, Boumpas DT, Kritikos HD. Concomitant onset of Graves disease and rheumatoid arthritis after a serious life event. J. Clin. Rheumatol. 12: 326-327 (2006).
Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 22: 331-337 (2008).
Bouros D, Pneumatikos I, Tzouvelekis A. Pleural involvement in systemic autoimmune disorders. Respiration 75: 361-371 (2008). *
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. Sigma receptor ligands: applications in inflammation and oncology. Curr. Opin. Investig. Drugs 5: 1158-1163 (2004).
Boutry N, Carmo CC, Flipo RM, Cotten A. Early rheumatoid arthritis and its differentiation from other joint abnormalities. Eur. J. Radiol. Apr 2 [Epub ahead of print] (2009).
Bouysset M, Noel E, Tebib JG. Rheumatoid arthritis: a general disease and local diseases. Rev. Prat. 55: 2121-2133 (2005).
Bouyssie D, Gonzalez de Peredo A, Mouton E, Albigot R, Roussel L, Ortega N, Cayrol C, Burlet-Schiltz O, Girard JP, Monsarrat B. Mascot file parsing and quantification (MFPaQ), a new software to parse, validate, and quantify proteomics data generated by ICAT and SILAC mass spectrometric analyses: application to the proteomics study of membrane proteins from primary � Mol. Cell. Proteomics 6: 1621-1637 (2007). *
Bovin LF, Brynskov J, Hegedus L, Jess T, Nielsen CH, Bendtzen K. Gene expression profiling in autoimmune diseases: chronic inflammation or disease specific patterns? Autoimmunity 40: 191-201 (2007).
Bovin LF, Rieneck K, Workman C, Nielsen H, Sorensen SF, Skjodt H, Florescu A, Brunak S, Bendtzen K. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. Immunol. Lett. 93: 217-226 (2004).
Bowcock AM. Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology. Immunol. Res. 32: 45-56 (2005). *
Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum. Mol. Genet. 13 Suppl. 1: R43-R55 (2004). *
Bowes J, Barton A. Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 47: 399-402 (2008). *
Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A; BRAGGSS. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet. Genomics 19: 319-323 (2009).
Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann. Pharmacother. 38: 58-61 (2004).
Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 43: 758-764 (2004). *
Bowness P. HLA B27 in health and disease: a double-edged sword? Rheumatology (Oxford) 41: 857-868 (2002). *
Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'keefe RJ, Xing L. TNFa and pathologic bone resorption. Keio. J. Med. 54: 127-131 (2005). *
Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr. Opin. Rheumatol. 18: 427-432 (2006).
Boyer JF, Balard P, Authier H, Faucon B, Bernad J, Mazieres B, Davignon JL, Cantagrel A, Pipy B, Constantin A. TNF alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res. Ther. 9: R22 (2007). *
Boyle DL, Jones TL, Hammaker D, Svensson CI, Rosengren S, Albani S, Sorkin L, Firestein GS. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med. 3: e338 (2006). *
Boyle DL, Kavanaugh A. The pathobiology of psoriatic synovium. Curr. Opin. Rheumatol. 20: 404-407 (2008).
Boyle K, Egan P, Rakar S, Willson TA, Wicks IP, Metcalf D, Hilton DJ, Nicola NA, Alexander WS, Roberts AW, Robb L. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 110: 1466-1474 (2007). *
Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 28: 51-57 (2007). *
Bracewell C, Isaacs J, Emery P, Ng W. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. Jun 12 [Epub ahead of print] (2009).
Braddock M, Murray C. 10th Anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit 20 - 21 March 2006, New Brunswick, USA. Expert Opin. Investig. Drugs 15: 721-727 (2006).
Bradley DS, Nabozny GH, Cheng S, Zhou P, Griffiths MM, Luthra HS, David CS. HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis. J. Clin. Invest. 100: 2227-2234 (1997). *
Bradley J. TNF-mediated inflammatory disease. J. Pathol. 214: 149-160 (2008). *
Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32: 417-423 (2005).
Bradley JD, Flusser D, Katz BP, Schumacher HR Jr, Brandt KD, Chambers MA, Zonay LJ. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J. Rheumatol. 21: 905-911 (1994).
Bradna P. Gout and diabetes. Vnitr. Lek. 52: 488-492 (2006).
Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J. Rheumatol. 35: 2119-2128 (2008).
Bramlage CP, Kaps C, Ungethum U, Bramlage P, Koziolek M, Wessels J, Krenn V, Pruss A, Muller GA, Strutz F, Burmester GR, Haupl T. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium. Scand. J. Rheumatol. 37: 401-409 (2008). *
Brand A, Griffiths DJ, Herve C, Mallon E, Venables PJ. Human retrovirus-5 in rheumatic disease. J. Autoimmun. 13: 149-154 (1999).
Brand DD, Kang AH, Rosloniec EF. The mouse model of collagen-induced arthritis. Methods Mol. Med. 102: 295-312 (2004).
Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25: 3-18 (2003). *
Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat. Protoc. 2: 1269-1275 (2007). *
Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin. Biol. Ther. 6: 99-107 (2006).
Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J. Rheumatol. 31: 531-538 (2004).
Brant SR. Exposed: the genetic underpinnings of ulcerative colitis relative to Crohn's disease. Gastroenterology 136: 396-399 (2009). *
Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Balloum M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally svailable Syk kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319: 998-1008 (2006). *
Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5: 9-16 (2006).
Brauer DJ. A method for pattern recognition. Res. Theory Nurs. Pract. 20: 277-289 (2006).
Braun J. Epidemiology and prognosis of ankylosing spondylitis. Radiologe 44: 209-210, 212-216 (2004).
Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. Curr. Opin. Rheumatol. May 20 [Epub ahead of print] (2009).
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 57: 639-647 (2007). *
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 41: 58-67 (1998). *
Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr. Opin. Rheumatol. 13: 245-249 (2001).
Braun J, Sieper J. Early diagnosis of spondyloarthritis. Nat. Clin. Pract. Rheumatol. 2: 536-545 (2006). *
Braun J, Sieper J. Spondylarthritides. Z. Rheumatol. 65: 613-632 (2006).
Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology (Oxford) 43: 1072-1084 (2004). *
Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3: 141-168 (2003).
Braun J, Sieper J. Rheumatologic manifestations of gastrointestinal disorders. Curr. Opin. Rheumatol. 11: 68-74 (1999).
Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin. Investig. Drugs 12: 1097-1109 (2003).
Braun J, Zochling J, Baraliakos X, Alten RH, Burmester GR, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial. Ann. Rheum. Dis. 65: 1147-1153 (2006). *
Braun WE. HLA molecules in autoimmune diseases. Clin. Biochem. 25: 187-191 (1992). *
Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr. Med. Assoc. J. 10: 277-281 (2008). *
Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J. Rheumatol. 33: 497-500 (2006).
Braun-Moscovici Y, Schapira D, Balbir-Gurman A, Sevilia R, Nahir AM. Ticlopidine-induced lupus. J. Clin. Rheumatol. 7: 102-105 (2001).
Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 46: 1729-1735 (2007). *
Braybrook C. Are patients with rheumatoid arthritis prone to accelerated atherosclerosis? Nat. Clin. Pract. Cardiovasc. Med. 3: 296-297 (2006).
Breban M, Falgarone G, Blanchard H, Dernis-Labous E, Lamarque D. Animal models of the spondyloarthropathies. Curr. Rheumatol. Rep. 2: 282-287 (2000).
Breban M, Hacquard-Bouder C, Falgarone G. Animal models of HLA-B27-associated diseases. Curr. Mol. Med. 4: 31-40 (2004).
Brechter AB, Persson E, Lundgren I, Lerner UH. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases. Bone 43: 72-83 (2008).
Breda L, Nozzi M, De Sanctis S, Chiarelli F. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update. Semin. Arthritis Rheum. Feb 24 [Epub ahead of print] (2009). *
Breedveld FC. Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept. Ned. Tijdschr. Geneeskd. 149: 2273-2277 (2005).
Breedveld FC. Current and future management approaches for rheumatoid arthritis. Arthritis Res. 4 Suppl. 2: S16-S21 (2002). *
Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 63: 149-155 (2004). *
Brenn D, Richter F, Schaible HG. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum. 56: 351-359 (2007). *
Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 46: 1345-1354 (2007). *
Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 296-301 (2007).
Brennan FM, Maini RN, Feldmann M. Cytokine expression in chronic inflammatory disease. Br. Med. Bull. 51: 368-384 (1995).
Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118: 3537-3545 (2008). *
Brennan P, Hajeer A, Ong KR, Worthington J, John S, Thomson W, Silman A, Ollier B. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 40: 1383-1386 (1997).
Brennan P, Ollier B, Worthington J, Hajeer A, Silman A. Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Lancet 348: 106-109 (1996). *
Brenner M, Laragione T, Mello A, Gulko PS. Cia25 on rat chromosome 12 regulates severity of autoimmune arthritis induced with pristane and collagen. Ann. Rheum. Dis. 66: 952-957 (2007). *
Brenner M, Laragione T, Yarlett NC, Gulko PS. Genetic regulation of T regulatory, CD4, and CD8 cell numbers by the arthritis severity loci Cia5a, Cia5d, and the MHC/Cia1 in the rat. Mol. Med. 13: 277-287 (2007). *
Brenner M, Laragione T, Yarlett NC, Li W, Mello A, Gulko PS. Cia27 is a novel non-MHC arthritis severity locus on rat chromosome 10 syntenic to the rheumatoid arthritis 17q22-q25 locus. Genes Immun. 7: 335-341 (2006). *
Brenner M, Meng HC, Yarlett NC, Griffiths MM, Remmers EF, Wilder RL, Gulko PS. The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage. Arthritis Rheum. 52: 322-332 (2005). *
Brenol CV, Chies JA, Brenol JC, Monticielo OA, Franciscatto P, Birriel F, Neves AG, Xavier RM. Endothelial nitric oxide synthase T-786C polymorphism in rheumatoid arthritis: association with extraarticular manifestations. Clin. Rheumatol. 28: 201-205 (2009).
Brenol CV, Monticielo OA, Xavier RM, Brenol JC. Rheumatoid arthritis and atherosclerosis. Rev. Assoc. Med. Bras. 53: 465-470 (2007).
Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis. Methods Mol. Biol. 517: 1-15 (2009). *
Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell. Immunol. 233: 90-96 (2005). *
Brentano F, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann. Rheum. Dis. 68: 143-150 (2009).
Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 56: 2829-2839 (2007). *
Bresnihan B. Synovial biomarkers in the spondylarthropathies. Curr. Opin. Rheumatol. 18: 359-363 (2006).
Bressan E, De Queiroz Cunha F, Tonussi CR. Contribution of TNFalpha, IL-1beta and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis. Cytokine 36: 83-89 (2006).
Brewer GJ. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discov. Today. 10: 1103-1109 (2005).
Breza TS Jr, Magro CM. Lichenoid and granulomatous dermatitis associated with atypical mycobacterium infections. J. Cutan. Pathol. 33: 512-515 (2006). *
Brezinschek HP, Brickmann K, Yazdani-Biuki B, Dorner T, Graninger WB, Brezinschek RI. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes. Wien. Med. Wochenschr. 156: 61-67 (2006).
Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, Frank MM. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J. Allergy Clin. Immunol. 77: 749-757 (1986).
Bridges SL Jr, Jenq G, Moran M, Kuffner T, Whitworth WC, McNicholl J. Single-nucleotide polymorphisms in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic differences. Arthritis Rheum. 46: 2045-2050 (2002). *
Briggs D, Stephens C, Vaughan R, Welsh K, Black C. A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. Arthritis Rheum. 36: 943-954 (1993).
Bright JJ. Curcumin and autoimmune disease. Adv. Exp. Med. Biol. 595: 425-451 (2007).
Brik R, Gepstein V, Shahar E, Goldsher D, Berkovitz D. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin. Rheumatol. 26: 1783-1785 (2007). *
Brik R, Livnat G, Pollack S, Catz R, Nagler R. Salivary gland involvement and oxidative stress in juvenile idiopathic arthritis: novel observation in oligoarticular-type patients. J. Rheumatol. 33: 2532-2537 (2006).
Brinar VV, Petelin Z, Brinar M, Djakovic V, Zadro I, Vranjes D. CNS demyelination in autoimmune diseases. Clin. Neurol. Neurosurg. 108: 318-326 (2006).
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J. Rheumatol. 30: 211-213 (2003).
Brinkman DM, Jol-van der Zijde CM, Ten Dam MM, Te Boekhorst PA, Ten Cate R, Wulffraat NM, Hintzen RQ, Vossen JM, van Tol MJ. Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J. Clin. Immunol. 27: 647-658 (2007). *
Brintnell W, Bell DA, Hill JA, Jevnikar AM, Sette A, Sidney J, Doege K, Cairns E. The influence of MHC class II molecules containing the rheumatoid arthritis shared epitope on the immune response to aggrecan G1 and its peptides. Scand. J. Immunol. 65: 444-452 (2007). *
Brintnell W, Zeggini E, Barton A, Thomson W, Eyre S, Hinks A, Silman AJ, Worthington J. Evidence for a novel rheumatoid arthritis susceptibility locus on chromosome 6p. Arthritis Rheum. 50: 3823-3830 (2004). *
Brinton LA, Buckley LM, Dvorkina O, Lubin JH, Colton T, Murray MC, Hoover R. Risk of connective tissue disorders among breast implant patients. Am. J. Epidemiol. 160: 619-627 (2004). *
Brinza D, Zelikovsky A. Design and validation of methods searching for risk factors in genotype case-control studies. J. Comput. Biol. 15: 81-90 (2008).
Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, Garnero P. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. J. Rheumatol. 35: 310-314 (2008).
Brito-Zeron P, Soria N, Munoz S, Bove A, Akasbi M, Belenguer R, Siso A, Ramos-Casals M. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjogren's syndrome. Semin. Arthritis Rheum. 38: 389-395 (2009). *
Britto MT, Devellis RF, Hornung RW, Defriese GH, Atherton HD, Slap GB. Health care preferences and priorities of adolescents with chronic illnesses. Pediatrics 114: 1272-1280 (2004). *
Brockhausen I. The role of galactosyltransferases in cell surface functions and in the immune system. Drug News Perspect. 19: 401-409 (2006).
Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 74: 148-154 (2007). *
Brodmerkel CM, Vaddi K. Transgenic animals in inflammatory disease models. Curr. Opin. Biotechnol. 14: 652-658 (2003). *
Brodsky B, Erlanger-Rosengarten A, Proscura E, Shapira E, Wormser U. From topical antidote against skin irritants to a novel counter-irritating and anti-inflammatory peptide. Toxicol. Appl. Pharmacol. 229: 342-350 (2008). *
Brodszky V, Balint P, Geher P, Hodinka L, Horvath G, Koo E, Pentek M, Polgar A, Sesztak M, Szanto S, Ujfalussy I, Gulacsi L. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol. Int. Apr 19 [Epub ahead of print] (2009). *
Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scand. J. Rheumatol. 37: 399-400 (2008).
Broere F, Wieten L, Klein Koerkamp EI, van Roon JA, Guichelaar T, Lafeber FP, van Eden W. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J. Immunol. 181: 899-906 (2008).
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ. Systemic vasculitis: a cause of indeterminate intestinal inflammation. J. Pediatr. Gastroenterol. Nutr. 42: 405-415 (2006). *
Brogan PA, Shah V, Klein N, Dillon MJ. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Arthritis Rheum. 50: 589-597 (2004). *
Broholm B, Ullman S, Halberg P, Jacobsen S. Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis. Clin. Rheumatol. 27: 1053-1056 (2008).
Bronson PG, Criswell LA, Barcellos LF. The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6,861 patients and 9,270 controls reveals no evidence for association. Ann. Rheum. Dis. 67: 933-936 (2008).
Brooklyn TN, Williams AM, Dunnill MG, Probert CS. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br. J. Dermatol. 157: 960-966 (2007). *
Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther. Drug Monit. 29: 619-625 (2007).
Brooks PM. Hematopoietic stem cell transplantation for autoimmune diseases. J. Rheumatol. Suppl. 48: 19-22 (1997).
Brooks PM. The burden of musculoskeletal disease - a global perspective. Clin. Rheumatol. 25: 778-781 (2006). *
Brooks WH. Autoimmune disorders result from loss of epigenetic control following chromosome damage. Med. Hypotheses 64: 590-598 (2005).
Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr. Opin. Gastroenterol. 23: 617-624 (2007).
Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, Lovell C, Calin A. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J. Rheumatol. 28: 2667-2673 (2001).
Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience. Semin. Arthritis Rheum. 34: 544-548 (2004). *
Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 54: 3761-3773 (2006). *
Brown C, Gaspar J, Pettit A, Lee R, Gu X, Wang H, Manning C, Voland C, Goldring SR, Goldring MB, Libermann TA, Gravalllese EM, Oettgen P. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J. Biol. Chem. 279: 12794-12803 (2004). *
Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, Weedon H, Milliken ST, Tak PP, Smith MD, Breit SN. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum. 56: 753-764 (2007). *
Brown JM, Pfau JC, Pershouse MA, Holian A. Silica, apoptosis, and autoimmunity. J. Immunotoxicol. 1: 177-187 (2005).
Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res. Ther. 10: 212 (2008). *
Brown KK, Heitmeyer SA, Hookfin EB, Hsieh L, Buchalova M, Taiwo YO, Janusz MJ. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J. Inflamm. (Lond.) 5: 22 (2008). *
Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, VON Feldt JM. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J. Rheumatol. 34: 740-746 (2007).
Brown LC, Majumdar SR, Newman SC, Johnson JA. Type 2 diabetes does not increase risk of depression. CMAJ 175: 42-46 (2006). *
Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111: 3388-3394 (2008). *
Brown MA, Brophy S, Bradbury L, Hamersma J, Timms A, Laval S, Cardon L, Calin A, Wordsworth BP. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum. 48: 2234-2239 (2003). *
Brown MA, Duncan EL. Genetic studies of osteoporosis. Expert Rev. Mol. Med. 1: 1-18 (1999). *
Brown MA, Pile KD, Kennedy LG, Campbell D, Andrew L, March R, Shatford JL, Weeks DE, Calin A, Wordsworth BP. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum. 41: 588-595 (1998). *
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46: 3151-3158 (2002). *
Brown WM. Anti-CD3 antibody MacroGenics Inc. Curr. Opin. Investig. Drugs 7: 381-388 (2006).
Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5: 564-576 (2006). *
Brownlie RJ, Lawlor KE, Niederer HA, Cutler AJ, Xiang Z, Clatworthy MR, Floto RA, Greaves DR, Lyons PA, Smith KG. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J. Exp. Med. 205: 883-895 (2008). *
Brownlie RJ, Myers LK, Wooley PH, Corrigall VM, Bodman-Smith MD, Panayi GS, Thompson SJ. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum. 54: 854-863 (2006). *
Brucato A, Brambilla G, Moreo A, Alberti A, Munforti C, Ghirardello A, Doria A, Shinar Y, Livneh A, Adler Y, Shoenfeld Y, Mauri F, Palmieri G, Spodick DH. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am. J. Cardiol. 98: 267-271 (2006). *
Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, Zanni D, Penco S, Boiani E, Ghirardello A, Caforio AL, Bergantin A, Tombini V, Moreo A, Ashtamkar L, Doria A, Shoenfeld Y, Livneh A. Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients. Lupus 14: 670-674 (2005).
Bruce IN, Gladman DD. Psoriatic arthritis: recognition and management. BioDrugs 9: 271-278 (1998).
Bruce SP, Boyce EG. Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. Ann. Pharmacother. 41: 1153-1162 (2007).
Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol. Med. 14: 109-115 (2008). *
Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, Nantz MH, Benson GD, Van de Water J, Luketic V, Roche TE, Ansari AA, Coppel RL, Gershwin ME. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 125: 1705-1713 (2003). *
Bruhl H, Cihak J, Plachy J, Kunz-Schughart L, Niedermeier M, Denzel A, Rodriguez Gomez M, Talke Y, Luckow B, Stangassinger M, Mack M. Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum. 56: 2975-2985 (2007). *
Bruhl H, Cihak J, Schneider MA, Plachy J, Rupp T, Wenzel I, Shakarami M, Milz S, Ellwart JW, Stangassinger M, Schlondorff D, Mack M. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. Immunol. 172: 890-898 (2004). *
Brulhart L, Ciurea A, Finckh A, Notter A, Waldburger JM, Kyburz D, Gabay C. Efficacy of B-cell depletion in rheumatoid arthritis patients refractory to anti-tumour necrosis factor (TNF)- a agents: an open label observational study. Ann. Rheum. Dis. 65: 1255-1257 (2006). *
Brumeanu TD, Bona CA, Casares S. T-cell tolerance and autoimmune diabetes. Int. Rev. Immunol. 20: 301-331 (2001).
Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, Mier R, Passo MH, Rennebohm R, Schikler K, Lovell DJ. Current medication choices in juvenile rheumatoid arthritis II - update of a survey performed in 1993. J. Clin. Rheumatol. 7: 295-300 (2001).
Brunner J, Kern PM, Gaipl US, Munoz LE, Voll RE, Kalden JR, Wiesenhutter CW, Herrmann M. The low-throughput protein A adsorber: an immune modulatory device. Hypothesis for the mechanism of action in the treatment of rheumatoid arthritis. Mod. Rheumatol. 15: 9-18 (2005).
Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis. Clin. Exp. Rheumatol. 24: 449-451 (2006).
Brunner JK, Sitzmann FC. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod. Rheumatol. 16: 372-375 (2006). *
Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report. Arthritis Rheum. 46: 1580-1584 (2002). *
Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc. Natl. Acad. Sci. U.S.A. 103: 6735-6740 (2006). *
Bruno O, Brullo C, Arduino N, Schenone S, Ranise A, Bondavalli F, Ottonello L, Dapino P, Dallegri F. Synthesis and biological evaluation of neutrophilic inflammation inhibitors. Farmaco 59: 223-235 (2004).
Bruyn GA. Thalidomide (Celgene Corp.). IDrugs 1: 490-500 (1998).
Bruzzese V. Diffused suberitrodermic psoriasis induced by infliximab. Reumatismo 59: 328-331 (2007).
Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 305: 127-160 (2006).
Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA, Soroosh P, Watford WT, O'Shea JJ, Kastner DL, Hoffman HM. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity Jun 3 [Epub ahead of print] (2009). *
Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 52: 2996-3003 (2005). *
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. alpha-Melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr. Rev. 29: 581-602 (2008). *
Bucala R, Lolis E. Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases. Drug News Perspect. 18: 417-426 (2005).
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, Font J, Asherson RA. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 54: 2568-2576 (2006). *
Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Emery P, Reece R, Quinn M. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum. 57: 448-453 (2007). *
Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 46: 1153-1156 (2007). *
Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P. Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: a histological, gene expression and dynamic MRI pilot study. Ann. Rheum. Dis. Sep 4 [Epub ahead of print] (2008).
Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis; a role for lymphotoxin-alpha? Ann. Rheum. Dis. 63: 1344-1346 (2004). *
Buch MH, Marzo-Ortega H, Bingham SJ, Emery P. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Rheumatology (Oxford) 43: 243-244 (2004). *
Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, Meehan A, Henderson L, Wengier L, van den Haak R. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. Intern. Med. J. 37: 591-600 (2007).
Buchs N, di Giovine FS, Silvestri T, Vannier E, Duff GW, Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun. 2: 222-228 (2001). *
Buckbinder L, Robinson RP. The glucocorticoid receptor: molecular mechanism and new therapeutic opportunities. Curr. Drug Targets Inflamm. Allergy 1: 127-36 (2002).
Budancamanak M, Kanter M, Demirel A, Ocakci A, Uysal H, Karakaya C. Protective effects of thymoquinone and methotrexate on the renal injury in collagen-induced arthritis. Arch. Toxicol. 80: 768-776 (2006). *
Budzynska R, Zakliczynska H. Methotrexate in the treatment of the patients with rheumatoid arthritis. Postepy. Hig. Med. Dosw. (Online) 58: 108-117 (2004).
Bueso MB, Caballero R, Castro HJ, Barakat A, Bellanti JA. Recurrent infections and joint pain. Allergy Asthma Proc. 27: 164-171 (2006).
Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. Autoimmun. Rev. 7: 137-142 (2007).
Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis - a critical approach. Semin. Arthritis Rheum. 36: 224-237 (2007). *
Buisson M, Berthelot JM, Le Goff P, Chastel C, Lamour A, Seigneurin JM, Youinou P. Lack of relationship between the Epstein-Barr virus and the antiperinuclear factor/'perinuclear antigen' system in rheumatoid arthritis. J. Autoimmun. 7: 485-495 (1994).
Buisson-Legendre N, Smith S, March L, Jackson C. Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis Rheum. 50: 2151-2156 (2004). *
Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum. 56: 2929-2935 (2007). *
Bukulmez H, Fife M, Tsoras M, Thompson SD, Twine NA, Woo P, Olson JM, Elston RC, Glass DN, Colbert RA. Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study. Arthritis Res. Ther. 7: R285-R290 (2005). *
Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, Evans BA, Rowley TF, Slebioda TJ, Taraban VY, Al-Shamkhani A, Wang EC. The death receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J. Exp. Med. 205: 2457-2464 (2008). *
Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB, Woolley JM. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag. Care Interface 19: 47-53 (2006).
Buller HA. Problems in diagnosis of IBD in children. Neth. J. Med. 50: S8-S11 (1997).
Bultink IE, Hamann D, Seelen MA, Hart MH, Dijkmans BA, Daha MR, Voskuyl AE. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus (SLE). Arthritis Res. Ther. 8: R183 (2006). *
Buning C, Schmidt HH, Molnar T, DE Jong DJ, Fiedler T, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Buttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment. Pharmacol. Ther. 26: 1025-1033 (2007). *
Bunte C, Popp-Habeler J, Mischer P, Tuppy H, Haidenthaler A, Knoflach P, Kirchgatterer A. Concomitant manifestation of pyoderma gangrenosum and colorectal carcinoma. Scand. J. Gastroenterol. 43: 756-758 (2008). *
Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, Schell RF. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect. Immun. 71: 3437-3442 (2003). *
Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J. Invest. Dermatol. 110: 958-960 (1998). *
Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract. Res. Clin. Rheumatol. 20: 879-896 (2006).
Burgos RA, Hancke JL, Bertoglio JC, Aguirre V, Arriagada S, Calvo M, Caceres DD. Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clin. Rheumatol. Apr 29 [Epub ahead of print] (2009).
Burgos-Vargas R. Spondyloarthropathies and psoriatic arthritis in children. Curr. Opin. Rheumatol. 5: 634-643 (1993).
Burgos-Vargas R. A case of childhood-onset ankylosing spondylitis: diagnosis and treatment. Nat. Clin. Pract. Rheumatol. 5: 52-57 (2009).
Burgoyne CH, Field SL, Brown AK, Hensor EM, English A, Bingham SL, Verburg R, Fearon U, Lawson CA, Hamlin JP, Straszynski L, Veale D, Conaghan P, Hull MA, van Laar JM, Tennant A, Emery P, Isaacs JD, Ponchel F. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse. Ann. Rheum. Dis. 67: 750-757 (2008).
Burke AP, Tavora F, Narula N, Tomaszewski JE, Virmani R. Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum. Pathol. 39: 514-526 (2008).
Burkhardt H, Huffmeier U, Spriewald B, Bohm B, Rau R, Kallert S, Engstrom A, Holmdahl R, Reis A. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. Arthritis Rheum. 54: 82-89 (2005). *
Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 35: 1643-1652 (2005). *
Burleson GR, Burleson FG. Testing human biologicals in animal host resistance models. J. Immunotoxicol. 5: 23-31 (2008).
Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J. Immunol. 174: 1693-1700 (2005). *
Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. Jan 15 [Epub ahead of print] (2009). *
Burnevich EZ, Lopatkina TN. System manifestations of primary biliary cirrhosis. Klin. Med. (Mosk.) 84: 42-46 (2006).
Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Ostor AJ. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47: 738-739 (2008). *
Burr ML, Naseem H, Hinks A, Eyre S, Gibbons L, Bowes J, Consortium B, Consortium Y, Wilson AG, Maxwell J, Morgan AW, Emery P, Steer S, Hocking L, Reid DM, Wordsworth BP, Harrison P, Thomson W, Worthington J, Barton A. PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Ann. Rheum. Dis. May 25 [Epub ahead of print] (2009).
Burrage PS, Huntington JT, Sporn MB, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. Arthritis Rheum. 56: 892-904 (2007). *
Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front. Biosci. 11: 529-543 (2006).
Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Res. Ther. 10: R139 (2008). *
Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 25: 133-137 (1984). *
Burt RK, Georganas C, Schroeder J, Traynor A, Stefka J, Schuening F, Graziano F, Mineishi S, Brush M, Fishman M, Welles C, Rosen S, Pope R. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum. 42: 2281-2285 (1999). *
Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H, Patel DD, Collier D, Heslop H, Krance R, Statkute L, Verda L, Traynor A, Kozak T, Hintzen RQ, Rose JW, Voltarelli J, Loh Y, Territo M, Cohen BA, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 54: 3750-3760 (2006). *
Burt RK, Traynor AE. SLE - hematopoietic stem cell transplantation for systemic lupus erythematosus. Arthritis Res. Ther. 5: 207-209 (2003). *
Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92: 3505-3514 (1998). *
Burton S, Lloyd M. An overview of rheumatoid arthritis. Nurs. Stand. 20: 46-49 (2006).
Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 46: 802-805 (2002). *
Bushell TJ. The emergence of PAR-2 as a novel target for the treatment of inflammation-related CNS disorders. J. Physiol. 581: 7-16 (2007). *
Buskila D. Hepatitis C-associated rheumatic disorders. Rheum. Dis. Clin. North Am. 35: 111-123 (2009).
Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J. Rheumatol. 26: 1167-1171 (1999).
Busquets-Perez N, Narvaez J, Valverde-Garcia J. Interstitial granulomatous dermatitis with arthritis (Ackerman syndrome). J. Rheumatol. 33: 1207-1209 (2006).
Busso N, Frasnelli M, Feifel R, Cenni B, Steinhoff M, Hamilton J, So A. Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum. 56: 101-107 (2007). *
Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3: e2267 (2008). *
Bussone G, Hachulla E, Sibilia J, Michel M, Godeau B, Guillevin L, Mouthon L. Treatment of systemic autoimmune and inflammatory diseases with rituximab. Presse. Med. 38: 808-823 (2009).
Busteed S, Bennett MW, Molloy C, Houston A, Stone MA, Shanahan F, Molloy MG, O'Connell J. Bcl-x(L) expression in vivo in rheumatoid synovium. Clin. Rheumatol. 25: 789-793 (2006). *
Butler GS, Sim D, Tam E, Devine D, Overall CM. Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis: potential role in human MBL deficiency. J. Biol. Chem. 277: 17511-17519 (2002). *
Butrimiene I, Ranceva J, Griskevicius A. Potential triggering infections of reactive arthritis. Scand. J. Rheumatol. 35: 459-462 (2006).
Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J. Rheumatol. 33: 1631-1633 (2006). *
Butt C, Lim S, Greenwood CM, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet. Disord. 8: 1 (2007). *
Butt C, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. Arthritis Res. Ther. 8: R27-R30 (2006). *
Butt C, Rahman P, Siannis F, Farewell VT, Gladman DD. Corneodesmosin polymorphisms in psoriatic arthritis. Rheumatology (Oxford) 44: 684-685 (2005). *
Butt C, Sun S, Greenwood C, Gladman D, Rahman P. Lack of association of SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 variants in psoriatic arthritis. Rheumatology (Oxford) 44: 820-821 (2005). *
Butt C, Sun S, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Association of nuclear factor-kappaB in psoriatic arthritis. J. Rheumatol. 32: 1742-1744 (2005).
Butz DE, Li G, Huebner SM, Cook ME. A mechanistic approach to understanding conjugated linoleic acid's role in inflammation using murine models of rheumatoid arthritis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R669-R676 (2007). *
Buzas EI, Vegvari A, Murad YM, Finnegan A, Mikecz K, Glant TT. T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis. Cell. Immunol. 235: 98-108 (2005). *
Caballero-Uribe CV, Acosta-Velez JG, Hernandez-Ruiz EA, Andrade Rodado FM, Penuela-Epalza M. Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city. J. Clin. Rheumatol. 14: 153-155 (2008).
Cabral DA, Petty RE, Malleson PN, Ensworth S, McCormick AQ, Shroeder ML. Visual prognosis in children with chronic anterior uveitis and arthritis. J. Rheumatol. 21: 2370-2375 (1994).
Cabrera Pivaral CE, Gutierrez Gonzalez TY, Gamez Nava JI, Nava A, Villa Manzano AI, Luce Gonzalez E. Clinical competence for autoimmune and non-autoimmune rheumatic disorders in primary care. Rev. Alerg. Mex. 56: 18-22 (2009).
Caccavo D, Afeltra A, Guido F, Di Monaco C, Ferri GM, Amoroso A, Vaccaro F, Bonomo L. Two spatially distant epitopes of human lactoferrin. Hybridoma 15: 263-269 (1996).
Caccavo D, Afeltra A, Rigon A, Vadacca M, Zobel BB, Zennaro D, Arcarese L, Buzzulini F, Pellegrino NM, Amoroso A. Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement. Int. J. Immunopathol. Pharmacol. 21: 659-668 (2008).
Cachafeiro-Vilar A, Garcia-Padilla C, Reyes E, Hernandez-Molina G. Polyarticular arthritis secondary to Mycobacterium bovis infection: an unusual clinical presentation. Joint Bone Spine 74: 107-109 (2007). *
Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M. Adult-onset Still's disease. Int. J. Clin. Pract. May 18 [Epub ahead of print] (2007).
Caggiano TJ, Brazzale A, Ho DM, Kraml CM, Trybulski E, Chadwick CC, Chippari S, Borges-Marcucci L, Eckert A, Keith JC, Kenney T, Harnish DC. Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid � J. Med. Chem. 50: 5245-5248 (2007). *
Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur. Cytokine Netw. 16: 289-292 (2005).
Cahoon Jr WD, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann. Pharmacother. 40: 295-298 (2006).
Cai C, La Cava A. Mimicking self-antigens with synthetic peptides in systemic autoimmune rheumatic diseases. Curr. Clin. Pharmacol. 4: 142-147 (2009).
Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 16: 10-21 (2001).
Cai X, Wong YF, Zhou H, Liu ZQ, Xie Y, Jiang ZH, Bian ZX, Xu HX, Liu L. Manipulation of the induction of adjuvant arthritis in Sprague-Dawley rats. Inflamm. Res. 55: 368-377 (2006). *
Cai X, Wong YF, Zhou H, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L. The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis. Naunyn. Schmiedebergs. Arch. Pharmacol. 373: 140-147 (2006). *
Cai X, Zhou H, Wong YF, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L. Suppressive effects of QFGJS, a preparation from an anti-arthritic herbal formula, on rat experimental adjuvant-induced arthritis. Biochem. Biophys. Res. Commun. 337: 586-594 (2005). *
Cai X, Zhou H, Wong YF, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L. Suppression of the onset and progression of collagen-induced arthritis in rats by QFGJS, a preparation from an anti-arthritic Chinese herbal formula. J. Ethnopharmacol. 110: 39-48 (2007). *
Calabuig E, Salavert M. Infectious risk. Actas Dermosifiliogr. 99 Suppl. 4: 14-22 (2008).
Calander AM, Starckx S, Opdenakker G, Bergin P, Quiding-Jarbrink M, Tarkowski A. Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis. Microbes Infect. 8: 1434-1439 (2006). *
Calcagni E, Elenkov I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann. N. Y. Acad. Sci. 1069: 62-76 (2006). *
Calder PC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83: 1505S-1519S (2006). *
Calder PC. n-3 Polyunsaturated fatty acids and cytokine production in health and disease. Ann. Nutr. Metab. 41: 203-234 (1997).
Calder PC. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease'. PUFA, inflammatory processes and rheumatoid arthritis. Proc. Nutr. Soc. 67: 409-418 (2008). *
Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36: 1007-1024 (2001).
Calder PC. n-3 Polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38: 343-352 (2003).
Calder PC. Dietary modification of inflammation with lipids. Proc. Nutr. Soc. 61: 345-358 (2002). *
Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors 35: 266-272 (2009).
Calder PC, Yaqoob P, Thies F, Wallace FA, Miles EA. Fatty acids and lymphocyte functions. Br. J. Nutr. 87 Suppl. 1: S31-S48 (2002). *
Calin A, Marder A, Becks E, Burns T. Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. Arthritis Rheum. 26: 1460-1464 (1983).
Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A, Yucel E, Muderrisoglu H. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196: 306-312 (2008).
Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr. Opin. Rheumatol. 16: 399-405 (2004).
Callegari PE, Schaible TF, Boscia JA. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296: 2202 (2006). *
Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther. Clin. Risk Manag. 4: 1305-1213 (2008). *
Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin. Cutan. Med. Surg. 26: 6-14 (2007).
Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum. Dis. Clin. North Am. 33: 787-802 (2007).
Callot V, Ochonisky S, Vabres P, Revuz J. Acute arthritis during isotretinoin treatment. Ann. Dermatol. Venereol. 121: 402-403 (1994).
Calvo-Alen J, Alarcon GS, Tew MB, Tan FK, McGwin G Jr, Fessler BJ, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 54: 1940-1945 (2006). *
Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases. Genes Immun. 5: 609-614 (2004). *
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54: 723-732 (2006). *
Cammelli D. Extra-articular manifestations of seronegative spondyloarthritis. Recenti Prog. Med. 97: 280-289 (2006).
Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun. 6: 467-471 (2005). *
Campbell AK, Waud JP, Matthews SB. The molecular basis of lactose intolerance. Sci. Prog. 88: 157-202 (2005).
Campbell IK, Kinkel SA, Drake SF, Nieuwenhuijze AV, Hubert FX, Tarlinton DM, Heath WR, Scott HS, Wicks IP. Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis. Arthritis Rheum. 60: 1683-1693 (2009). *
Campione E, Mazzotta A, Paterno EJ, Diluvio L, Prinz JC, Chimenti S. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm. Venereol. 89: 288-291 (2009).
Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11: 936-943 (2005). *
Candia L, Cuellar ML, Marlowe SM, Marquez J, Iglesias A, Espinoza LR. Charcot-like arthropathy: a newly-recognized subset of psoriatic arthritis. Clin. Exp. Rheumatol. 24: 172-175 (2006).
Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin. Arthritis Rheum. 35: 49-56 (2005). *
Candia L, Marquez J, Gonzalez C, Santos AM, Londono J, Valle R, Zabaleta J, Yaqub Z, Espinoza LR. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J. Clin. Rheumatol. 12: 226-229 (2006).
Candia L, Marquez J, Hernandez C, Zea AH, Espinoza LR. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J. Rheumatol. 34: 374-379 (2007).
Canete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmarti R, Palacin A, Lora D, de la Cruz J, Pablos JL. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68: 751-756 (2009).
Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmarti R, Baeten D. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. Arthritis Res. Ther. 11: R17 (2009). *
Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R, Graell E, Gil-Torregrosa B, Baeten D, Pablos JL. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann. Rheum. Dis. 66: 720-726 (2007). *
Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F. Influence of variants of Fcgamma receptors IIA and IIIA on the ACR and EULAR responses to anti-TNFalpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. Oct 17 [Epub ahead of print] (2008).
Canhao H, Fonseca JE, Caetano-Lopes J, Saldanha C, Queiroz MV. Assessment of laboratory measurements and -308 TNFalpha gene promoter polymorphisms in normal bone mineral density. Clin. Rheumatol. 27: 301-307 (2008). *
Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J. Rheumatol. 35: 421-424 (2008).
Cantaert T, Coucke P, De Rycke L, Veys EM, De Keyser F, Baeten D. Functional haplotypes of PADI4: relevance for rheumatoid arthritis-specific synovial intracellular citrullinated proteins and anti-citrullinated protein antibodies. Ann. Rheum. Dis. 64: 1316-1320 (2005). *
Cantaert T, De Rijcke L, Mavragani CP, Wijbrandts CA, Niewold TB, Niers T, Vandooren B, Veys EM, Richel D, Tak PP, Crow MK, Baeten D. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during TNF alpha blockade. Ann. Rheum. Dis. 68: 1022-1029 (2009).
Cantaert T, De Rycke L, Bongartz T, Matteson EL, Tak PP, Nicholas AP, Baeten D. Citrullinated proteins in rheumatoid arthritis: crucial ... but not sufficient! Arthritis Rheum. 54: 3381-3389 (2006). *
Cantaert T, Stone MA, Terborg M, Mog R, de Vries N, Wilson AG, Tak PP, Baeten D. A functional polymorphism of TIR-domain-containing adaptor protein is not associated with axial spondyloarthritis. Ann. Rheum. Dis. 67: 720-722 (2008).
Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, Constantin A, Laroche M, Mazieres B. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 42: 1093-1100 (1999). *
Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int. J. Immunopathol. Pharmacol. 22: 551-555 (2009).
Canter PH, Wider B, Ernst E. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. Rheumatology (Oxford) 46: 1223-1233 (2007). *
Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 47: 872-876 (2008). *
Cantor RM, Yuan J, Napier S, Kono N, Grossman JM, Hahn BH, Tsao BP. Systemic lupus erythematosus genome scan: support for linkage at 1q23, 2q33, 16q12-13, and 17q21-23 and novel evidence at 3p24, 10q23-24, 13q32, and 18q22-23. Arthritis Rheum. 50: 3203-3210 (2004). *
Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc. Soc. Exp. Biol. Med. 223: 230-233 (2000). *
Cantorna MT, Humpal-Winter J, DeLuca HF. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch. Biochem. Biophys. 377: 135-138 (2000). *
Cantorna MT, Mahon BD. D-hormone and the immune system. J. Rheumatol. Suppl. 76: 11-20 (2005). *
Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. (Maywood) 229: 1136-1142 (2004). *
Cao Q, Si JM, Gao M, Zhou G, Hu WL, Li JH. Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in eastern China. Chin. Med. J. (Engl.) 118: 747-752 (2005).
Cao Y, Brombacher F, Tunyogi-Csapo M, Glant TT, Finnegan A. Interleukin-4 regulates proteoglycan-induced arthritis by specifically suppressing the innate immune response. Arthritis Rheum. 56: 861-870 (2007). *
Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J. Immunol. 180: 922-930 (2008). *
Cao Y, Wang Z, Bu X, Tang S, Mei Z, Liu P. A synthetic peptide derived from A1 module in CRD4 of human TNF receptor-1 inhibits binding and proinflammatory effect of human TNF-alpha. Inflammation 32: 139-145 (2009). *
Caparbo VF, Prada F, Silva CA, Regio PL, Pereira RM. Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts "in vitro". Clin. Rheumatol. 28: 71-77 (2009).
Caparroz-Assef SM, Bersani-Amado CA, Kelmer-Bracht AM, Bracht A, Ishii-Iwamoto EL. The metabolic changes caused by dexamethasone in the adjuvant-induced arthritic rat. Mol. Cell. Biochem. 302: 87-98 (2007). *
Capellino S, Montagna P, Villaggio B, Cutolo M. Effects of estrogen peripheral metabolism in rheumatoid arthritis. Reumatismo 57: 78-82 (2005).
Capini C, Jaturanpinyo M, Chang HI, Mutalik S, McNally A, Street S, Steptoe R, O'Sullivan B, Davies N, Thomas R. Antigen-specific suppression of inflammatory arthritis using liposomes. J. Immunol. 182: 3556-3565 (2009).
Caplan L, Russell AS, Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J. Rheumatol. 32: 1863-1865 (2005).
Capocasale RJ, Makropoulos DA, Achuthanandam R, Stowell N, Quinn J, Rafferty PA, O'Brien J, Emmell E, Bugelski PJ. Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice. Cytometry A. 73: 148-159 (2008).
Caponi L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, Pratesi F, Pierlot C, Osorio J, Chapuy-Regaud S, Guerrin M, Cornelis F, Serre G, Migliorini P; ECRAF. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann. Rheum. Dis. 64: 587-593 (2005). *
Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun. Rev. 8: 274-280 (2009).
Cappello F, Czarnecka AM, Rocca GL, Stefano AD, Zummo G, Macario AJ. Hsp60 and Hsp10 as antitumor molecular agents. Cancer Biol. Ther. 6: 487-489 (2007). *
Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res. Ther. 7: R250-R255 (2005). *
Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol. Int. 26: 209-214 (2006). *
Caramaschi P, Ruzzenente O, Pieropan S, Volpe A, Carletto A, Bambara LM, Biasi D. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. Rheumatol. Int. 27: 649-654 (2007). *
Caramella C, Avouac J, Sogni P, Puechal X, Kahan A, Allanore Y. Association between rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 74: 279-281 (2007). *
Caramia G. Omega-3: from cod-liver oil to nutrigenomics. Minerva Pediatr. 60: 443-455 (2008).
Carbone J, Perez-Rojas J, Sarmiento E. Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor. Curr. Infect. Dis. Rep. 11: 229-236 (2009).
Cardoso CC, Pinto AC, Marques PR, Gayer CR, Afel MI, Coelho MG, Sabino KC. Suppression of T and B cell responses by Pterodon pubescens seeds ethanolic extract. Pak. J. Biol. Sci. 11: 2308-2313 (2008).
Carette S. All patients with rheumatoid arthritis should receive corticosteroids as part of their management. J. Rheumatol. 34: 656-660 (2007).
Carl PL, Temple BR, Cohen PL. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res. Ther. 7: R1360-R1374 (2005). *
Carlisle AC, John AM, Fife-Schaw C, Lloyd M. The self-regulatory model in women with rheumatoid arthritis: relationships between illness representations, coping strategies, and illness outcome. Br. J. Health Psychol. 10: 571-587 (2005).
Carlsen H, Alexander G, Austenaa LM, Ebihara K, Blomhoff R. Molecular imaging of the transcription factor NF-kappaB, a primary regulator of stress response. Mutat. Res. 551: 199-211 (2004).
Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B-cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 104: 3021-3027 (2004). *
Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin. Rheumatol. Apr 16 [Epub ahead of print] (2009).
Carlsen S, Lu S, Holmdahl R. Arthritis induced with minor cartilage proteins. Methods Mol. Med. 136: 225-242 (2007).
Carlsten C, de Roos AJ, Kaufman JD, Checkoway H, Wener M, Seixas N. Cell markers, cytokines, and immune parameters in cement mason apprentices. Arthritis Rheum. 57: 147-153 (2007). *
Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, Alexander HC, Chang M, Catanese JJ, Leong DU, Ardlie KG, Kastner DL, Seldin MF, Criswell LA, Gregersen PK, Beasley E, Thomson G, Amos CI, Begovich AB. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 77: 567-581 (2005). *
Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo Ibanez T, Gomez-Reino JJ, Study Groups EB. All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists. Ann. Rheum. Dis. 66: 880-885 (2007). *
Caro-Oleas JL, Fernandez-Suarez A, Reneses Cesteros S, Porrino C, Nunez-Roldan A, Wichmann Schlipf I. Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow-up. Clin. Exp. Rheumatol. 26: 461-463 (2008).
Carpenter GH, Proctor GB, Pankhurst CL, O'Donohue J, Scott D, Hunnable MP. Sialochemical markers of salivary gland involvement with Sjogren's syndrome secondary to rheumatoid arthritis and primary biliary cirrhosis. J. Oral. Pathol. Med. 29: 452-459 (2000).
Carreira PE, Gonzalez-Crespo MR, Ciruelo E, Pablos JL, Santiago B, Gomez-Camara A, Gomez-Reino JJ. Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. Arthritis Rheum. 52: 3015-3019 (2005). *
Carrera C, Mascaro JM Jr, Moreno-Romero JA, Iranzo P, Palou J, Zamora E, Herrero C. Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept. Dermatology 214: 77-81 (2007).
Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J. Autoimmun. 26: 182-196 (2006).
Carrier N, Cossette P, Daniel C, de Brum-Fernandes A, Liang P, Menard HA, Boire G. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies. Arthritis Rheum. 60: 698-707 (2009). *
Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U.S.A. 104: 282-287 (2007). *
Carroll L, Frazer IH, Turner M, Marwick T, Thomas R. The receptor for advanced glycation end products glycine 82 serine polymorphism and the risk of cardiovascular events in rheumatoid arthritis. Arthritis Res. Ther. 9: R39 (2007). *
Carroll L, Hannawi S, Marwick T, Thomas R. Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. Wien. Med. Wochenschr. 156: 42-52 (2006).
Carron PN, Yerly S, Ksontini R, Meylan P, Calandra T. Pyoderma gangrenosum: diagnostic and therapeutic challenge. Rev. Med. Suisse. 4: 1938-1940, 1942-1943 (2008).
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 113: 4834-4840 (2009). *
Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by TNF antagonists: a skin-deep medical conundrum. Ann. Rheum. Dis. 67: 1181-1183 (2008).
Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J. Rheumatol. 33: 1014-1017 (2006).
Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J. Rheumatol. 31: 1973-1980 (2004).
Carter JD, Vasey FB. Psoriatic arthritis: genetics, immunology, and therapies. J. Clin. Rheumatol. 7: 363-365 (2001).
Carter JD, Vasey FB, Kanik KS, Valeriano-Marcet J. Polymyalgia rheumatica and temporal arteritis with sacroiliitis and osteitis pubis. J. Clin. Rheumatol. 7: 261-264 (2001).
Carter RH. B cells in health and disease. Mayo Clin. Proc. 81: 377-384 (2006). *
Carthy D, Ollier W, Papasteriades C, Pappas H, Thomson W. A shared HLA-DRB1 sequence confers RA susceptibility in Greeks. Eur. J. Immunogenet. 20: 391-398 (1993).
Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 27: 246-256 (2007). *
Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT, Mathieu A, Sorrentino R. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia. Arthritis Rheum. 56: 2640-2651 (2007). *
Casciola-Rosen L, Miagkov A, Nagaraju K, Askin F, Jacobson L, Rosen A, Drachman DB. Granzyme B: evidence for a role in the origin of myasthenia gravis. J. Neuroimmunol. 201-202: 33-40 (2008).
Casellini C, Citera G, Rosemffet M, Ruggeri S, Saviotti A, Cocco JA. Audiovestibular disorders in patients with ankylosing spondylitis. J. Clin. Rheumatol. 11: 81-85 (2005).
Casimiro L, Barnsley L, Brosseau L, Milne S, Robinson V, Tugwell P, Wells G, Casimiro L. Acupuncture and electroacupuncture for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 4: CD003788 (2005). *
Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, Levartovsky D, Litinsky I, Elkayam O. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum. 55: 53-56 (2006). *
Cassano N, Galluccio A, De Simone C, Loconsole F, Massimino SD, Plumari A, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Fenizi G, Altamura V, Congedo M, Pellicano R, Vena GA. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J. Biol. Regul. Homeost. Agents 22: 233-237 (2008).
Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int. J. Immunopathol. Pharmacol. 19: 237-240 (2006).
Cassatella MA, da Silva GP, Tinazzi I, Facchetti F, Scapini P, Calzetti F, Tamassia N, Wei P, Nardelli B, Roschke V, Vecchi A, Mantovani A, Bambara LM, Edwards SW, Carletto A. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J. Immunol. 178: 7325-7333 (2007). *
Cassell S, Kavanaugh A. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J. Immune Based Ther. Vaccines 3: 6 (2005). *
Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J. Rheumatol. 33: 1452-1456 (2006).
Casserly B, Donat W. Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha. Lung 187: 149-152 (2009).
Cassidy JT, Walker SE, Soderstrom SJ, Petty RE, Sullivan DB. Diagnostic significance of antibody to native deoxyribonucleic acid in children with juvenile rheumatoid arthritis and other connective tissue diseases. J. Pediatr. 93: 416-420 (1978).
Cassinotti P, Bas S, Siegl G, Vischer TL. Association between human parvovirus B19 infection and arthritis. Ann. Rheum. Dis. 54: 498-500 (1995). *
Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology. Dermatol. Ther. 22: 22-33 (2009).
Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect. Genet. Evol. 8: 541-544 (2008).
Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 18: 491-500 (2009).
Castro F, Acevedo E, Ciusani E, Angulo JA, Wollheim FA, Sandberg-Wollheim M. Tumour necrosis factor microsatellites and HLA-DRB1*, HLA-DQA1*, and HLA-DQB1* alleles in Peruvian patients with rheumatoid arthritis. Ann. Rheum. Dis. 60: 791-795 (2001). *
Castro-Caldas M. Annexin-1: 2nd messanger of the anti-inflammatory actions of glucocorticoids. Acta Reumatol. Port. 31: 293-302 (2006).
Castro-Rueda H, Kavanaugh A. The treatment of psoriatic arthritis and inflammatory spondylitis. Curr. Pain Headache Rep. 12: 412-417 (2008).
Castro-Santos P, Suarez A, Lopez-Rivas L, Mozo L, Gutierrez C. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am. J. Gastroenterol. 101: 1039-1047 (2006). *
Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345: 1809-1817 (2001). *
Caterson B. Notice of retraction: "Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids" (Arthritis Rheum 2002;46:1544-53). Arthritis Rheum. 54: 2933 (2006). *
Catsarou-Catsari A, Katsambas A, Theodoropoulos P, Stratigos J. Ophthalmological manifestations in patients with psoriasis. Acta Derm. Venereol. 64: 557-559 (1984).
Cauley JA. Osteoporosis in men: prevalence and investigation. Clin. Cornerstone 8 Suppl. 3: S20-S25 (2006).
Cauli A, Vacca A, Mameli A, Passiu G, Fiorillo MT, Sorrentino R, Mathieu A. A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403. Arthritis Rheum. 56: 2807-2809 (2007). *
Cauvi DM, Cauvi G, Pollard KM. Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease. Arthritis Rheum. 56: 1934-1944 (2007). *
Cauwels A, Brouckaert P. Survival of TNF toxicity: dependence on caspases and NO. Arch. Biochem. Biophys. 462: 132-139 (2007). *
Cauwels A, Bultinck J, Brouckaert P. Dual role of endogenous nitric oxide in tumor necrosis factor shock: induced NO tempers oxidative stress. Cell. Mol. Life Sci. 62: 1632-1640 (2005). *
Cauza E, Dunky A. Psoriatic arthritis. Wien. Med. Wochenschr. 156: 587-595 (2006).
Cauza E, Hanusch-Enserer U, Etemad M, Koller M, Kostner K, Georg P, Dunky A, Ferenci P. HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis. Clin. Exp. Rheumatol. 23: 7-12 (2005).
Cavazzana I, Bobbio-Pallavicini F, Bazzani C, Bravi E, Zingarelli S, Ceribelli A, Caporali R, Cattaneo R, Franceschini F, Montecucco C. TNFalpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunological effects. Reumatismo 58: 275-282 (2006).
Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun. Rev. 8: 104-106 (2008).
Cavazzana I, Ceribelli A, Franceschini F, Cattaneo R. Unusual association between pure red cell aplasia and primary Sjogren's syndrome: a case report. Clin. Exp. Rheumatol. 25: 309-311 (2007).
Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, Franceschini F. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus 17: 727-732 (2008).
Cavazzana I, Franceschini F, Danieli E, Frassi M, Vianelli M, Gorla R, Airo P, Cattaneo R. Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies. Reumatismo 57: 267-272 (2005).
Cavazzana I, Franceschini F, Quinzanini M, Manera C, Del Papa N, Maglione W, Comina D, Radice A, Sinico RA, Cattaneo R. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin. Exp. Rheumatol. 24: 59-64 (2006).
Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand. J. Immunol. 59: 261-266 (2004). *
Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr. Med. Res. Opin. 22: 731-737 (2006).
Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract. Res. Clin. Rheumatol. 20: 983-1002 (2006).
Ceccato F, Gongora V, Zunino A, Roverano S, Paira S. Unusual manifestation of histoplasmosis in connective tissue diseases. Clin. Rheumatol. 26: 1717-1719 (2007). *
Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Washington Parks R, Venzon D, Douek DC, O'Shea JJ, Franchini G. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 1: 279-288 (2008). *
Cecil DL, Appleton CT, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. J. Immunol. 182: 5024-5031 (2009).
Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J. Immunol. 175: 8296-8302 (2005). *
Cellini M, Versura P, Leonetti P, Frigato M, Manfredini E, Malavolta N, Campos EC. Ocular surface and intraocular inflammation are related in SS-I and rheumatoid arthritis patients. Rheumatol. Int. 27: 853-857 (2007). *
Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2003-2005. MMWR Morb. Mortal. Wkly. Rep. 55: 1089-1092 (2006).
Centers for Disease Control and Prevention (CDC). Projected state-specific increases in self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitations - United States, 2005-2030. MMWR Morb. Mortal. Wkly. Rep. 56: 423-425 (2007). *
Centers for Disease Control and Prevention (CDC). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions - United States, 2003. MMWR Morb. Mortal. Wkly. Rep. 56: 4-7 (2007).
Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb. Mortal. Wkly. Rep. 53: 683-686 (2004).
Centola M, Frank MB, Bolstad AI, Alex P, Szanto A, Zeher M, Hjelmervik TO, Jonsson R, Nakken B, Szegedi G, Szodoray P. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: a potential breakthrough diagnostic and individualized therapy-design tool. Scand. J. Immunol. 64: 236-242 (2006). *
Cervera R, Asherson RA, Acevedo ML, Gomez-Puerta JA, Espinosa G, De La Red G, Gil V, Ramos-Casals M, Garcia-Carrasco M, Ingelmo M, Font J. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann. Rheum. Dis. 63: 1312-1317 (2004). *
Cevik R, Nas K, Gur A, Ayyildiz O, Arica M. Small joint monoarthritis and pyoderma gangrenosum in newly diagnosed ulcerative colitis: an unusual presentation. J. Clin. Rheumatol. 10: 360-362 (2004).
Cha HS, Bae EK, Koh JH, Chai JY, Jeon CH, Ahn KS, Kim J, Koh EM. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J. Rheumatol. 34: 16-19 (2007).
Cha S, Choi CB, Han TU, Kang CP, Kang C, Bae SC. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis Rheum. 56: 1454-1463 (2007). *
Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations, and prognosis. Eur. Respir. J. 28: 364-369 (2006).
Chabane N, Zayed N, Afif H, Mfuna-Endam L, Benderdour M, Boileau C, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Histone deacetylase inhibitors suppress interleukin-1beta-induced nitric oxide and prostaglandin E(2) production in human chondrocytes. Osteoarthritis Cartilage 16: 1267-1274 (2008).
Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3: 168-177 (2001). *
Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44: 1293-1303 (2001). *
Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J. Immunol. 167: 6015-6020 (2001). *
Chabchoub G, Petit-Teixeira E, Maalej A, Pierlot C, Bahloul Z, Cornelis F, Ayadi H. Lack of association between signaling lymphocytic activation molecule family member 1 gene and rheumatoid arthritis in the French and Tunisian populations. Ann. Rheum. Dis. 65: 1538-1539 (2006). *
Chabchoub G, Teixiera EP, Maalej A, Hamad MB, Bahloul Z, Cornelis F, Ayadi H. The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population. Ann. Hum. Biol. 36: 342-349 (2009).
Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C. Topical silver sulfadiazine-induced acute renal failure. Ann. Dermatol. Venereol. 132: 891-893 (2005).
Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum. 55: 163-166 (2006). *
Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC Jr, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc. Natl. Acad. Sci. U.S.A. 102: 2543-2548 (2005). *
Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br. J. Haematol. May 14 [Epub ahead of print] (2009).
Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. U.S.A. 103: 9982-9987 (2006). *
Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, Gumucio DL, Shoham NG, Kastner DL. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 112: 1794-1803 (2008). *
Chae SC, Park YR, Shim SC, Lee IK, Chung HT. Eotaxin-3 gene polymorphisms are associated with rheumatoid arthritis in a Korean population. Hum. Immunol. 66: 314-320 (2005).
Chae SC, Park YR, Shim SC, Yoon KS, Chung HT. The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis. Immunol. Lett. 95: 91-95 (2004).
Chae SC, Park YR, Song JH, Shim SC, Yoon KS, Chung HT. The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population. Immunogenetics 56: 696-701 (2005). *
Chae SC, Shim SC, Chung HT. Association of TBX21 polymorphisms in a Korean population with rheumatoid arthritis. Exp. Mol. Med. 41: 33-41 (2009). *
Chagnon P, Schneider R, Hebert J, Fortin PR, Provost S, Belisle C, Gingras M, Bolduc V, Perreault C, Silverman E, Busque L. Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis Rheum. 54: 1270-1278 (2006). *
Chakravarty EF. Viral infection and reactivation in autoimmune disease. Arthritis Rheum. 58: 2949-2957 (2008). *
Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54: 899-907 (2006). *
Chamberlain G, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS ONE 3: e2934 (2008). *
Chamberlain MA. A family study of Behcet's syndrome. Ann. Rheum. Dis. 37: 459-465 (1978). *
Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can. Fam. Physician 53: 409-412 (2007).
Chambers MS. Sjogren's syndrome. ORL Head Neck Nurs. 22: 22-30 (2004).
Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14: 210-214 (2005).
Chan AY, Liu DT. Methotrexate and chronic uveitis associated with juvenile idiopathic arthritis. J. Rheumatol. 33: 198 (2006).
Chan AY, Westcott JM, Mooney JM, Wakeland EK, Schatzle JD. The role of SAP and the SLAM family in autoimmunity. Curr. Opin. Immunol. 18: 656-664 (2006).
Chan CY, Browning JC, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol. Online J. 14: 12 (2008).
Chan EK, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: Is microRNA-146 all we need? Arthritis Rheum. 60: 912-915 (2009). *
Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, Leung WK, Lee YT, To KF, Chung SC, Sung JJ. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127: 1038-1043 (2004). *
Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin. Exp. Dermatol. 19: 298-302 (1994).
Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J. Drugs Dermatol. 3: 315-318 (2004).
Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, McHugh NJ. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J. Rheumatol. 35: 77-83 (2008).
Chan SH, Lin YN, Wee GB, Koh WH, Boey ML. HLA class 2 genes in Singaporean Chinese rheumatoid arthritis. Br. J. Rheumatol. 33: 713-717 (1994).
Chan TM. Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. Arthritis Rheum. 56: 702-704 (2007). *
Chan V, Tett SE. Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004. Pharmacoepidemiol. Drug Saf. 15: 462-468 (2006).
Chanda P, Sucheston L, Zhang A, Brazeau D, Freudenheim JL, Ambrosone C, Ramanathan M. AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environment interactions associated with complex phenotypes. Genetics 180: 1191-1210 (2008). *
Chanda P, Sucheston L, Zhang A, Ramanathan M. The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur. J. Hum. Genet. Mar 18 [Epub ahead of print] (2009).
Chandran NS, Greaves M, Gao F, Lim L, Cheng BC. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis. J. Dermatol. 34: 805-810 (2007).
Chandran V. Epidemiology of psoriatic arthritis. J. Rheumatol. 36: 213-215 (2009).
Chandran V, Pellett F, Gladman DD. Killer cell immunoglobulin-like receptor gene's repertoire in rheumatoid arthritis. Scand. J. Rheumatol. 36: 409 (2007).
Chandran V, Schentag CT. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J. Rheumatol. 35: 2069-2070 (2008).
Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugrajah S, Toloza SM, Rahman P, Gladman DD. Familial aggregation of psoriatic arthritis. Ann. Rheum. Dis. 68: 664-667 (2009).
Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J. Rheumatol. 35: 469-471 (2008).
Chandran V, Upadhyaya SK, Haroon N, Aggarwal A, Misra R. Lack of clinical association with antibodies to ribosomal p proteins in Indian patients with systemic lupus erythematosus. J. Rheumatol. 33: 1987-1989 (2006).
Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46: 2924-2927 (2002). *
Chang H, Qin W, Li Y, Zhang J, Lin Z, Lv M, Sun Y, Feng J, Shen B. A novel human scFv fragment against TNF-alpha from de novo design method. Mol. Immunol. 44: 3789-3796 (2007). *
Chang HK, Bang KT, Lee BH, Kim JH, Bae KW, Kim MJ, Kim SK. Concurrence of Sjogren's syndrome in a patient with Chlamydia-induced reactive arthritis; an unusual finding. Korean J. Intern. Med. 21: 116-119 (2006).
Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents - a guide for GPs. Aust. Fam. Physician 36: 1035-1038 (2007). *
Chang M, Rowland CM, Garcia VE, Schrodi SJ, Catanese JJ, van der Helm-van Mil AH, Ardlie KG, Amos CI, Criswell LA, Kastner DL, Gregersen PK, Kurreeman FA, Toes RE, Huizinga TW, Seldin MF, Begovich AB. A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. PLoS Genet. 4: e1000107 (2008). *
Chang X, Yamada R, Sawada T, Suzuki A, Kochi Y, Yamamoto K. The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 44: 293-298 (2005). *
Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 44: 1374-1382 (2005). *
Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44: 40-50 (2005). *
Chang YH, Lin IL, Tsay GJ, Yang SC, Yang TP, Ho KT, Hsu TC, Shiau MY. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Biochem. 41: 955-959 (2008). *
Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ, Tsai SF. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br. J. Dermatol. 156: 899-905 (2007). *
Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, Doty JL, Sun J, Kent CR, Magnuson KS, Perregaux DG, Sawyer PS, Kudlacz EM. The specificity of JAK3 kinase inhibitors. Blood 111: 2155-2157 (2008). *
Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol. Ther. 22: 61-73 (2009).
Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann. Pharmacother. 39: 1552-1556 (2005).
Chao YC, Cheng TS, Chou CT. Panniculitis: an unusual cutaneous manifestation of rheumatoid arthritis. J. Clin. Rheumatol. 12: 190-193 (2006).
Chaouat D, Belange G, Gompel H. Polymyalgia rheumatica in primary biliary cirrhosis: value of the search for antimitochondrial antibodies in rhizomelic pseudo-polyarthritis and Horton disease. Rev. Med. Interne. 15: 775-776 (1994).
Chaoui Z, Bernoussi A, Belmekki M, Berraho A. Uveitis and chronic intestinal inflammatory diseases: three case studies. J. Fr. Ophtalmol. 28: 854-856 (2005).
Chaouni I, Lefranc MP, d'Angeac AD, Zanin C, Pellet F, Clot J, Combe B, Sany J, Reme T. T cell receptor gamma variable gene locus polymorphism in patients with rheumatoid arthritis. Arthritis Rheum. 35: 756-760 (1992).
Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R, Tsezou A, Malizos KN, Kloppenburg M, Shi D, Southam L, van der Breggen R, Donn R, Qin J, Doherty M, Slagboom PE, Wallis G, Kamatani N, Jiang Q, Gonzalez A, Loughlin J, Ikegawa S. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. Hum. Mol. Genet. 17: 1497-1504 (2008).
Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Seckl JR. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. Ann. N. Y. Acad. Sci. 1088: 265-273 (2006). *
Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).
Chapuy-Regaud S, Sebbag M, Baeten D, Clavel C, Foulquier C, De Keyser F, Serre G. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J. Immunol. 174: 5057-5064 (2005). *
Charalabopoulos K, Mittari E, Peschos D, Golias C, Charalabopoulos A, Tsanou E, Batistatou A. Rare association of chronic lymphocytic thyroiditis with dermatomyositis. Arch. Med. Res. 37: 563-565 (2006).
Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J. Biol. Chem. 282: 33714-33724 (2007). *
Charbonnier LM, van Duivenvoorde LM, Apparailly F, Cantos C, Han WG, Noel D, Duperray C, Huizinga TW, Toes RE, Jorgensen C, Louis-Plence P. Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells. J. Immunol. 177: 3806-3813 (2006). *
Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin. Immunol. 127: 234-244 (2008). *
Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, Cohen P, Mouthon L, Guillevin L. Risk factors for major infections in Wegener's granulomatosis: analysis of 113 patients. Ann. Rheum. Dis. 68: 658-663 (2009).
Charmley P, Nelson JL, Hansen JA, Branchaud A, Barrington RA, Templin D, Boyer G, Lanier AP, Concannon P. T-cell receptor polymorphisms in Tlingit Indians with rheumatoid arthritis. Autoimmunity 19: 247-251 (1994).
Charmley P, Nepom BS, Concannon P. HLA and T cell receptor beta-chain DNA polymorphisms identify a distinct subset of patients with pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 37: 695-701 (1994).
Charniot JC, Genereau T, Mouthon L. Celiprolol-induced lupus-like syndrome. Acta Cardiol. 61: 661-663 (2006).
Charoonpatrapong K, Shah R, Robling AG, Alvarez M, Clapp DW, Chen S, Kopp RP, Pavalko FM, Yu J, Bidwell JP. HMGB1 expression and release by bone cells. J. Cell Physiol. 207: 480-490 (2006). *
Charpin C, Balandraud N, Guis S, Roudier C, Toussirot E, Rak J, Lambert N, Martin M, Reviron D, Roudier J, Auger I. HLA-DRB1*0404 is strongly associated with high titers of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 627-631 (2008).
Charrier-Hisamuddin L, Laboisse CL, Merlin D. ADAM-15: a metalloprotease that mediates inflammation. FASEB J. 22: 641-653 (2008). *
Charron DJ. New aspects of HLA: perspectives for rheumatoid arthritis. Clin. Exp. Rheumatol. 10: 293-296 (1992).
Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern. Med. J. 37: 377-382 (2007). *
Chatzikyriakidou A, Georgiou I, Voulgari PV, Georgiadis AN, Argyriou ES, Drosos AA. Glucocorticoid receptor variants may predispose to rheumatoid arthritis susceptibility. Scand. J. Rheumatol. 38: 1-5 (2009). *
Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA. Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol. Int. 27: 1057-1061 (2007). *
Chatzikyriakidou A, Georgiou I, Voulgari PV, Venetsanopoulou AI, Drosos AA. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 46: 1034-1035 (2007). *
Chauhan A, Mikulik Z, Hackshaw KV. Multicentric reticulohistiocytosis with positive anticyclic citrullinated antibodies. J. Natl. Med. Assoc. 99: 678-680 (2007). *
Chavanas S, Mechin MC, Takahara H, Kawada A, Nachat R, Serre G, Simon M. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 330: 19-27 (2004). *
Chaves Y, Duarte G, Ben-Said B, Tebib J, Berard F, Nicolas JF. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 217: 380 (2008).
Chavez-Lopez M, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol. Immunopathol. (Madr.) 33: 291-292 (2005).
Chavez-Lopez MA, Ramirez-Gonzalez A, Martinez-Guevara MA. Acute hepatitis associated to leflunomide in a patient with rheumatoid arthritis. Gastroenterol. Hepatol. 30: 430 (2007).
Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D'Angelo WA. Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum. 20: 1546-1549 (1977).
Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44: 1313-1319 (2001). *
Chelala C, Duchatelet S, Joffret ML, Bergholdt R, Dubois-Laforgue D, Ghandil P, Pociot F, Caillat-Zucman S, Timsit J, Julier C. PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits. Diabetes 56: 522-526 (2007). *
Chen CC, Isomoto H, Narumi Y, Sato K, Oishi Y, Kobayashi T, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K. Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clin. Immunol. 126: 165-171 (2008). *
Chen CS, Roberton D, Hammerton ME. Juvenile arthritis-associated uveitis: visual outcomes and prognosis. Can. J. Ophthalmol. 39: 614-620 (2004).
Chen D, Wei Y, Li X, Epstein S, Wolosin JM, Asbell P. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised. Exp. Eye Res. 88: 880-888 (2009).
Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J. Formos. Med. Assoc. 108: 310-319 (2009). *
Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 55: 250-258 (2009).
Chen DY, Lan JL, Lin FJ, Hsieh TY. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease. Clin. Rheumatol. 26: 393-400 (2007). *
Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635 (2002). *
Chen G, Li N, Zang YC, Zhang D, He D, Feng G, Ni L, Xu R, Wang L, Shen B, Zhang JZ. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum. 56: 453-463 (2007). *
Chen G, Ward MF, Sama AE, Wang H. Extracellular HMGB1 as a proinflammatory cytokine. J. Interferon Cytokine Res. 24: 329-333 (2004).
Chen H, Qin J, Wei P, Zhang J, Li Q, Fu L, Li S, Ma C, Cong B. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot. Essent. Fatty Acids 80: 195-200 (2009). *
Chen HY, Guo JL, Li ZG. Significance of anti-cell membrane-associated DNA (mDNA) antibodies in systemic lupus erythematosus. Clin. Rheumatol. 27: 183-187 (2008). *
Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J. Rheumatol. 33: 722-731 (2006).
Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst. Rev. 2: CD004800 (2005). *
Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev. 3: CD004524 (2004).
Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev. 4: CD004524 (2006). *
Chen J, Liu X. The role of interferon gamma in regulation of CD4(+) T-cells and its clinical implications. Cell. Immunol. 254: 85-90 (2009). *
Chen JY, Wang CM, Ma CC, Luo SF, Edberg JC, Kimberly RP, Wu J. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum. 54: 3908-3917 (2006). *
Chen JY, Wang CM, Wu JM, Ho HH, Luo SF. Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis. Clin. Exp. Immunol. 144: 10-16 (2006). *
Chen LN, Wang CH, Zhu P, Fan CM, Wang YH, Li XY. The changes of CD4(+) CD25(high) regulatory T cells in the course of rheumatoid arthritis and their significances. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23: 331-334 (2007).
Chen M, Dittmann A, Kuhn A, Ruzicka T, Mikecz AV. Recruitment of topoisomerase I (Scl-70) to nucleoplasmic proteasomes in response to xenobiotics suggests a role for altered antigen processing in scleroderma. Arthritis Rheum. 52: 877-884 (2005). *
Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, Lee DM. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 203: 837-842 (2006). *
Chen M, von Mikecz A. Xenobiotic-induced recruitment of autoantigens to nuclear proteasomes suggests a role for altered antigen processing in scleroderma. Ann. N. Y. Acad. Sci. 1051: 382-389 (2005). *
Chen Q, Li X, He W, Zhang H, Gao A, Cheng Y, Lei J, Li S, Zeng L. The epitope study of alpha-fodrin autoantibody in primary Sjogren's syndrome. Clin. Exp. Immunol. 149: 497-503 (2007). *
Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G, Pernis AB. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 29: 899-911 (2008). *
Chen R, Fang M, Cai Q, Duan S, Lv K, Cheng N, Ren D, Shen J, He D, He L, Sun S. Tumor necrosis factor alpha -308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China. Rheumatol. Int. 28: 121-126 (2007). *
Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J. Autoimmun. 16: 309-318 (2001).
Chen WS, Lin KC, Chen CH, Liao HT, Wang HP, Li WY, Lee HT, Tsai CY, Chou CT. Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjogren's syndrome. J. Rheumatol. 36: 989-996 (2009).
Chen WV, Amos CI, Etzel CJ, Shete S, Gregersen PK. Comparison of genome-wide single-nucleotide polymorphism linkage analyses in Caucasian and Hispanic NARAC families. BMC Proc. 1 Suppl. 1: S97 (2007). *
Chen WY, Chang MS. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J. Immunol. 182: 5003-5012 (2009).
Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP Jr, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood 113: 3226-3234 (2009). *
Chen X, Oppenheim JJ, Howard OM. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell. Mol. Immunol. 1: 336-342 (2004). *
Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum. 52: 1585-1594 (2005). *
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10: 1-248 (2006). *
Chen YJ, Lin CH, Ou TT, Wu CC, Tsai WC, Liu HW, Yen JH. Solute carrier family 11 member A1 gene polymorphisms in reactive arthritis. J. Clin. Immunol. 27: 46-52 (2007). *
Chen YS, Chou PH, Li SN, Tsai WC, Lin KH, Tsai KB, Yen JH, Liu HW. Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan. J. Rheumatol. 33: 887-891 (2006).
Chen Z, de Kauwe AL, Keech C, Wijburg O, Simpfendorfer K, Alexander WS, McCluskey J. Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses. Tissue Antigens 68: 210-219 (2006). *
Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. U.S.A. 103: 8137-8142 (2006). *
Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol. 19: 400-408 (2007). *
Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41: 87-102 (2008). *
Chen Z, O'Shea JJ. Regulation of IL-17 production in human lymphocytes. Cytokine 41: 71-78 (2008).
Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 56: 2936-2946 (2007). *
Chenevier-Gobeaux C, Lemarechal H, Bonnefont-Rousselot D, Poiraudeau S, Ekindjian OG, Borderie D. Superoxide production and NADPH oxidase expression in human rheumatoid synovial cells: regulation by interleukin-1beta and tumour necrosis factor-alpha. Inflamm. Res. 55: 483-490 (2006). *
Chenevier-Gobeaux C, Simonneau C, Therond P, Bonnefont-Rousselot D, Poiraudeau S, Ekindjian OG, Borderie D. Implication of cytosolic phospholipase A(2) (cPLA(2)) in the regulation of human synoviocyte NADPH oxidase (Nox2) activity. Life Sci. 81: 1050-1058 (2007). *
Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, Haraoui P, Raynauld JP, Choquette D, Fahmi H. Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee. Ann. Rheum. Dis. 65: 1394-1397 (2006). *
Cheng VC, Ho PL, Yuen KY. Two probable cases of serious drug interaction between clarithromycin and colchicine. South Med. J. 98: 811-813 (2005).
Cheon H, Rho YH, Choi SJ, Lee YH, Song GG, Sohn J, Won NH, Ji JD. Prostaglandin E2 augments IL-10 signaling and function. J. Immunol. 177: 1092-1100 (2006). *
Chernajovsky Y. Gene therapy for arthritis - where do we stand? Arthritis Res. Ther. 7: 227-229 (2005). *
Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis? Nat. Rev. Immunol. 4: 800-811 (2004). *
Cheung YH, Chang NH, Cai YC, Bonventi G, Macleod R, Wither JE. Functional interplay between intrinsic B and T cell defects leads to amplification of autoimmune disease in New Zealand Black chromosome 1 congenic mice. J. Immunol. 175: 8154-8164 (2005). *
Chi ZC, Ma SZ. Rheumatologic manifestations of hepatic diseases. Hepatobiliary Pancreat. Dis. Int. 2: 32-37 (2003). *
Chia WT, Chen YW, Cheng LY, Lee HS, Chang DM, Sytwu HK. MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J. Formos. Med. Assoc. 107: 245-252 (2008).
Chiang TM, Postlethwaite AE. A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim. Biophys. Acta 1770: 1181-1186 (2007). *
Chiavaroli C, Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs 20: 141-149 (2006).
Chiba K. A new orally active anti-rheumatic drug targets IL-15 and IL-17. Nihon Rinsho Meneki Gakkai Kaishi 30: 375-382 (2007).
Chiba K. A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720). Yakugaku Zasshi 129: 655-665 (2009).
Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108: 308-319 (2005). *
Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J. Endocrinol. 179: 301-310 (2003). *
Chikazawa H, Nishiya K, Matsumori A, Hashimoto K. Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. J. Clin. Immunol. 20: 279-286 (2000). *
Chillingworth NL, Morham SG, Donaldson LF. Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291: R327-334 (2006). *
Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6: 1-14 (2008).
Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB. The human genome and gene expression profiling. J. Plast. Reconstr. Aesthet. Surg. 59: 902-911 (2006).
Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol. Dial. Transplant. 20: 2824-2826 (2005).
Chin RK, Zhu M, Christiansen PA, Liu W, Ware C, Peltonen L, Zhang X, Guo L, Han S, Zheng B, Fu YX. Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen. J. Immunol. 177: 290-297 (2006). *
Chinoy H, Platt H, Lamb JA, Betteridge Z, Gunawardena H, Fertig N, Varsani H, Davidson J, Oddis CV, McHugh NJ, Wedderburn LR, Ollier WE, Cooper RG. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum. 58: 3247-3254 (2008). *
Chintalacharuvu SR, Sandusky GE, Burris TP, Burmer GC, Nagpal S. Liver X receptor is a therapeutic target in collagen-induced arthritis. Arthritis Rheum. 56: 1365-1367 (2007). *
Chiou CF, Sherbourne CD, Cornelio I, Lubeck DP, Paulus HE, Dylan M, Chang CH, Weisman MH. Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument. Arthritis Rheum. 55: 856-863 (2006). *
Chirino YI, Orozco-Lbarra M, Pedraza-Chaverri J. Role of peroxynitrite anion in different diseases. Rev. Invest. Clin. 58: 350-358 (2006).
Chistiakov DA, Chistiakov AP. Is FCRL3 a new general autoimmunity gene? Hum. Immunol. 68: 375-383 (2007).
Chitale S, Moots R. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 8: 115-122 (2008).
Chitkara P, Stojanov S, Kastner DL. The hereditary autoinflammatory syndromes. Pediatr. Infect. Dis. J. 26: 353-354 (2007).
Chizzolini C, Parel Y, Scheja A, Dayer JM. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res. Ther. 8: R10 (2006). *
Cho ML, Heo YJ, Park MK, Oh HJ, Park JS, Woo YJ, Ju JH, Park SH, Kim HY, Min JK. Grape seed proanthocyanidin extract (GSPE) attenuates collagen-induced arthritis. Immunol. Lett. May 13 [Epub ahead of print] (2009).
Cho ML, Ju JH, Kim HR, Oh HJ, Kang CM, Jhun JY, Lee SY, Park MK, Min JK, Park SH, Lee SH, Kim HY. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol. Lett. 108: 121-128 (2007).
Cho ML, Ju JH, Kim KW, Moon YM, Lee SY, Min SY, Cho YG, Kim HS, Park KS, Yoon CH, Lee SH, Park SH, Kim HY. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4(+) T cells via down-regulation of PI3K/Akt and NF-kappaB. Immunol. Lett. 108: 88-96 (2007).
Cho ML, Jung YO, Kim KW, Park MK, Oh HJ, Ju JH, Cho YG, Min JK, Kim SI, Park SH, Kim HY. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp. Mol. Med. 40: 237-245 (2008). *
Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, Jin HT, Min SY, Ju JH, Park KS, Cho YG, Yoon CH, Park SH, Sung YC, Kim HY. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol. 176: 5652-5661 (2006). *
Cho ML, Min SY, Chang SH, Kim KW, Heo SB, Lee SH, Park SH, Cho CS, Kim HY. Transforming growth factor beta 1(TGF-beta1) down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaB-mediated transcriptional repression. Immunol. Lett. 105: 159-166 (2006).
Cho ML, Yoon CH, Hwang SY, Park MK, Min SY, Lee SH, Park SH, Kim HY. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum. 50: 776-784 (2004). *
Cho SG, Min SY, Park MJ, Lee KW, Cho YG, Cho ML, Chang HS, Park SH, Lee JW, Min WS, Kim CC, Kim HY. Immunoregulatory effects of allogeneic mixed chimerism induced by nonmyeloablative bone marrow transplantation on chronic inflammatory arthritis and autoimmunity in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum. 54: 1878-1887 (2006). *
Cho SM, Kim J, Ryu HJ, Kim JJ, Kim HH, Park JH, Kim HT, Kim KH, Cho HY, Oh B, Park C, Kimm K, Jo I, Lee JE, Shin HD, Lee JK. Identification of single nucleotide polymorphisms in the tumor necrosis factor (TNF) and TNF receptor superfamily in the Korean population. Hum. Immunol. 65: 710-718 (2004).
Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun. Rev. 7: 65-70 (2007).
Cho YJ, Han DS, Kim TY, Jang SJ, Jeon YC, Sohn JH, Lee IH, Park KN. Negative conversion of antimitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis. J. Korean Med. Sci. 14: 102-106 (1999). *
Chogle AR, Chakravarty A. Cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis: emerging concepts, early diagnosis and management. J. Assoc. Physicians India 55: 32-40 (2007).
Choi CB, Kang CP, Seong SS, Bae SC, Kang C. The -169C/T polymorphism in FCRL3 is not associated with susceptibility to rheumatoid arthritis or systemic lupus erythematosus in a case-control study of Koreans. Arthritis Rheum. 54: 3838-3841 (2006). *
Choi EM. Oxidative status of DBA/1J mice with type II collagen-induced arthritis. J. Appl. Toxicol. 27: 472-481 (2007). *
Choi EM. Ligularia fischeri leaf extract prevents the oxidative stress in DBA/1J mice with type II collagen-induced arthritis. J. Appl. Toxicol. 27: 176-182 (2007). *
Choi HK. Dietary risk factors for rheumatic diseases. Curr. Opin. Rheumatol. 17: 141-146 (2005).
Choi J, Ha KH, Byun MS, Min SY, Park MJ, Park HS, Oh HJ, Ju JH, Kim HY, Jue DM. Treatment with N-tosyl-L-phenylalanine chloromethyl ketone after the onset of collagen-induced arthritis reduces joint erosion and NF-kappaB activation. Eur. J. Pharmacol. 595: 108-113 (2008).
Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, Cho CS. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin. Exp. Immunol. 153: 269-276 (2008). *
Choi JM, Kim SH, Shin JH, Gibson T, Yoon BS, Lee DH, Lee SK, Bothwell AL, Lim JS, Lee SK. Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A. 105: 19875-19880 (2008). *
Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J. Abrogation of skin disease in LUPUS-prone MRL/FAS(lpr) mice by means of a novel tylophorine analog. Arthritis Rheum. 54: 3277-3283 (2006). *
Choi KH, Lee EB, Yoo CD, Baek HJ, Kang SW, Shin KC, Lee YJ, Kim HA, Jeon JH, Kim CW, Shin DM, Kim IG, Son YW. Clinical significance of anti-filaggrin antibody recognizing uncitrullinated filaggrin in rheumatoid arthritis. Exp. Mol. Med. 37: 546-552 (2005). *
Choi SJ, Rho YH, Ji JD, Song GG, Lee YH. Genome scan meta-analysis of rheumatoid arthritis. Rheumatology (Oxford) 45: 166-170 (2006). *
Choi SW, Lim MK, Shin DH, Park JJ, Shim SC. Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in korean patients with rheumatoid arthritis. J. Korean Med. Sci. 20: 473-478 (2005). *
Chong BF, Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin. Exp. Dermatol. Nov 26 [Epub ahead of print] (2008).
Chong KT, Ho WF, Koo SH, Thompson P, Lee EJ. Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore. Br. J. Clin. Pharmacol. 63: 328-332 (2007). *
Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, McInnes IB, Garside P. TNF-blocking therapies: an alternative mode of action? Trends Immunol. 26: 518-522 (2005). *
Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin. Investig. Drugs 17: 1411-1425 (2008).
Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl. Acad. Sci. U.S.A. 102: 13562-13567 (2005). *
Chorny A, Gonzalez-Rey E, Ganea D, Delgado M. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. Ann. N. Y. Acad. Sci. 1070: 190-195 (2006). *
Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M. Signaling mechanisms of vasoactive intestinal peptide on inflammatory conditions. Regul. Pept. 137: 67-74 (2006).
Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterol. 5: 27 (2005). *
Chowdary Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, Fiehn C, Dick Ho A, Lorenz HM. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25(high),CD127(-/low) regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58: 2120-2130 (2008). *
Chowdhry IA, Kowal C, Hardin J, Zhou Z, Diamond B. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen. Arthritis Rheum. 52: 2403-2410 (2005). *
Choy E. T cells in psoriatic arthritis. Curr. Rheumatol. Rep. 9: 437-441 (2007).
Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41: 1133-1137 (2002). *
Choy EH, Smith CM, Farewell V, Walker DJ, Hassell A, Chau L, Scott DL; CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann. Rheum. Dis. 67: 656-663 (2008).
Christensen T, Moller-Larsen A. Human endogenous retroviruses and disease? Ugeskr. Laeger. 165: 556-561 (2003).
Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin. Exp. Med. 6: 13-19 (2006). *
Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig. Liver Dis. 34: 781-786 (2002).
Christophers E. Comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 20 Suppl. 2: 52-55 (2006). *
Christophers E. Comorbidities in psoriasis. Clin. Dermatol. 25: 529-534 (2007).
Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik SA. A comprehensive review on nettle effect and efficacy profiles, Part I: Herba urticae. Phytomedicine 14: 423-435 (2007).
Chrubasik S, Chrubasik C, Kunzel O, Black A. Patient-perceived benefit during one year of treatment with Doloteffin. Phytomedicine 14: 371-376 (2007).
Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 56: 1145-1151 (2007). *
Chu SC, Yang SF, Lue KH, Hsieh YS, Hsiao TY, Lu KH. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J. Rheumatol. 33: 311-317 (2006).
Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed. 78 Suppl. 1: 255-261 (2007).
Chubinskaya S, Frank BS, Michalska M, Kumar B, Merrihew CA, Thonar EJ, Lenz ME, Otten L, Rueger DC, Block JA. Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate. Arthritis Res. Ther. 8: R73 (2006). *
Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 68: 1089-1100 (2004). *
Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol. 26: 1228-1233 (2007). *
Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res. Ther. 8: R186 (2006). *
Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T, Avalos I, Stein CM. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 52: 3045-3053 (2005). *
Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196: 756-763 (2008).
Chung EY, Kim SJ, Ma XJ. Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res. 16: 154-161 (2006). *
Chung HV, Riley M, Ho JK, Leung B, Jevon GP, Arbour LT, Barker C, Schreiber R, Yoshida EM. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can. J. Gastroenterol. 21: 565-568 (2007).
Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 60: 584-591 (2009). *
Chung SA, Criswell LA. PTPN22: its role in SLE and autoimmunity. Autoimmunity 40: 582-590 (2007).
Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. Glycobiology 19: 229-239 (2009).
Chung YM, Liao HT, Lin KC, Lin YC, Chou CT, Chen CH, Tsai CP. Prevalence of spondyloarthritis in 504 Chinese patients with HLA-B27-associated acute anterior uveitis. Scand. J. Rheumatol. 38: 84-90 (2009).
Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat. Clin. Pract. Rheumatol. 4: 34-42 (2008). *
Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxford) 47: 753-759 (2008). *
Cianci R, Giambra V, Mattioli C, Esposito M, Cammarota G, Scibilia G, Magazz� G, Orlando A, Sandri G, Bianchi L, Gasbarrini GB, Pandolfi F, Frezza D. Increased frequency of Ig heavy-chain HS1,2-A enhancer (*)2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis. J. Invest. Dermatol. 128: 1920-1924 (2008). *
Ciantar M, Adlam DM. Treatment with infliximab: implications in oral surgery? A case report. Br. J. Oral Maxillofac. Surg. 45: 507-510 (2007).
Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, Peralta S, Franco V, Giardina E, Craxi A, Pitzalis C, Triolo G. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 60: 955-965 (2009). *
Cimaz R, Cazalis MA, Raynaud C, Gerloni V, Zulian F, Biggioggero M, Martini G, Pontikaki I, Fantini F, Mougin B, Miossec P. IL-1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann. Rheum. Dis. 66: 900-904 (2007). *
Cimaz R, Vijay S, Haase C, Coppa GV, Bruni S, Wraith E, Guffon N. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin. Exp. Rheumatol. 24: 196-202 (2006).
Cimmino MA. Does magnetic resonance represent the gold-standard of imaging for the follow-up of arthritis? Reumatismo 58: 245-252 (2006).
Cimmino MA. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo 59 Suppl. 1: 19-24 (2007). *
Cimmino MA. Magnetic resonance imaging of the joints: a revolution for the practicing rheumatologist. Reumatismo 60: 239-241 (2008).
Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, Kulich M, Sumnik Z. No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res. Clin. Pract. 76: 297-303 (2007).
Cinek O, Vavrincova P, Striz I, Drevinek P, Sedlakova P, Vavrinec J, Slavcev A. Association of single nucleotide polymorphisms within cytokine genes with juvenile idiopathic arthritis in the Czech population. J. Rheumatol. 31: 1206-1210 (2004).
Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey. Am. J. Clin. Dermatol. 9: 111-117 (2008).
Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one and the same? Br. J. Dermatol. 157: 850-860 (2007). *
Ciszak L, Pawlak E, Kosmaczewska A, Potoczek S, Frydecka I. Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch. Immunol. Ther. Exp. (Warsz.) 55: 373-386 (2007).
Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EK. Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum. 52: 3079-3086 (2005). *
Clancy RM, Zheng P, O'Mahony M, Izmirly P, Zavadil J, Gardner L, Buyon JP. Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum. 56: 4120-4131 (2007). *
Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Ann. Rheum. Dis. 64 Suppl. 4: iv77-iv80 (2005). *
Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 18: 335-343 (2007).
Clark IM, Swingler TE, Young DA. Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression. Front. Biosci. 12: 528-535 (2007).
Clark KL. Nutritional considerations in joint health. Clin. Sports Med. 26: 101-118 (2007).
Clark LN, Lebwohl M. Recent advances in medical dermatology. Int. J. Dermatol. 46: 1005-1010 (2007). *
Clarke AK, Galbraith RM, Hamilton EB, Williams R. Rheumatic disorders in primary biliary cirrhosis. Ann. Rheum. Dis. 37: 42-47 (1978). *
Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J. Am. Acad. Dermatol. 56: 686-690 (2007).
Claudepierre P, Bagot M. Psoriatic arthritis. Ann. Dermatol. Venereol. 135 Suppl. 4: S263-S268 (2008).
Claudepierre P, Wendling D, Cohen JD. Anti-TNF alpha in the treatment of psoriatic arthritis. Presse. Med. 35: 647-655 (2006).
Claudio E, Sonder SU, Saret S, Carvalho G, Ramalingam TR, Wynn TA, Chariot A, Garcia-Perganeda A, Leonardi A, Paun A, Chen A, Ren NY, Wang H, Siebenlist U. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J. Immunol. 182: 1617-1630 (2009).
Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loet X, Boissier MC. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin. Immunol. 124: 158-164 (2007). *
Clavel G, Valvason C, Yamaoka K, Lemeiter D, Laroche L, Boissier MC, Bessis N. Relationship between angiogenesis and inflammation in experimental arthritis. Eur. Cytokine Netw. 17: 202-210 (2006).
Clayton A, Ramamurthy S. The impact of physical illness on sexual dysfunction. Adv. Psychosom. Med. 29: 70-88 (2008).
Cleland LG, Caughey GE, James MJ, Proudman SM. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J. Rheumatol. 33: 1973-1979 (2006).
Cleland LG, James MJ, Keen H, Danda D, Caughey G, Proudman SM. Fish oil - an example of an anti-inflammatory food. Asia Pac. J. Clin. Nutr. 14: S66-S71 (2005).
Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know. Arthritis Res. Ther. 8: 402 (2006). *
Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know. Arthritis Res. Ther. 8: 202 (2005). *
Cleland LG, James MJ, Proudman SM. Food inflammation and the anti-inflammatory aspects of food. Asia Pac. J. Clin. Nutr. 13: S26 (2004).
Coakley G, Brooks D, Iqbal M, Kondeatis E, Vaughan R, Loughran TP Jr, Panayi GS, Lanchbury JS. Major histocompatility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401. Rheumatology (Oxford) 39: 393-398 (2000). *
Coates LC, Anderson RR, Fitzgerald O, Gottlieb AB, Kelly SG, Lubrano E, McGonagle DG, Olivieri I, Ritchlin CT, Tan AL, De Vlam K, Helliwell PS. Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. J. Rheumatol. 35: 1438-1442 (2008).
Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann. Rheum. Dis. 67: 717-719 (2008).
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann. Rheum. Dis. Jan 15 [Epub ahead of print] (2009).
Coates LC, Helliwell PS. Classification and categorisation of psoriatic arthritis. Clin. Rheumatol. 27: 1211-1216 (2008).
Cobb BA, Kasper DL. Coming of age: carbohydrates and immunity. Eur. J. Immunol. 35: 352-356 (2005). *
Cobb BL, Lessard CJ, Harley JB, Moser KL. Genes and Sjogren's syndrome. Rheum. Dis. Clin. North Am. 34: 847-868 (2008).
Cobb CS, Ernst E. Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin. Rheumatol. 25: 275-284 (2006). *
Cobo Ibanez T, Zamora F, Herranz P, Steiner M. Anti-tumour necrosis factor treatment in HIV-positive patients with psoriatic arthritis. Med. Clin. (Barc.) Feb 23 [Epub ahead of print] (2009).
Codolo G, Amedei A, Steere AC, Papinutto E, Cappon A, Polenghi A, Benagiano M, Paccani SR, Sambri V, Del Prete G, Baldari CT, Zanotti G, Montecucco C, D'Elios MM, de Bernard M. Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis Rheum. 58: 3609-3617 (2008). *
Coelho FM, Pradella-Hallinan M, Alves GR, Bittencourt LR, Pedrazzoli Neto M, Moreira F, Tufik S. A study of T CD4, CD8 and B lymphocytes in narcoleptic patients. Arq. Neuropsiquiatr. 65: 423-427 (2007).
Coenen C, Wegener M, Wedmann B. Severe backache in clinically inactive ulcerative colitis. Fortschr. Med. 111: 476-478 (1993).
Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin. Chem. 53: 498-504 (2007). *
Coenen MJ, Gregersen PK. Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun. 10: 101-111 (2009). *
Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8: 761-773 (2007).
Coffman FD. Chitinase 3-like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit. Rev. Clin. Lab. Sci. 45: 531-562 (2008).
Cogan E. When thinking to scleroderma? Rev. Med. Brux. 28: 285-289 (2007).
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 216: 152-155 (2008).
Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 23: 795-800 (2005).
Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B. Radiological damage in rheumatoid arthritis patients on sustained remission. Ann. Rheum. Dis. 66: 358-363 (2007). *
Cohen HD, Das KM. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. J. Clin. Gastroenterol. 40 Suppl. 3: S150-S154 (2006).
Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann. Rheum. Dis. 67: 1647-1648 (2008).
Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J. Rheumatol. 34: 380-385 (2007).
Cohen JD, Zaltni S, Kaiser MJ, Bozonnat MC, Jorgensen C, Daures JP, Sany J. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann. Rheum. Dis. 63: 209-210 (2004). *
Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21: 317-324 (2009).
Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm. Bowel Dis. 14: 738-743 (2008). *
Cohen SB. Updates from B cell trials: efficacy. J. Rheumatol. Suppl. 77: 12-17 (2006). *
Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, Simon LS, Weaver AL. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J. Rheumatol. Suppl. 81: 4-30 (2008).
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54: 2793-2806 (2006). *
Cohen-Kaminsky S, Jambou F. Prospects for a T-cell receptor vaccination against myasthenia gravis. Expert Rev. Vaccines 4: 473-492 (2005).
Cohran VC, Griffiths M, Heubi JE. Bone mineral density in children exposed to chronic glucocorticoid therapy. Clin. Pediatr. (Phila.) 47: 469-475 (2008).
Colaco CB, Awad J, Festenstein H, Fielder A, Batchelor JR, Alonso A, McCloskey D, Shipley M, Corbett M, Roitt IM. HLA frequency and haplotype analysis in a family study of adult onset rheumatoid arthritis. Dis. Markers 4: 99-102 (1986).
Colak B, Gurlek B, Yegin ZA, Deger SM, Elbek S, Pasaoglu H, Dogan I, Ozturk MA, Unal S, Guz G. The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial Mediterranean fever. Ren. Fail. 30: 187-191 (2008).
Colbert RA, Delay ML, Layh-Schmitt G, Sowders DP. HLA-B27 misfolding and spondyloarthropathies. Prion Jan 3 [Epub ahead of print] (2009).
Colbert RA, Deodhar AA, Khan MA, Lories RJ, Maksymowych WP, Reveille JD, Ritchlin CT, Rosenbaum JT, Targan SR, Weisman M, Clegg DO. 2007 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J. Rheumatol. 35: 1398-1402 (2008).
Cole A. Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs. BMJ 335: 416-417 (2007). *
Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice. J. Am. Acad. Orthop. Surg. 13: 37-46 (2005).
Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol. Annu. Rev. 12: 269-300 (2006).
Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 61: 813-821 (2009). *
Colina M, Govoni M, Trotta F. Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation. Rheumatol. Int. Dec 2 [Epub ahead of print] (2008). *
Coll J, Palazon J, Yazbeck H, Gutierrez J, Aubo C, Benito P, Jagiello P, Maldyk H, Marrugat J, Anglada J, et al. Antibodies to human immunodeficiency virus (HIV-1) in autoimmune diseases: primary Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroid diseases. Clin. Rheumatol. 14: 451-457 (1995).
Coll J, Rives A, Grino MC, Setoain J, Vivancos J, Balcells A. Prevalence of Sjogren's syndrome in autoimmune diseases. Ann. Rheum. Dis. 46: 286-289 (1987). *
Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59: 996-1001 (2008). *
Collantes E, Zarco P, Munoz E, Juanola X, Mulero J, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, Gonzalez C, Batlle E, Fernandez P, Linares LF, Brito E, Carmona L. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) - extended report. Rheumatology (Oxford) 46: 1309-1315 (2007). *
Collier S, Bolte A, Manolios N. Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition. Scand. J. Immunol. 64: 388-391 (2006). *
Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J. Leukoc. Biol. 75: 995-1000 (2004). *
Collins-Racie LA, Yang Z, Arai M, Li N, Majumdar MK, Nagpal S, Mounts WM, Dorner AJ, Morris E, Lavallie ER. Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage. Reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis. Osteoarthritis Cartilage Jan 19 [Epub ahead of print] (2009).
Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des. 12: 2599-2607 (2006).
Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. Rheum. Dis. Clin. North Am. 35: 95-110 (2009).
Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin. Microbiol. Rev. 17: 348-369 (2004). *
Colmegna I, Sainz B Jr, Citera G, Maldonado-Cocco JA, Garry RF, Espinoza LR. Anti-20S proteasome antibodies in psoriatic arthritis. J. Rheumatol. 35: 674-676 (2008).
Colombo E, Latiano A, Palmieri O, Bossa F, Andriulli A, Annese V. Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease? World J. Gastroenterol. 15: 2456-2462 (2009). *
Colonna L, Dinnall JA, Shivers DK, Frisoni L, Caricchio R, Gallucci S. Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus. Arthritis Res. Ther. 8: R49 (2006). *
Comabella M, Altet L, Peris F, Villoslada P, Sanchez A, Montalban X. Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. Mult. Scler. 10: 618-620 (2004). *
Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract. Res. Clin. Rheumatol. 21: 27-42 (2007).
Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Khandker R, Singh A, Wajdula J, Fatenejad S. Efficacy, safety, and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomized two-year study. Ann. Rheum. Dis. Sep 15 [Epub ahead of print] (2008). *
Combe B, Sany J, Le Quellec A, Clot J, Eliaou JF. Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J. Rheumatol. 25: 94-98 (1998).
Combe BG, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen J, Wajdula J, Fatenejad S. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann. Rheum. Dis. 65: 1357-1362 (2006). *
Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J. Rheumatol. 33: 24-30 (2006).
Comeau JL, Lin TJ, Macken MB, Li B, Ku CL, von Bernuth H, Casanova JL, Issekutz AC. Staphylococcal pericarditis, and liver and paratracheal abscesses as presentations in two new cases of interleukin-1 receptor associated kinase 4 deficiency. Pediatr. Infect. Dis. J. 27: 170-174 (2008).
Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 56: 1966-1973 (2007). *
Comte C, Guillot B, Durand L, Picot E, Dereure O. Interstitial granulomatous dermatitis with arthritis: four cases. Ann. Dermatol. Venereol. 135: 38-43 (2008).
Conen KL, Jeanneret C, Hecker B, Cathomas G, Biedermann BC. Acute occlusive large vessel disease leading to fatal stroke in a patient with systemic lupus erythematosus: arteritis or atherosclerosis? Arthritis Rheum. 54: 908-913 (2006). *
Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 20: 865-878 (2006).
Connelly M, Schanberg L. Opioid therapy for the treatment of refractory pain in children with juvenile rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2: 636-637 (2006). *
Connolly MK. Sjogren's syndrome. Semin. Cutan. Med. Surg. 20: 46-52 (2001).
Conrad C, Nestle FO. Animal models of psoriasis and psoriatic arthritis: an update. Curr. Rheumatol. Rep. 8: 342-347 (2006).
Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus 14: 794-797 (2005).
Constantin A, Dieude P, Lauwers-Cances V, Jamard B, Mazieres B, Cambon-Thomsen A, Cornelis F, Cantagrel A. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum. 50: 742-747 (2004). *
Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A. Collagenase-1 (MMP-1) and HLA-DRB1 gene polymorphisms in rheumatoid arthritis: a prospective longitudinal study. J. Rheumatol. 29: 15-20 (2002). *
Constantin A, Lauwers-Cances V, Navaux F, Abbal M, van Meerwijk J, Mazieres B, Cambon-Thomsen A, Cantagrel A. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum. 46: 1754-1762 (2002). *
Constantin A, Navaux F, Lauwers-Cances V, Abbal M, van Meerwijk JP, Mazieres B, Cambon-Thomsen A, Cantagrel A. Interferon gamma gene polymorphism and susceptibility to, and severity of, rheumatoid arthritis. Lancet 358: 2051-2052 (2001). *
Conte FD, Barja-Fidalgo C, Verri WA Jr, Cunha FQ, Rae GA, Penido C, Henriques MD. Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1. J. Leukoc. Biol. 84: 652-660 (2008). *
Conti F, Ceccarelli F, Marocchi E, Magrini L, Romana Spinelli F, Spadaro A, Scrivo R, Valesini G. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann. Rheum. Dis. 66: 1393-1397 (2007). *
Conti F, Ceccarelli F, Priori R, Iagnocco A, Signore A, Valesini G. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha. Ann. Rheum. Dis. 67: 1787-1790 (2008).
Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun. Rev. 8: 124-128 (2008).
Cook AD, Stockman A, Brand CA, Tait BD, Mackay IR, Muirden KD, Bernard CC, Rowley MJ. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum. 42: 2569-2576 (1999). *
Cooke A. Th17 cells in inflammatory conditions. Rev. Diabet. Stud. 3: 72-75 (2006). *
Cooke SP, Rigby SP, Griffiths DJ, Venables PJ. Viral studies in rheumatic disease. Ann. Med. Interne. (Paris) 149: 30-33 (1998).
Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ. Health Perspect. 107 Suppl. 5: 693-700 (1999).
Cooper GS, Parks CG. Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr. Rheumatol. Rep. 6: 367-374 (2004).
Cooper GS, Wither J, McKenzie T, Claudio JO, Bernatsky S, Fortin PR. The prevalence and accuracy of self-reported history of 11 autoimmune diseases. J. Rheumatol. 35: 2001-2004 (2008).
Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J, Knight KR, Daskalakis M, Doery JC. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin. Rheumatol. Int. 19: 129-136 (2000). *
Cope AP. Harmful waste products as novel immune modulators for treating inflammatory arthritis? PLoS Med. 3: e385 (2006). *
Cope AP. T cells in rheumatoid arthritis. Arthritis Res. Ther. 10 Suppl. 1: S1 (2008). *
Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin. Exp. Rheumatol. 25: S4-S11 (2007).
Coppieters K, Dewint P, Van Beneden K, Jacques P, Seeuws S, Verbruggen G, Deforce D, Elewaut D. NKT cells: manipulable managers of joint inflammation. Rheumatology (Oxford) 46: 565-571 (2007). *
Copple SS, Martins TB, Masterson C, Joly E, Hill HR. Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera. Ann. N. Y. Acad. Sci. 1109: 464-472 (2007). *
Corallini F, Bossi F, Gonelli A, Tripodo C, Castellino G, Mollnes TE, Tedesco F, Rizzi L, Trotta F, Zauli G, Secchiero P. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology (Oxford) 48: 293-298 (2009). *
Cordiali Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigo M, Mastroianni A, Vento A, Solivetti F, Berardesca E, Ensoli F. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J. Autoimmune Dis. 3: 5 (2006). *
Cordiali-Fei P, Ardigo M, Mastroianni A, Giuliani A, D' Agosto G, Bordignon V, Trento E, Vento A, Berardesca E. Serum cytokines and biohumoral immunological characterization of psoriatic patients in long term etanercept treatment. Int. J. Immunopathol. Pharmacol. 21: 643-650 (2008).
Cordiali-Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardig� M, Mastroianni A, Vento A, Solivetti F, Berardesca E, Ensoli F. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann. N. Y. Acad. Sci. 1110: 578-589 (2007). *
Cordoro KM, Feldman SR. TNF-a inhibitors in dermatology. Skin Therapy Lett. 12: 4-6 (2007). *
Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, Alves H, Barrera P, de Vries N, Balsa A, Pascual-Salcedo D, Maenaut K, Westhovens R, Migliorini P, Tran TH, Delaye A, Prince N, Lefevre C, Thomas G, Poirier M, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc. Natl. Acad. Sci. U.S.A. 95: 10746-10750 (1998). *
Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr. Pharm. Des. 13: 367-385 (2007).
Cornelissen F, van Hamburg JP, Lubberts E. The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis. Curr. Opin. Investig. Drugs 10: 452-462 (2009).
Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebert C, Aupee M, Caulet-Maugendre S, Faucheux M, Lelong B, Leray E, Guiguen C, Gangneux JP. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin. Infect. Dis. 43: 577-584 (2006). *
Coroi M, Bontas E, Defranceschi M, Bartos D, Dorobantu M. Ocular manifestations of antiphospholipid (Hughes') syndrome - minor features? Oftalmologia 51: 16-22 (2007).
Corominas H, Figuls R, Riera M, Baiget M. Phenotype of ulcerative colitis, rheumatoid arthritis, and interleukin-10 gene polymorphism. Rev. Esp. Enferm. Dig. 98: 704-705 (2006).
Corporaal S, Bijl M, Kallenberg CG. Familial occurrence of autoimmune diseases and autoantibodies in a Caucasian population of patients with systemic lupus erythematosus. Clin. Rheumatol. 21: 108-113 (2002).
Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS. Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann. Rheum. Dis. 68: 257-263 (2009).
Corrao S, Puleo A, Pistone G, Calvo L, Scaglione R, Licata G. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis. Clin. Exp. Rheumatol. 26: 164-165 (2008).
Correa PA, Gomez LM, Anaya JM. Polymorphism of TNF-alpha in autoimmunity and tuberculosis. Biomedica 24 Supp. 1: 43-51 (2004).
Correa PA, Gomez LM, Cadena J, Anaya JM. Autoimmunity and tuberculosis. Opposite association with TNF polymorphism. J. Rheumatol. 32: 219-224 (2005).
Correa PA, Tobon GJ, Citera G, Cadena J, Schneeberger E, Camargo JF, Maldonado-Cocco JA, Anaya JM. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1. Biomedica 24: 140-152 (2004).
Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10: 149-166 (2007). *
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin. Arthritis Rheum. 37: 381-387 (2008). *
Costas J, Perez-Pampin E, Ferreiros-Vidal I, Torres M, Phillips C, Vicario JL, Pablos JL, Carracedo A, Gomez-Reino JJ, Gonzalez A. SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis. J. Rheumatol. 33: 1048-1051 (2006).
Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Frances C, Wechsler B, Huong DL, Ghillani P, Musset L, Lechat P, Piette JC. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 3284-3290 (2006). *
Costello JC, Halverson PB. A new era in rheumatoid arthritis treatment. WMJ 102: 29-33 (2003).
Costello P, FitzGerald O. Disease mechanisms in psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 3: 419-427 (2001).
Costenbader KH, Chang SC, De Vivo I, Plenge R, Karlson EW. PTPN22, PADI-4 and CTLA-4 genetic polymorphisms and risk of rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res. Ther. 10: R52 (2008). *
Costenbader KH, Feskanich D, Benito-Garcia E, Holmes M, Karlson E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 67: 530-535 (2008).
Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am. J. Med. 119: 503, e1-9 (2006). *
Costenbader KH, Glass R, Cui J, Shadick N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296: 2201 (2006).
Costenbader KH, Karlson EW. Epstein-Barr virus and rheumatoid arthritis: is there a link? Arthritis Res. Ther. 8: 204 (2006). *
Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus 15: 737-745 (2006).
Costenbader KH, Karlson EW, Gall V, Pablo PD, Finckh A, Lynch M, Bermas B, Schur PH, Liang MH. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum. 53: 718-723 (2005). *
Costescu I, V�lciu A. Clinical observations of a case of anterior uveitis associated with ankylosing spondylitis and psoriatic arthritis. Paraclinical studies. Oftalmologia 42: 74-77 (1998).
Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 39: 87-92 (1996).
Couffinhal T, Dufourcq P, Barandon L, Leroux L, Duplaa C. Mouse models to study angiogenesis in the context of cardiovascular diseases. Front. Biosci. 14: 3310-3325 (2009).
Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat. Med. 14: 81-87 (2008). *
Covic A, Mutica C, Ignat A, Boaru I, Veisa G, Gusbeth-Tatomir P, Enea M, Covic M. Retrospective study of 97 ANCA-positive patients: epidemiological and clinical spectrum. Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 305-310 (2004).
Covington MB. Omega-3 fatty acids. Am. Fam. Physician 70: 133-140 (2004). *
Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35: 3332-3342 (2005). *
Cox NL, Prowse MV, Maddison MC, Maddison PJ. Treatment of early rheumatoid arthritis with rifampicin. Ann. Rheum. Dis. 51: 32-34 (1992). *
Cragnolini JJ, Garcia-Medel N, Lopez de Castro JA. Endogenous processing and presentation of T-cell epitopes from Chlamydia trachomatis with relevance in HLA-B27-associated reactive arthritis. Mol. Cell. Proteomics May 13 [Epub ahead of print] (2009). *
Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA. Role of NOD2 variants in spondylarthritis. Arthritis Rheum. 46: 1629-1633 (2002). *
Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 25: 613-631 (2007).
Cravo AR, Tavares V, Canas Da Silva J. Anti-TNF alfa therapy in ankylosing spondylitis. Acta Med. Port. 19: 141-150 (2006).
Crestani B. The respiratory system in connective tissue disorders. Allergy 60: 715-734 (2005). *
Cribier B. Urticaria and hepatitis. Clin. Rev. Allergy Immunol. 30: 25-30 (2006).
Crispin JC, Martinez-Banos D, Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin. Medicine (Baltimore) 84: 331-337 (2005).
Crispin-Acuna JC, Remes-Troche JM, Uribe M. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjogren's syndrome. Ann. Hepatol. 6: 150-155 (2007). *
Cristea A, Badea T, Bodizs G, Olinic N. Antineutrophil cytoplasmic autoantibodies (ANCA) - markers in diagnosis and monitoring systemic vasculitides. Rom. J. Intern. Med. 33: 37-46 (1995).
Cristofaro P, Opal SM. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 66: 15-29 (2006).
Criswell LA. Familial clustering of disease features: implications for the etiology and investigation of systemic autoimmune disease. Arthritis Rheum. 50: 1707-1708 (2004). *
Criswell LA, Amos CI. Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis. Curr. Opin. Rheumatol. 12: 85-90 (2000).
Criswell LA, Chen WV, Jawaheer D, Lum RF, Wener MH, Gu X, Gregersen PK, Amos CI. Dissecting the heterogeneity of rheumatoid arthritis through linkage analysis of quantitative traits. Arthritis Rheum. 56: 58-68 (2007). *
Criswell LA, Gregersen PK. Current understanding of the genetic aetiology of rheumatoid arthritis and likely future developments. Rheumatology (Oxford) 44 Suppl. 4: iv9-iv13 (2005). *
Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50: 2750-2756 (2004). *
Criswell LA, Mu H, Such CL, King MC. Inheritance of the shared epitope and long-term outcomes of rheumatoid arthritis among community-based Caucasian females. Genet. Epidemiol. 15: 61-72 (1998).
Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76: 561-571 (2005). *
Criswell LA, Saag KG, Mikuls TR, Cerhan JR, Merlino LA, Lum RF, Pfeiffer KA, Woehl B, Seldin MF. Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. Ann. Rheum. Dis. 65: 1163-1167 (2006). *
Crombez L, Marques B, Lenormand JL, Mouz N, Polack B, Trocme C, Toussaint B. High level production of secreted proteins: example of the human tissue inhibitor of metalloproteinases 1. Biochem. Biophys. Res. Commun. 337: 908-915 (2005). *
Crombie DE, Turer M, Zuasti BB, Wood B, McNaughton D, Nandakumar KS, Holmdahl R, Van Damme MP, Rowley MJ. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res. Ther. 7: R927-R937 (2005). *
Cronstein BN. Pharmacogenetics in the rheumatic diseases. Bull. Hosp. Jt. Dis. 64: 16-19 (2006).
Cronstein BN. Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull. N.Y.U. Hosp. Jt. Dis. 65 Suppl. 1: S11-S15 (2007). *
Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res. Ther. 8 Suppl. 1: S3 (2006). *
Crosdale DJ, Poulton KV, Ollier WE, Thomson W, Denning DW. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J. Infect. Dis. 184: 653-656 (2001). *
Crouzet J, Claudepierre P, Aribi EH, Malbrunot C, Beraneck L, Juan LH, Larget-Piet B. Two cases of discitis due to Propionibacterium acnes. Rev. Rhum. Engl. Ed. 65: 68-71 (1998).
Crowe JP, Molloy MG, Wells I, Thompson BR, Holborow EJ, Hamilton E, Williams R. Increased C1q binding and arthritis in primary biliary cirrhosis. Gut 21: 418-422 (1980). *
Crowson AN, Mihm MC Jr, Magro CM. Cutaneous vasculitis: a review. J. Cutan. Pathol. 30: 161-173 (2003). *
Crowson CS, Nicola PJ, Kremers HM, O'fallon WM, Therneau TM, Jacobsen SJ, Roger VL, Ballman KV, Gabriel SE. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum. 52: 3039-3044 (2005). *
Crowther SD, Rees PJ. Current treatment of asthma - focus on leukotrienes. Expert Opin. Pharmacother. 1: 1021-1040 (2000).
Cruyssen BV, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res. Ther. 8: R112 (2006). *
Cruz AA, Akaishi PM, Vargas MA, de Paula SA. Association between thyroid autoimmune dysfunction and non-thyroid autoimmune diseases. Ophthal. Plast. Reconstr. Surg. 23: 104-108 (2007).
Csaki C, Matis U, Mobasheri A, Ye H, Shakibaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem. Cell Biol. 128: 507-520 (2007).
Csepregi A, Obermayer-Straub P, Kneip S, Kayser A, Loges S, Schmidt E, Nemesanszky E, Szalay F, Manns MP, Strassburg CP. Characterization of a lipoyl domain-independent B-cell autoepitope on the human branched-chain acyltransferase in primary biliary cirrhosis and overlap syndrome with autoimmune hepatitis. Clin. Dev. Immunol. 10: 173-181 (2003). *
Csernok E, Ahlquist D, Ullrich S, Gross WL. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 41: 1313-1317 (2002). *
Csipo I, Kiss E, Bako E, Szegedi G, Kavai M. Soluble complement receptor 1 (CD35) bound to immune complexes in sera of patients with systemic lupus erythematosus. Arthritis Rheum. 52: 2950-2951 (2005). *
Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med. Hypotheses 63: 696-698 (2004).
Ctirad A, Lenka B, David P, Zdenek F, Kveta H, Karel E, Jan K. Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level. Int. J. Dermatol. 47: 1011-1014 (2008). *
Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Perez C, Aguirre A, Salazar-Onfray F, Aguillon J. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 33: 228-232 (2004). *
Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L, Gatica H, Schiattino I, Salazaro L, Catalan D, Valenzuela O, Salazar-Onfray F, Aguillon JC. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 35: 435-440 (2006).
Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J. Clin. Rheumatol. 14: 353-356 (2008).
Cuchacovich R, Espinoza LR. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? Clin. Rheumatol. Jun 11 [Epub ahead of print] (2009).
Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin. Rheumatol. 26: 1769-1771 (2007). *
Cuchacovich RS, Espinoza LR. Ustekinumab for psoriatic arthritis. Lancet 373: 605-606 (2009). *
Cuenca J, Cuchacovich M, Perez C, Ferreira L, Aguirre A, Schiattino I, Soto L, Cruzat A, Salazar-Onfray F, Aguillon JC. The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology (Oxford) 42: 308-313 (2003). *
Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr. Vasc. Pharmacol. Jan 1 [Epub ahead of print] (2009).
Cui J, Taylor K, Destefano A, Criswell L, Izmailova E, Alex P, Roubenoff R, Plenge R, Weinblatt M, Shadick N, Karlson E. Genome wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. Mol. Med. Mar 14 [Epub ahead of print] (2009).
Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient. Optometry 76: 250-258 (2005).
Culver B, Itkin A, Pischel K. Case report and review of minocycline-induced cutaneous polyarteritis nodosa. Arthritis Rheum. 53: 468-470 (2005). *
Culverhouse R, Hinrichs AL, Jin CH, Suarez BK. Gene x gene and gene x environment interactions for complex disorders. BMC Proc. 1 Suppl. 1: S72 (2007). *
Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. 21: 385-389 (2005). *
Cummins EP, Comerford KM, Scholz C, Bruning U, Taylor CT. Hypoxic regulation of NF-kappaB signaling. Methods Enzymol. 435: 479-492 (2007).
Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Benazeth S, Cynober L. Almost all about citrulline in mammals. Amino Acids 29: 177-205 (2005). *
Curtin K, Wong J, Allen-Brady K, Camp NJ. Meta-genetic association of rheumatoid arthritis and PTPN22 using PedGenie 2.1. BMC Proc. 1 Suppl. 1: S12 (2007). *
Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann. Rheum. Dis. Jan 15 [Epub ahead of print] (2009).
Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46: 1688-1693 (2007). *
Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 56: 1125-1133 (2007). *
Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann. Rheum. Dis. 64 Suppl. 4: iv18-iv23 (2005). *
Cutolo M. Sex and rheumatoid arthritis: mouse model versus human disease. Arthritis Rheum. 56: 1-3 (2007). *
Cutolo M. Vitamin D or hormone D deficiency in autoimmune rheumatic diseases, including undifferentiated connective tissue disease. Arthritis Res. Ther. 10: 123 (2008).
Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases. Ann. N. Y. Acad. Sci. 1089: 538-547 (2006). *
Cutolo M, Lahita RG. Estrogens and arthritis. Rheum. Dis. Clin. North Am. 31: 19-27 (2005).
Cutolo M, Otsa K. Review: vitamin D, immunity and lupus. Lupus 17: 6-10 (2008).
Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, Sulli A, Paolino S, Seriolo B. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 24: 702-704 (2006).
Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun. Rev. 7: 59-64 (2007).
Cutolo M, Straub RH. Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation 13: 277-282 (2006).
Cutolo M, Straub RH. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 7: 223-238 (2008).
Cutolo M, Straub RH. Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res. Ther. 11: 218 (2009).
Cutolo M, Straub RH, Bijlsma JW. Neuroendocrine-immune interactions in synovitis. Nat. Clin. Pract. Rheumatol. 3: 627-634 (2007). *
Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Pizzorni C, Paolino S, Seriolo B, Felli L, Straub RH. Anti-TNF and sex hormones. Ann. N. Y. Acad. Sci. 1069: 391-400 (2006). *
Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13: 635-638 (2004).
Cutolo M, Sulli A, Pizzorni C, Secchi ME, Soldano S, Seriolo B, Straub RH, Otsa K, Maestroni GJ. Circadian rhythms: glucocorticoids and arthritis. Ann. N. Y. Acad. Sci. 1069: 289-299 (2006). *
Cutolo M, Villaggio B, Otsa K, Aakre O, Sulli A, Seriolo B. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms. Autoimmun. Rev. 4: 497-502 (2005).
Cuzzocrea S. Role of nitric oxide and reactive oxygen species in arthritis. Curr. Pharm. Des. 12: 3551-3570 (2006).
Cuzzocrea S, Saadat F, Di Paola R, Mirshafiey A. Artemether: a new therapeutic strategy in experimental rheumatoid arthritis. Immunopharmacol. Immunotoxicol. 27: 615-630 (2005).
Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs 20: 293-311 (2006).
Czaja AJ. Autoimmune liver disease and rheumatic manifestations. Curr. Opin. Rheumatol. 19: 74-80 (2007).
Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262 (2007).
D'Acquisto F, Ianaro A. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors. Curr. Opin. Pharmacol. 6: 387-392 (2006).
D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F, Marchini M, Scorza R, Danieli MG, Cappelli M, Migliaresi S, Bigliardo B, Sabbadini MG, Baldissera E, Galeazzi M, Sebastiani GD, Minisola G, Ravazzolo R. Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 52: 539-547 (2005). *
D'Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum. 43: 120-128 (2000). *
D'Angelo S, Mennillo GA, Cutro MS, Leccese P, Nigro A, Padula A, Olivieri I. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J. Rheumatol. 36: 368-370 (2009).
D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr. Metab. Immune Disord. Drug Targets 8: 62-68 (2008).
D'Arienzo A, Manguso F, Scarpa R, Astarita C, D'Armiento FP, Bennato R, Gargano D, Sanges M, Mazzacca G. Ulcerative colitis, seronegative spondyloarthropathies and allergic diseases: the search for a link. Scand. J. Gastroenterol. 37: 1156-1163 (2002). *
D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, Sabbadini MG. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J. Intern. Med. 255: 409-418 (2004). *
D'Inca R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo GC. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig. Liver Dis. Mar 9 [Epub ahead of print] (2009).
D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, Pontillo A, Corona F, Barcellona R, Di Duca M, Santamaria G, Traverso F, Picco P, Baldi M, Plebani A, Ravazzolo R, Ceccherini I, Martini A, Gattorno M. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum. 54: 998-1008 (2006). *
Da Silva JA, Jacobs JW, Bijlsma JW. Revisiting the toxicity of low-dose glucocorticoids: risks and fears. Ann. N. Y. Acad. Sci. 1069: 275-288 (2006). *
Dagfinrud H, Heiberg MS, Bakland G, Skomsvoll J, Kvien TK. Ankylosing spondylitis - a consensus on diagnosis and treatment. Tidsskr. Nor. Laegeforen. 127: 3209-3212 (2007).
Daha NA, Kurreeman FA, Marques RB, Stoeken-Rijsbergen G, Verduijn W, Huizinga TW, Toes RE. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum. 60: 1255-1260 (2009). *
Dai J, Liu B, Cua DJ, Li Z. Essential roles of IL-12 and dendritic cells but not IL-23 and macrophages in lupus-like diseases initiated by cell surface HSP gp96. Eur. J. Immunol. 37: 706-715 (2007). *
Dai J, Rabie AB. The use of recombinant adeno-associated virus for skeletal gene therapy. Orthod. Craniofac. Res. 10: 1-14 (2007).
Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IKK inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279: 37219-37222 (2004). *
Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum. 50: 432-443 (2004). *
Dai SM, Shan ZZ Dr, Xu H, Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann. Rheum. Dis. 66: 1411-1418 (2007). *
Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206: 793-805 (2009). *
Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. Clin. Exp. Rheumatol. 24: 38-44 (2006).
Dakwar E, Reddy J, Vale FL, Uribe JS. A review of the pathogenesis of ankylosing spondylitis. Neurosurg. Focus 24: E2 (2008).
Dalakos TG, MacSween RN, Whaley K, Dick WC, Boyle JA, Jasani MK, Wilson ME, Buchanan WW, Goudie RB. Conjugal prevalence of rheumatoid arthritis, rheumatoid factor and other autoantibodies in rheumatoid arthritis. Clin. Exp. Immunol. 3: 761-769 (1968). *
Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, Herman D, McQueen FM. A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis. Ann. Rheum. Dis. 63: 718-722 (2004). *
Daldrup-Link HE, Steinbach L. MR imaging of pediatric arthritis. Magn. Reson. Imaging Clin. N. Am. 17: 451-467 (2009).
Dall'era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat. Rev. Rheumatol. 5: 348-351 (2009).
Dalmolin RJ, Zanotto-Filho A, De Oliveira RB, Duarte RF, Pasquali MA, Moreira JC. Retinol and retinoic acid increase MMP-2 activity by different pathways in cultured Sertoli cells. Free Radic. Res. 41: 1338-1347 (2007).
Damjanovska L, Thabet MM, Levarht EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE, Huizinga TW, van der Helm-van Mil AH. The diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann. Rheum. Dis. May 17 [Epub ahead of print] (2009).
Dammann HG. Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity. Z. Gastroenterol. 37: 45-58 (1999).
Damore M, Minenna G, D'Amore S. Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia. Recenti Prog. Med. 96: 552-555 (2005).
Damsker JM, Okwumabua I, Pushkarsky T, Arora K, Bukrinsky MI, Constant SL. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology 126: 55-62 (2009). *
Danese S, Rutella S. The Janus face of CD4(+)CD25(+) regulatory T cells in cancer and autoimmunity. Curr. Med. Chem. 14: 649-666 (2007).
Daneshtalab N, Lewanczuk RZ, Russell AS, Jamali F. Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis. J. Clin. Pharmacol. 46: 1344-1355 (2006). *
Dang DT, Eriste E, Liepinsh E, Trinh TT, Erlandsson-Harris H, Sillard R, Larsson P. A novel anti-inflammatory compound, artonkin-4'-O-glucoside, from the leaves of Artocarpus tonkinensis suppresses experimentally induced arthritis. Scand. J. Immunol. 69: 110-118 (2009). *
Danila MI, Hughes LB, Bridges SL. Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics 9: 1011-1015 (2008).
Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr. Opin. Rheumatol. 20: 327-333 (2008).
Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis. Markers. 12: 127-133 (1995).
Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, Sibilia J. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J. Rheumatol. 33: 1377-1381 (2006).
Danneskiold-Samsoe B, Bartels EM, Dreyer L. Gender differences in autoimmune diseases illustrated by rheumatoid arthritis. Ugeskr. Laeger. 169: 2440-2442 (2007).
Dao K, Cush JJ. Acute polyarthritis. Best Pract. Res. Clin. Rheumatol. 20: 653-672 (2006).
Daoud L, Dhaoui MR, Youssef S, Jaber K, Doss N. Management of severe psoriasis: about 50 cases. Tunis. Med. 85: 849-856 (2007).
Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG Axis. Semin. Arthritis Rheum. Dec 16 [Epub ahead of print] (2008). *
Dapena Diaz JL, Diaz de Heredia Rubio C, Bastida Vila P, Llort Sales A, Elorza Alvarez I, Olive Oliveras T, Sanchez de Toledo Codina J. Haemophagocytic syndrome: a common pathogenic mechanism of various aetiologies. An. Pediatr. (Barc.) May 28 [Epub ahead of print] (2009).
Darabi K, Jaiswal R, Hostetler S, Bechtel M, Zirwas M. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate. J. Drugs Dermatol. 8: 175-178 (2009).
Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr. Opin. Rheumatol. 21: 205-210 (2009).
Das P, Abraham R, David C. HLA transgenic mice as models of human autoimmune diseases. Rev. Immunogenet. 2: 105-114 (2000).
Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network. Prostaglandins Leukot. Essent. Fatty Acids 51: 207-213 (1994).
Daser A, Mitchison H, Mitchison A, Muller B. Non-classical-MHC genetics of immunological disease in man and mouse. The key role of pro-inflammatory cytokine genes. Cytokine 8: 593-597 (1996).
Dasgupta S, Murumkar PR, Giridhar R, Yadav MR. Current perspective of TACE inhibitors: a review. Bioorg. Med. Chem. 17: 444-459 (2009).
Dass S, Vital EM, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. 7: 2559-2570 (2006).
Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56: 2715-2718 (2007). *
Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr. Opin. Investig. Drugs 8: 364-372 (2007).
Date Y, Seki N, Kamizono S, Higuchi T, Hirata T, Miyata K, Ohkuni M, Tatsuzawa O, Yokota S, Joo K, Ueda K, Sasazuki T, Kimura A, Itoh K, Kato H. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum. 42: 2577-2582 (1999). *
Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192: 391-395 (2007).
Dauendorffer JN, Rivet J, Allard A, Bachelez H. Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br. J. Dermatol. 156: 742-743 (2007).
Davaine A, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, Schoenlaub P, Talarmin F, Zagnoli A, Misery L. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 22: 1471-1477 (2008).
David CS, Taneja V. Role of major histocompatibility complex genes in murine collagen-induced arthritis: a model for human rheumatoid arthritis. Am. J. Med. Sci. 327: 180-187 (2004).
Davidson NJ. The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease. Expert Opin. Investig. Drugs 7: 1115-1120 (1998).
Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J. Rheumatol. 36: 16-26 (2009).
Davies JM. Molecular mimicry: can epitope mimicry induce autoimmune disease? Immunol. Cell Biol. 75: 113-126 (1997).
Davies MR, Ribeiro LR, Downey-Jones M, Needham MR, Oakley C, Wardale J. Ligands for retinoic acid receptors are elevated in osteoarthritis and may contribute to pathologic processes in the osteoarthritic joint. Arthritis Rheum. 60: 1722-1732 (2009). *
Davies NP, Roubin RH, Whitelock JM. Characterization and purification of glycosaminoglycans from crude biological samples. J. Agric. Food Chem. 56: 343-348 (2008). *
Davis GE Jr, Lowell WE. Solar cycles and their relationship to human disease and adaptability. Med. Hypotheses 67: 447-461 (2006).
Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum. 51: 302-304 (2004). *
Davis JC Jr, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin. Arthritis Rheum. 38: 83-100 (2008). *
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48: 3230-3236 (2003). *
Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 56: 820-830 (2007). *
Davis JM, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J. Rheumatol. 32: 1856-1862 (2005).
Davis Jr JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. The definition of disease duration in ankylosing spondylitis: reassessing the concept. Ann. Rheum. Dis. 65: 1518-1520 (2006). *
Davis KA, Finger DR, Shparago NI. Disseminated histoplasmosis mimicking Felty's syndrome. J. Clin. Rheumatol. 8: 38-43 (2002).
Davis L, Chen Y, Sen M. WISP-3 functions as a ligand and promotes superoxide dismutase activity. Biochem. Biophys. Res. Commun. 342: 259-265 (2006). *
Davis MC, Affleck G, Zautra AJ, Tennen H. Daily interpersonal events in pain patients: applying action theory to chronic illness. J. Clin. Psychol. 62: 1097-1113 (2006). *
Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav. Immun. 22: 24-32 (2008). *
Dawczynski C, Schubert R, Hein G, Muller A, Eidner T, Vogelsang H, Basu S, Jahreis G. Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis. Br. J. Nutr. 101: 1517-1526 (2009). *
Dawkins RL, Kay PH, Christiansen FT. Immunogenetics of rheumatoid arthritis. Ann. Acad. Med. Singapore 12: 155-163 (1983).
Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? Arthritis Rheum. 52: 2984-2995 (2005). *
Day TG, Ramanan AV, Hinks A, Lamb R, Packham J, Wise C, Punaro M, Donn RP. Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. Arthritis Rheum. 58: 2142-2146 (2008). *
Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch. Dermatol. Res. 299: 487-491 (2007). *
Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C. Adipose tissue has anti-inflammatory properties: focus on IL-1 receptor antagonist (IL-1Ra). Ann. N. Y. Acad. Sci. 1069: 444-453 (2006). *
Dayer JM, Molnarfi N, Burger D. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation? Expert Opin. Biol. Ther. 5 Suppl. 1: S83-S96 (2005).
Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 53: 146-147 (2005). *
Daza L, Martin-Jimenez R, De la Torre PX, Hernandez E, Murillo B. Improvement of ACTH response to insulin tolerance test in female patients with rheumatoid arthritis due to tumor necrosis factor inhibition. Eur. J. Endocrinol. 157: 47-51 (2007).
Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Curr. Opin. Oncol. 19: 650-655 (2007).
Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res. Ther. 9: 206 (2007). *
de Andrade M, Allen AS, Brinza D, Cheng R, Da Y, de Vries AR, Ewhida A, Feng Z, Jung H, Hsieh HJ, K�hler K, Liu Y, Liu-Mares W, Luan J, Marquard V, Nolte IM, Oh S, Platt A, Qin X, Yoo YJ, Yuan A, Tian X, Won S. Summary of contributions to GAW15 Group 13: candidate gene association studies. Genet. Epidemiol. 31 Suppl. 1: S110-S117 (2007).
De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand. J. Rheumatol. 36: 14-21 (2007). *
De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary 8: 25-30 (2005). *
de Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52: 687-693 (2005). *
De Benedetti F, Ravelli A. Juvenile idiopathic arthritis: will etanercept be an improvement over current therapies? BioDrugs 14: 93-98 (2000).
De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24: 488-522 (2003). *
de Buys P, Khanna D, Furst DE. Hemopoietic stem cell transplantation in rheumatic diseases-an update. Autoimmun. Rev. 4: 442-449 (2005).
De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J. Dermatolog. Treat. 17: 355-358 (2006).
De Filippis D, D'Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J. Neuroendocrinol. 20 Suppl.1: 20-25 (2008).
De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. Panminerva Med. 48: 129-135 (2006).
de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch. Dermatol. 143: 223-231 (2007). *
De Hertogh G, Geboes K. Crohn's disease and infections: a complex relationship. MedGenMed. 6: 14 (2004). *
De Jager PL, Richardson A, Vyse TJ, Rioux JD. Genetic variation in Toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum. 54: 1279-1282 (2006). *
De Jager PL, Sawcer S, Waliszewska A, Farwell L, Wild G, Cohen A, Langelier D, Bitton A, Compston A, Hafler DA, Rioux JD. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. Eur. J. Hum. Genet. 14: 317-321 (2006). *
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis; a cross-sectional study. Ann. Rheum. Dis. 66: 589-598 (2007). *
de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10: 133-139 (2003). *
de Jongh BM, Westedt ML, de Vries RR, Valkenburg HA, Cats A. Genetic heterogeneity of rheumatoid arthritis. Dis. Markers 4: 29-33 (1986).
De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, Veys E. Gut inflammation and spondyloarthropathies. Curr. Rheumatol. Rep. 4: 525-532 (2002).
De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis. Drugs 64: 2793-2811 (2004).
de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Puga Yung G, Albani S, Kuis W, Wulffraat N, Prakken B. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T-cells and restoring the CD4+CD25+ immune regulatory network. Blood 107: 1696-1702 (2006). *
de Kruijf P, van Heteren J, Lim HD, Conti PG, van der Lee MM, Bosch L, Ho KK, Auld D, Ohlmeyer M, Smit MJ, Wijkmans JC, Zaman GJ, Smit MJ, Leurs R. Non-peptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. J. Pharmacol. Exp. Ther. 329: 783-790 (2009). *
de la Fontaine L, Schwarz M, Plischke H, Kleindienst N, Gruber R. Lack of association of the CD14/C-159T polymorphism with susceptibility and serological activity parameters of rheumatoid arthritis. Scand. J. Rheumatol. 35: 20-22 (2006). *
de la Fontaine L, Schwarz MJ, Riedel M, Dehning S, Douhet A, Spellmann I, Kleindienst N, Zill P, Plischke H, Gruber R, Muller N. Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. Psychiatry Res. 144: 39-47 (2006).
de Matos CT, Berg L, Michaelsson J, Fellander-Tsai L, Karre K, Soderstrom K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 122: 291-301 (2007). *
De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin. Exp. Rheumatol. 21: 726-732 (2003).
de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C. Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center. Acta Reumatol. Port. 32: 139-150 (2007).
de Pablo P, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat. Rev. Rheumatol. 5: 218-224 (2009). *
De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, Balow JE, Barron KS, Turner ML, Gallin JI, Malech HL. Chronic granulomatous disease as a risk factor for autoimmune disease. J. Allergy Clin. Immunol. 122: 1097-1103 (2008).
de Rham C, Ferrari-Lacraz S, Jendly S, Schneiter G, Dayer JM, Villard J. The pro-inflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res. Ther. 9: R125 (2007). *
de Rie MA, van Kuijk AW, Goedkoop AY, Tak PP. Arthritis psoriatica. Ned. Tijdschr. Geneeskd. 151: 1716-1722 (2007).
De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect. Control Hosp. Epidemiol. 24: 477-482 (2003). *
De Rosa G, Mignogna C. The histopathology of psoriasis. Reumatismo 59 Suppl. 1: 46-48 (2007). *
De Rycke L, Kruithof E, Vandooren B, Tak PP, Baeten D. Pathogenesis of spondyloarthritis: insights from synovial membrane studies. Curr. Rheumatol. Rep. 8: 275-282 (2006).
De Rycke L, Nicholas AP, Cantaert T, Kruithof E, Echols JD, Vandekerckhove B, Veys EM, De Keyser F, Baeten D. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 52: 2323-2330 (2005). *
De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann. Rheum. Dis. 63: 1587-1593 (2004). *
De Sanctis JB, Garmendia JV, Moreno D, Larocca N, Mijares M, Di Giulio C, Salazar-Bookaman M, Wojewodka G, Radzioch D. Pharmacological modulation of Th17. Recent Pat. Inflamm. Allergy Drug Discov. 3: 149-156 (2009).
de Seny D, Fillet M, Meuwis MA, Geurts P, Lutteri L, Ribbens C, Bours V, Wehenkel L, Piette J, Malaise M, Merville MP. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 52: 3801-3812 (2005). *
de Seny D, Fillet M, Ribbens C, Maree R, Meuwis MA, Lutteri L, Chapelle JP, Wehenkel L, Louis E, Merville MP, Malaise M. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin. Chem. 54: 1066-1075 (2008). *
De Souza TB, Mentz EF, Brenol CV, Xavier RM, Brenol JC, Chies JA, Simon D. Association between the aggrecan gene and rheumatoid arthritis. J. Rheumatol. 35: 2325-2328 (2008).
De Vita S, Boiocchi M, Sorrentino D, Carbone A, Avellini C, Dolcetti R, Marzotto A, Gloghini A, Bartoli E, Beltrami CA, Ferraccioli G. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum. 40: 318-331 (1997).
De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev. 5: 443-448 (2006).
De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig. Liver Dis. 39 Suppl. 1: S122-S128 (2007).
De Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J. Rheumatol. 35: 1443-1448 (2008).
de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 45: 321-324 (2006). *
de Vlam K, Lories RJ. Remission in psoriatic arthritis. Curr. Rheumatol. Rep. 10: 297-302 (2008).
de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111: 1-66 (2008). *
de Vries N, Prinsen CF, Mensink EB, van Riel PL, van't Hof MA, van de Putte LB. A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 52: 327-331 (1993). *
de Vries N, Ronningen KS, Tilanus MG, Bouwens-Rombouts A, Segal R, Egeland T, Thorsby E, van de Putte LB, Brautbar C. HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype. Tissue Antigens 41: 26-30 (1993).
de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis Rheum. 46: 921-928 (2002). *
de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: to be or not to be anti-CCP positive. J. Autoimmun. 25: S21-S25 (2005).
de Vries RR, Huizinga TW, Toes RE. HLA and RA revisited: citrullinated food for the SE hypothesis, the DR6 effect, and NIMA. Hum. Immunol. 67: 454-459 (2006).
de Vries RR, Nijenhuis LE, Khan MA, Mehra NK. Paradoxical inheritance of HLA-linked susceptibility to rheumatoid arthritis. Tissue Antigens 26: 286-292 (1985).
de Vries-Bouwstra J, Le Cessie S, Allaart C, Breedveld F, Huizinga T. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. J. Rheumatol. 33: 1747-1753 (2006).
De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, Hulsmans HJ, de Craen AJ, Breedveld FC, Dijkmans BA, Allaart CF, Huizinga TW. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage. Ann. Rheum. Dis. 66: 1033-1037 (2007). *
De Wall SL, Painter C, Stone JD, Bandaranayake R, Wiley DC, Mitchison TJ, Stern LJ, Dedecker BS. Noble metals strip peptides from class II MHC proteins. Nat. Chem. Biol. 2: 197-201 (2006). *
Decker P, Briand JP, de Murcia G, Pero RW, Isenberg DA, Muller S. Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. Arthritis Rheum. 41: 918-926 (1998). *
Degreef I, De Smet L. Vanishing finger in psoriatic arthritis: a case report. Clin. Rheumatol. 26: 1391-1392 (2007). *
Deighton C, Criswell LA. Recent advances in the genetics of rheumatoid arthritis. Curr. Rheumatol. Rep. 8: 394-400 (2006).
Deighton C, Hyrich K. Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement. Rheumatology (Oxford) 47: 1600-1602 (2008). *
Deighton CM, Cavanagh G, Rigby AS, Lloyd HL, Walker DJ. Both inherited HLA-haplotypes are important in the predisposition to rheumatoid arthritis. Br. J. Rheumatol. 32: 893-898 (1993).
Deighton CM, Fay A, Walker DJ. Rheumatoid arthritis in thyroid disease positive and negative same-sexed sibships. Br. J. Rheumatol. 31: 13-17 (1992).
Deighton CM, George E, Kiely PD, Ledingham J, Luqmani RA, Scott DG. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). Rheumatology (Oxford) 45: 649-652 (2006). *
Deighton CM, Kelly PJ, Walker DJ. Linkage of rheumatoid arthritis with HLA. Ann. Rheum. Dis. 52: 638-642 (1993). *
Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis. Rheumatol. Int. Jun 9 [Epub ahead of print] (2009).
Dejaco C, Duftner C, Wipfler E, Schirmer M. A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation. Wien. Med. Wochenschr. 159: 70-75 (2009).
Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res. Ther. 8: R119 (2006). *
Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72: 1161-1179 (2006). *
Dejica DI, Manea EM. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives. Roum. Arch. Microbiol. Immunol. 65: 66-74 (2006).
Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22: 252-258 (2004).
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Agenant D, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann. Rheum. Dis. 37: 33-35 (1978). *
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Meijers KA, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease. Ann. Rheum. Dis. 37: 36-41 (1978). *
del Rincon I, Battafarano DF, Arroyo RA, Murphy FT, Escalante A. Heterogeneity between men and women in the influence of the HLA-DRB1 shared epitope on the clinical expression of rheumatoid arthritis. Arthritis Rheum. 46: 1480-1488 (2002). *
del Rincon I, Escalante A. HLA-DRB1 alleles associated with susceptibility or resistance to rheumatoid arthritis, articular deformities, and disability in Mexican Americans. Arthritis Rheum. 42: 1329-1338 (1999). *
Del Val Del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin. Exp. Rheumatol. 24: 281-286 (2006).
Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjogren's syndrome - associations with specific autoimmune manifestations. Arthritis Res. Ther. 10: R22 (2008). *
Delaleu N, Jonsson R. Altered fractalkine cleavage results in an organ-specific 17 kDa fractalkine fragment in salivary glands of NOD mice. Arthritis Res. Ther. 10: 114 (2008).
Delavallee L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, Zagury D, Boissier MC. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann. Rheum. Dis. 67: 1332-1338 (2008).
Deleuran B, Abraham DJ. Possible implication of the effector CD4(+) T-cell subpopulation T(H)17 in the pathogenesis of systemic scleroderma. Nat. Clin. Pract. Rheumatol. 3: 682-683 (2007). *
Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80: 16-24 (2002). *
Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. PACAP in immunity and inflammation. Ann. N. Y. Acad. Sci. 992: 141-157 (2003). *
Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum. 58: 1010-1019 (2008). *
Delgado M, Toscano MG, Benabdellah K, Cobo M, O'Valle F, Gonzalez-Rey E, Marti N F. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum. 58: 1026-1037 (2008). *
Delgado-Vega AM, Anaya JM. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. Autoimmun. Rev. 6: 402-408 (2007).
Delgado-Vega AM, Castiblanco J, Gomez LM, Diaz-Gallo LM, Rojas-Villarraga A, Anaya JM. BCL2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women. Ann. Rheum. Dis. Mar 11 [Epub ahead of print] (2009).
Delgado-Vega AM, Martin J, Granados J, Anaya JM. Genetic epidemiology of rheumatoid arthritis: what to expect from Latin America? Biomedica 26: 562-584 (2006).
Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 15: 2579-2585 (2001). *
DeLuca HF, Zierold C. Mechanisms and functions of vitamin D. Nutr. Rev. 56: S4-S10 (1998).
Delunardo F, Conti F, Margutti P, Alessandri C, Priori R, Siracusano A, Rigano R, Profumo E, Valesini G, Sorice M, Ortona E. Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behcet's disease. Arthritis Res. Ther. 8: R71 (2006). *
Demetter P, De Vos M, Van Huysse JA, Baeten D, Ferdinande L, Peeters H, Mielants H, Veys EM, De Keyser F, Cuvelier CA. Colon mucosa of both spondyloarthritis and Crohn's disease patients is enriched with macrophages expressing the scavenger receptor CD163. Ann. Rheum. Dis. 64: 321-324 (2005). *
Demirtas-Ertan G, Rowshani AT, Ten Berge IJ. Azathioprine-induced shock in a patient suffering from undifferentiated erosive oligoarthritis. Neth. J. Med. 64: 124-126 (2006). *
Dempfle A, Hein R, Beckmann L, Scherag A, Nguyen TT, Schafer H, Chang-Claude J. Comparison of the power of haplotype-based versus single- and multilocus association methods for gene x environment (gene x sex) interactions and application to gene x smoking and gene x sex interactions in rheumatoid arthritis. BMC Proc. 1 Suppl. 1: S73 (2007). *
den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J. Rheumatol. 34: 689-695 (2007).
Dendle C, Woolley IJ, Korman TM. Rat-bite fever septic arthritis: illustrative case and literature review. Eur. J. Clin. Microbiol. Infect. Dis. 25: 791-797 (2006). *
Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch. Dermatol. 142: 198-202 (2006). *
Deng GM. Tumor necrosis factor receptor pre-ligand assembly domain is an imp